aripiprazole has been researched along with carbostyril in 1600 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (0.94) | 18.2507 |
| 2000's | 785 (49.06) | 29.6817 |
| 2010's | 764 (47.75) | 24.3611 |
| 2020's | 36 (2.25) | 2.80 |
| Authors | Studies |
|---|---|
| Hirose, T; Kikuchi, T; Miwa, T; Morita, S; Oshiro, Y; Tottori, K; Uwahodo, Y | 1 |
| Kito, S; Semba, J; Toru, M; Watanabe, A | 1 |
| Domae, M; Furukawa, T; Inoue, T; Yamada, K | 1 |
| Fujikawa, M; Furukawa, T; Inoue, T; Nagashima, M; Yamada, K | 1 |
| Amano, T; Momiyama, T; Sasa, M; Todo, N | 1 |
| Fukamauchi, F; Kito, S; Mataga, N; Miyoshi, R; Sakai, M; Semba, J | 1 |
| Harano, M; Tanaka, M; Yamada, S; Yokoo, H | 1 |
| Inoue, A; Kikuchi, T; Miki, S; Misu, Y; Morita, S; Nakata, Y; Seto, M; Ueda, H | 1 |
| Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y | 1 |
| Cañive, JM; Davis, JT; Edgar, JC; Lewine, JD; Miller, GA; Torres, F; Tuason, VB | 1 |
| Hide, I; Hirose, T; Inoue, A; Kikuchi, T; Koga, N; Nakata, Y; Seto, M; Sugita, S | 1 |
| Inoue, A; Nakata, Y | 1 |
| Gonzalez, AM; Jiang, D; Lawler, CP; Lewis, MM; Mailman, RB; Mak, C; Prioleau, C; Schetz, JA; Sibley, DR | 1 |
| Amano, T; Matsubayashi, H; Sasa, M | 1 |
| Schetz, JA; Sibley, DR | 1 |
| Hashimoto, K; Satoh, Y; Sugiyama, A | 1 |
| Stahl, SM | 4 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Fourie, J; Ozdemir, V; Ozdener, F | 1 |
| Altar, CA; Chen, R; Jordan, S; Kikuchi, T; Koprivica, V; Tottori, K | 1 |
| Burris, KD; Kikuchi, T; Molinoff, PB; Molski, TF; Ryan, E; Tottori, K; Xu, C; Yocca, FD | 1 |
| Biziere, K; Bramer, S; Dannals, RF; Dogan, AS; Gründer, G; Ravert, H; Stephane, M; Suri, A; Wong, DF; Yokoi, F | 1 |
| Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
| Goa, KL; McGavin, JK | 1 |
| Minamikawa, J; Nishi, T; Shinhama, K; Torisawa, Y | 1 |
| Goodnick, PJ; Jerry, JM | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Ali, MW; Carson, WH; Casey, DE; Ingenito, GG; Jody, D; Liebeskind, A; Saha, AR | 1 |
| Bailey, KP | 1 |
| Keck, PE; McElroy, SL | 1 |
| Buckley, PF | 2 |
| Bowles, TM; Levin, GM | 1 |
| Crismon, ML; DeLeon, A; Miller, AL | 1 |
| Kutscher, EC | 1 |
| Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E | 1 |
| Arrington, E; Chiodo, LA; Liu, LX; Mailman, R; Renock, S; Roth, BL; Shapiro, DA; Sibley, DR | 1 |
| Gasperoni, TL; Grady, MA; Kirkpatrick, P | 1 |
| Woods, SW | 1 |
| Sajatovic, M | 1 |
| Altar, CA; Burris, KD; Dunn, B; Hirose, T; Imaoka, T; Kikuchi, T; Miwa, T; Molinoff, PB; Nakai, M; Nakai, S; Okazaki, H; Tottori, K; Uwahodo, Y; Yamada, S | 1 |
| Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J | 1 |
| Ali, M; Ingenito, G; Keck, PE; Liebeskind, A; Marcus, R; Saha, A; Tourkodimitris, S | 1 |
| Hedges, D; Jeppson, K; Whitehead, P | 1 |
| Carlsson, A; Grunder, G; Wong, DF | 1 |
| Staller, JA | 1 |
| Kaplan, D; Koliatsos, V; Lindsey, RL; Sandson, NB; Walters, JK | 1 |
| Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A | 1 |
| Carson, WH; Ingenito, GG; Pigott, TA; Saha, AR; Stock, EG; Torbeyns, AF | 1 |
| Marona-Lewicka, D; Nichols, DE | 1 |
| Tamminga, CA | 1 |
| Winans, E | 1 |
| Altar, CA; Dunn, R; Jordan, S; Kikuchi, T; Koprivica, V; Tottori, K | 1 |
| Duggal, HS | 2 |
| Bramer, SL; Mallikaarjun, S; Salazar, DE | 1 |
| Connemann, BJ; Schönfeldt-Lecuona, C | 1 |
| Carlsson, A; Carlsson, ML; Nilsson, M | 1 |
| Buckley, PF; Glazer, W; Sebastian, CS | 1 |
| DeQuardo, JR | 2 |
| Argo, TR; Carnahan, RM; Perry, PJ | 1 |
| Green, B | 1 |
| Lieberman, JA | 1 |
| Aihara, K; Burris, KD; Horie, M; Kikuchi, T; Miwa, T; Shimada, J; Tottori, K; Yocca, FD | 1 |
| Lyseng-Williamson, KA; Perry, CM | 1 |
| Buck, ML; Davenport, JD; McCarthy, MW | 1 |
| Petty, F; Praveen, F; Ramaswamy, S; Sattar, SP; Vijay, D; William, M | 1 |
| El-Sayeh, HG; Morganti, C | 2 |
| Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B | 1 |
| Dai, J; Ichikawa, J; Li, Z; Meltzer, HY | 1 |
| Crismon, ML; DeLeon, A; Patel, NC | 1 |
| Mack, JE; Reeves, RR | 1 |
| Mendhekar, DN | 1 |
| Perry, CM; Swainston Harrison, T | 1 |
| Ismail, MS; Profenno, LA; Tariot, PN | 1 |
| Kasper, S; Winkler, D | 1 |
| Myers, WC; Ruiz, R | 1 |
| Goforth, HW; Rao, M; Sucholeiki, R | 1 |
| Altar, CA; Burris, KD; Hirose, T; Kikuchi, T; Kitagawa, H; Miwa, T; Nabeshima, T; Uwahodo, Y; Yamada, S | 1 |
| Davids, E; Fischer, B; Gastpar, M | 1 |
| Bowers, MB; Cooper, C; Lim, S; Pralea, C; Schnitt, J | 1 |
| Anghelescu, I; Wolf, J | 1 |
| Andrade, C | 1 |
| McLean, AJ | 1 |
| Jagadheesan, K; Muirhead, D | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Fear, C | 1 |
| Shayegan, DK; Stahl, SM | 1 |
| Chakraborty, N; Johnston, T | 1 |
| Tsai, SJ | 3 |
| Citrome, L; Volavka, J | 1 |
| Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Reddy, H | 1 |
| Finkel, S | 1 |
| Katz, IR | 1 |
| Alessi, NE; Radwan, K; Spalding, S | 1 |
| Oberpichler-Schwenk, H | 1 |
| Baum, CR; Douglas, L; Schonberger, RB | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Lambert, M; Naber, D | 1 |
| Hellerstein, DJ | 1 |
| Davies, MA; Roth, BL; Sheffler, DJ | 1 |
| Cheney, EM; DeQuardo, JR; Sajbel, TA | 1 |
| Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S | 1 |
| Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE | 1 |
| Kinrys, G; Pollack, MH; Worthington, JJ; Wygant, LE | 1 |
| Bolonna, AA; Kerwin, RW | 1 |
| Bartels, M; Kastrup, A; Plewnia, C; Schlotter, W | 1 |
| De Mathis, A; Hounie, A; Mercadante, MT; Sampaio, AS | 1 |
| McDougle, CJ; Posey, DJ; Stigler, KA | 1 |
| Durkin, JP | 1 |
| Barzman, DH; Campbell, P; DelBello, MP; Delgado, SV; Fleck, DE; Gernert, B; Kowatch, RA; Pathak, S; Rappaport, K; Strakowski, SM | 1 |
| Connor, KM; Davidson, JR; Gadde, KM; Payne, VM; Zhang, W | 1 |
| Cohen, ST; Pies, R; Rulf, D | 1 |
| Duggal, HS; Kithas, J | 1 |
| Aleardi, M; Biederman, J; Falzone, R; McDonnell, MA; Mick, E; Spencer, T; Wozniak, J | 1 |
| Dehning, S; Müller, N; Riedel, M | 1 |
| Errico, JR; Yates, WR | 1 |
| Keck, PE | 1 |
| Carstairs, SD; Williams, SR | 1 |
| Azuma, J; Fukuda, T; Inaba, A; Koue, T; Kubo, M; Maune, H; Takeda, H | 1 |
| Aubry, JM; Bertschy, G; Bryois, C; Eliez, S; Etter, M; Nanzer, N | 1 |
| Vieta, E | 1 |
| Dubois, D | 1 |
| Cousins, DA; Young, AH | 1 |
| Adson, DE; Fahnhorst, TA; Kushner, MG | 1 |
| Kerpel-Fronius, S; Lóránt, M | 1 |
| Malik, AR; Ravasia, S | 1 |
| Winter, AS; Witschy, JK | 1 |
| Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH | 1 |
| Bengtson, MA; Edge, PJ; Murphy, TK; Sajid, MW; Shapira, N; Soto, O; Yang, M | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Burris, KD; Kikuchi, T; Miwa, T; Mori, T; Stark, A; Tadori, Y; Tottori, K | 1 |
| Akiyama, H; Kashiyama, E; Koga, T; Miyamoto, G; Shimokawa, Y | 1 |
| Andrade, C; Mendhekar, DN | 1 |
| Bhatia, SC; Petty, F; Sattar, SP; Warsi, M | 1 |
| Klein-Schwartz, W; Lofton, AL | 1 |
| Schwartz, MD; Seifert, SA; Thomas, JD | 1 |
| Kuehn, BM | 1 |
| Launer, M | 1 |
| Kinghorn, WA; McEvoy, JP | 1 |
| Beard, L; Brown, ES; Garza, M; Jeffress, J; Liggin, JD | 1 |
| Bartholomä, A; Gregor, A; Hein, J; Heinz, A; Juckel, G | 1 |
| Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW; Vansickel, AR | 1 |
| Britt, CS; Daniels, AJ; Grizzle, MK; Ignar, DM; Jones, DN; Kalinichev, M; Rourke, C | 1 |
| Bridler, R | 1 |
| Hirao, Y; Kubo, M; Mizooku, Y; Osumi, T | 1 |
| Bruins Slot, LA; Kleven, MS; Newman-Tancredi, A | 1 |
| Alfers, J; Beresford, HF; Beresford, TP; Clapp, L; Martin, B; Wiberg, JL | 1 |
| Fabbri, D; Heidbreder, CA; Zocchi, A | 1 |
| Budin, R; Fleming, AS; Kapur, S; Li, M | 1 |
| LoVecchio, F; Watts, D; Winchell, J | 1 |
| Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
| Ball, MP; Cates, ME; Hooper, ET; Skipwith, DF | 1 |
| Ostroff, R; Wahl, R | 1 |
| Berk, M; Bourin, M; Dodd, S; Ivanovski, B; Lagopoulos, J; Malhi, GS; Mitchell, PB | 1 |
| Been, A; de Bruijn, C; Vergouwen, AC | 1 |
| Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Saria, A; Zernig, G | 1 |
| Abou-Gharbia, N; Bourin, M; Carson, W; Iwamoto, T; Marcus, R; McQuade, R; Sanchez, R; Stock, E; Swanink, R; Vieta, E | 1 |
| Janvier, YM; Rugino, TA | 1 |
| Breder, C; Carson, WH; De Deyn, P; Iwamoto, T; Jeste, DV; Kostic, D; Swanink, R | 1 |
| Fricchione, GL; Huffman, JC | 1 |
| Calliess, IT; Kropp, S; Sieberer, M; Ziegenbein, M | 2 |
| Church, CO; Fugate, SE; Stevens, DL | 1 |
| López-Meza, E; Ramirez-Bermudez, J; Ruiz-Chow, A | 1 |
| Fleischhacker, WW | 1 |
| Baldessarini, RJ; Grant, MJ | 1 |
| Balit, CR; Isbister, GK; Kilham, HA | 1 |
| Briggs, JR; Klosin, J; Whiteker, GT | 1 |
| Bennett, N; Hirsch, J; Kafantaris, V; Saito, E | 1 |
| Scholten, MR; Selten, JP | 1 |
| Minervini, L; Romano, M; Ruffatti, A; Sonino, N | 1 |
| Engelhardt, E; Laks, J; Marinho, V; Miotto, R | 1 |
| Nemeroff, CB; Simon, JS | 1 |
| Alpert, JE; Burns, AM; Fava, M; Kinrys, G; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Worthington, JJ | 1 |
| Basson, BR; Treuer, T | 1 |
| Barnas, ME; Hussain, N; Petrides, G | 1 |
| Murphy, TK; Negin, B | 1 |
| Howland, RH | 2 |
| Fletcher, PJ; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| Borras, L; Constant, EL; Eytan, A; Huguelet, P | 1 |
| Dunlop, J; Kowal, DM; Lou, Z; Nawoschik, SP; Zhang, JY | 1 |
| Hao, X; Jiang, Y; Liu, H | 1 |
| Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R | 1 |
| Hirose, T; Kikuchi, T | 1 |
| Kim, TS; Lee, C; Pae, CU; Paik, IH | 2 |
| Hatchett, AD; Zacher, JL | 1 |
| Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S | 2 |
| Odiyoor, M; Salmoiraghi, A | 1 |
| Abou-Gharbia, N; Carson, W; Impellizzeri, C; Iwamoto, T; Kaplita, S; Marcus, R; McQuade, R; Rollin, L; Sachs, G; Sanchez, R; Stock, E | 1 |
| Bourgeois, JA; Sanchez, R; Srephichit, S | 1 |
| Duggal, V; Glick, ID; Hodulik, C | 1 |
| Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J | 1 |
| Eap, CB; Holzer, L | 1 |
| Sharma, A; Sorrell, JH | 1 |
| Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD | 1 |
| Bork, B; Christensen, A; Christensen, AF; Christensen, M; Nielsen, CT; Poulsen, J | 1 |
| Aderhold, V; Haasen, C; Lambert, M; Reimer, J | 1 |
| Ballard, C; Waite, J | 1 |
| Mendhekar, DN; Sharma, JB; Srilakshmi, P | 1 |
| Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R | 1 |
| Raja, M | 1 |
| Bruins Slot, LA; Cussac, D; De Vries, L; Newman-Tancredi, A | 1 |
| Baciu, D; Walther, S | 1 |
| Dagerman, K; Insel, PS; Schneider, LS | 1 |
| Ebrecht, M; Göröcs, T; Gründer, G; Kungel, M; Modell, S | 1 |
| Arends, J; Slooff, CJ | 1 |
| Beers, E; Loonen, AJ; Van Grootheest, AC | 1 |
| Lambert, MT | 1 |
| Glaser, PE; Lile, JA; Rush, CR; Stoops, WW | 1 |
| Blashki, G; Keks, N | 1 |
| Assié, MB; Carilla-Durand, E; Cosi, C; Leduc, N; Maraval, M; Newman-Tancredi, A; Ormiere, AM | 1 |
| Mailman, RB; Urban, JD; Vargas, GA; von Zastrow, M | 1 |
| Harms, E; Kropp, S; Luebbe, G; Ziegenbein, M | 1 |
| Kantrowitz, JT; Srihari, VH; Tek, C | 2 |
| Fountoulakis, KN; Iacovides, A; Kantartzis, S; Kaprinis, GS; Panagiotidis, P; Siamouli, M | 1 |
| Kim, YK; Lee, BH; Park, SH | 1 |
| Hara, C; Rocha, FL | 2 |
| Anvar, J; Bachler, E; Buschmann, W; Egger, C; Fartacek, R; Kaplan, P; Kettler, C; Loew, TH; Muehlbacher, M; Nickel, C; Nickel, MK; Pedrosa Gil, F; Rother, N; Rother, WK | 1 |
| Calabrese, JR; Carlson, BX; Carson, WH; Keck, PE; Marcus, RN; McQuade, RD; Rollin, LM; Sanchez, R | 1 |
| Duggal, HS; Mendhekar, DN | 1 |
| Clarke, LA; Kaushik, S; Lindenmayer, JP | 1 |
| Alao, AO; Koss, M; Pohl, EL; Soderberg, M | 1 |
| Adjan, S; Hamann, J; Kissling, W; Leucht, S | 1 |
| Strawn, JR | 1 |
| Bubl, E; Perlov, E; Tebartz Van Elst, L | 1 |
| Bahta, E; Levine, S; Manas, K; Reddymasu, S; Slay, LE | 1 |
| Andrade, C; Mendhekar, DN; Sunder, KR | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Caroff, SN; Hammerman, S; Lam, C | 1 |
| Malevani, J; Mobascher, A; Mobascher, J; Schlemper, V; Winterer, G | 1 |
| Borras, L; Constant, EL; Seghers, A | 1 |
| Desarkar, P; Sinha, VK; Thakur, A | 1 |
| Bourin, M | 1 |
| Altar, CA; Feltenstein, MW; See, RE | 1 |
| Ali, M; Carson, WH; Cornblatt, BA; Green, MF; Kern, RS; Marcus, R; McQuade, RD; Owen, JR | 1 |
| Maytal, G; Ostacher, M; Stern, TA | 1 |
| Ali, IM; Morris, HR; Wickremaratchi, M | 1 |
| Gaszner, P | 1 |
| Bergesio, G; Demicheli, CM; Dettoni, E; Rota, E | 1 |
| Lacasse, JR; Leo, J | 1 |
| Tsai, JF | 1 |
| Ali, S; Patel, P; Pearlman, RL; Upadhyay, A | 1 |
| Egger, C; Geretsegger, C; Muehlbacher, M; Nickel, M; Rauscher, A; Stuppaeck, C | 1 |
| Cipriani, A; Geddes, JR; Rendell, JM | 1 |
| Ehret, MJ; Levin, GM | 1 |
| Forrester, MB | 1 |
| Adams, CE; El-Sayeh, HG; Morganti, C | 1 |
| Crossman, AM; Lindenmayer, JP | 1 |
| Alla, L; Sabaratnam, M; Shastri, M | 1 |
| Duane, DD | 1 |
| Clarke, K; Davies, CH; Forbes, IT; Gribble, A; Hill, M; Jones, DN; Newson, M; Reavill, C; Rourke, C; Scott, C; Westaway, J; Wood, MD | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 3 |
| Gründer, G; Paulzen, M | 1 |
| Carson, WH; Cutler, AJ; Hardy, SA; Marcus, RN; McQuade, RD; O'Donnell, A | 1 |
| Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E | 1 |
| Koch, M; Schwabe, K | 1 |
| Coffey, B; Jummani, R; Vito, J | 1 |
| Kim, CY; Kim, JY; Yoo, HK | 1 |
| Balhara, YP; Kayal, M; Varghese, ST | 1 |
| Chen, CK; Lin, SK | 1 |
| Carter, WG; Shillcutt, SD | 1 |
| Fernald, DS; Hovens, JE; Loonen, AJ; van Dellen, RT | 1 |
| Kang, SG; Kim, L; Lee, HJ; Lee, MS; Park, JS | 1 |
| Cho, JY; Jang, IJ; Kim, E; Kim, YY; Kwon, JS; Shin, SG; Shin, YW; Yoo, SY; Yu, KS | 1 |
| Chou, JC; Fazzio, L | 1 |
| Berman, RM; Carson, WH; Factor, SA; Friedman, JH; Goetz, CG; Marcus, RN; Ondo, WG; Wojcieszek, J | 1 |
| Anolik, R; Johnson, RA; Kunkel, EJ; Mago, R | 1 |
| Agrawal, N; Davies, L; Robertson, MM; Stern, JS | 1 |
| Dekeyne, A; Iob, L; Millan, MJ; Péglion, JL | 1 |
| Harborne, GC; Karunakaran, K; Tungaraza, TE | 1 |
| Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A | 1 |
| Demb, H; Valicenti-McDermott, MR | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Kovács, G; Kovács, L | 1 |
| Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E | 1 |
| Dimopoulos, NP; Kararizou, EG; Katsa, AN; Katsanou, MN; Mitropoulos, PA; Mitsonis, CI; Tsakiris, FE | 1 |
| Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y | 1 |
| Hirose, T; Kameya, T; Kikuchi, T; Mamiya, N; Taguchi, M; Yamada, S | 1 |
| Padala, KP; Padala, PR; Sadiq, HJ | 1 |
| Abu-Tair, F; Bergemann, N; Kopitz, J | 1 |
| Jun, TY; Lee, C; Masand, PS; Pae, CU; Paik, IH; Patkar, AA | 1 |
| Stoops, WW | 1 |
| Chavez, B; Poveda, RA | 1 |
| Kropp, S; Wittmann, G; Ziegenbein, M | 1 |
| Lunde, H; Lunder, N; Molden, E; Refsum, H | 1 |
| Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 2 |
| De Oliveira, IR; Juruena, MF | 1 |
| Cassano, GB; Fagiolini, A; Lattanzi, L; Monteleone, P; Niolu, C; Sacchetti, E; Siracusano, A; Vita, A | 1 |
| García-Amador, M; Goikolea, JM; Pacchiarotti, I; Sanchez, RF; Valentí, M; Vieta, E | 1 |
| Chen, CH; Haw-Ming, L; Lin, CC; Shen, YC | 1 |
| Sokolski, KN | 3 |
| Liskow, BI; Moeller, KE; Shireman, TI | 1 |
| Arlien-Soborg, P; Kondziella, D | 1 |
| Föhr, J; Haukka, J; Kuikanmäki, O; Kuoppasalmi, K; Meririnne, E; Sokero, P; Tiihonen, J; Tuomola, P; Vorma, H | 1 |
| Padala, PR; Petty, F; Wengel, SP | 1 |
| Belcher, HM; Gonzalez, N; Heligman, SD; Logue, DD; McLaughlin, JV | 1 |
| Oosterhuis, M; Tenback, D; Van De Kraats, G | 1 |
| Hamamura, T; Harada, T | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Ge, HX; Jiang, ZZ; Ni, SL; Wang, LC | 1 |
| Altshuler, LL; Frye, MA; Keck, PE; Leverich, GS; Martens, B; McElroy, SL; Post, RM; Stanford, K; Suppes, T | 1 |
| Dago, PL; Fleck, J; Gilmer, WS; Karaffa, M; Kemp, DE; Straus, JL | 2 |
| Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C | 1 |
| Allers, KA; Bertekap, RL; Burris, KD; Chen, R; Jordan, S; Kikuchi, T; Mistry Kannan, T; Molski, TF; Sharp, T; Stark, AD; Yocca, FD | 1 |
| Li, HD; Li, KY; Ren, HY; Wang, F; Zhang, BK; Zhou, YG | 1 |
| Artigas, F; Bortolozzi, A; Celada, P; Díaz-Mataix, L; Toth, M | 1 |
| Chan, HY; Chiang, SC; Hwang, TJ; Hwu, HG; Lin, SK; Lin, WW; Su, TP | 1 |
| Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK | 1 |
| Gründer, G; Hiemke, C; Kircher, T; Leube, D; Schlotterbeck, P | 1 |
| Crismon, ML; Fischer, C; Gibson, AP; Mican, LM | 1 |
| Pinninti, NR; Sanghadia, M | 1 |
| Adler, CM; DelBello, MP; Singh, MK | 1 |
| Loew, TH; Nickel, MK; Pedrosa Gil, F | 1 |
| Koob, GF; Pulvirenti, L; Wang, Z; Wee, S; Woolverton, WL | 1 |
| Modestin, J; Schneiter, R; Traber, R | 1 |
| Kellner, M | 1 |
| Carson, WH; Kane, JM; Marcus, RN; McQuade, RD; Meltzer, HY; Sanchez, R | 1 |
| Keller Ashton, A | 1 |
| Thomas, P | 1 |
| Geffken, GR; Lehmkuhl, H; Murphy, TK; Storch, EA; Touchton, A | 1 |
| Devanand, D; Eisenstadt, R; Miyazaki, M; Roose, S; Rutherford, B; Sackeim, H; Sneed, J | 1 |
| Limosin, F | 1 |
| Fiedler, U; Wolf, J | 1 |
| Lamberti, JS; Olsen, D; Spurling, RD; Tang, W; Tu, X | 1 |
| Demirdaş, A; Eren, I; Naziroğlu, M | 1 |
| Dobkin, RD; Marin, H; Menza, MA | 1 |
| Auby, P; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E; Zimbroff, DL | 1 |
| Brunelle, J; Gouin, P; Guigueno, S; Tamion, F; Thibaut, F | 1 |
| Carroll, BT; Goforth, HW | 1 |
| Baup, N; Baylé, FJ; Gallarda, T; Mouaffak, F; Olié, JP | 1 |
| Alici-Evcimen, Y; Basil, B; Evcimen, H; Gorman, JM; Mania, I; Mathews, M | 1 |
| Freeman, B; Gorman, JM; Levy, W | 1 |
| Brahm, NC; Brown, RC; McElwain, DL | 1 |
| Singh Ajit, S | 1 |
| Novaes, CM; Pondé, MP | 1 |
| Chen, YY; Hung, GC | 2 |
| Baghai, TC; Born, C; Eser, D; Häfner, S; Hecht, S; Hermisson, I; Nothdurfter, C; Rupprecht, R; Schüle, C | 1 |
| Bartenstein, P; Fellgiebel, A; Hiemke, C; Müller, MJ; Schreckenberger, M | 1 |
| Knopf, U; Kuwilsky, A; Zink, M | 1 |
| Konarski, JZ; McIntyre, RS; Miranda, A; Soczynska, JK; Woldeyohannes, HO | 1 |
| Behere, RV; Gangadhar, BN; Naveen, MN; Venkatasubramanian, G | 1 |
| Reavill, C; Wood, M | 1 |
| Boulton, DW; Citrome, L; Macher, JP; Mallikaarjun, S; Salazar, DE | 1 |
| Das, A; Desarkar, P; Nizamie, SH | 1 |
| Crandall, DT; Gutierrez-Esteinou, R; Lau, GS; Marcus, RN; Marder, SR; Pikalov, A; Pultz, JA; West, B | 1 |
| Bowers, MB; Lim, S | 1 |
| Ahuja, N; Lloyd, AJ | 1 |
| Hamuro, A | 1 |
| Calais, LA; Cañive, JM; Lundy, SL; Pickard, J; Toney, G; Villarreal, G | 1 |
| Chen, CH; Chen, SJ; Lin, CC; Shen, YC | 1 |
| Oldham, J | 1 |
| Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL | 1 |
| Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL | 1 |
| Fan, XW; Luo, JW; Zeng, DZ | 1 |
| Corsini, GU; Maggio, R; Millan, MJ; Novi, F | 1 |
| Castberg, I; Spigset, O | 1 |
| Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M | 1 |
| LaPorta, LD | 1 |
| Bienroth, M; Jones, M; Millar, H; Ratna, L; Sullivan, G; Taylor, D | 1 |
| Berman, RM; Carson, WH; Corey-Lisle, PK; Khan, A; Marcus, RN; McQuade, RD; Swanink, R | 1 |
| Feldman, JJ; Rosenberg, J; Salzman, C | 1 |
| Abdallah, TA; Friedman, S; Guelfi, JD; Oumaya, M; Rouillon, F | 1 |
| Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA | 1 |
| Crow, TJ | 1 |
| Gutierrez-Esteinou, R; McQuade, RD; Silver, GA | 1 |
| Chiu, HJ; Hu, TM; Huang, HC; Lan, TH; Liu, CH; Tseng, YL; Wu, YC | 1 |
| Di Nicola, M; Janiri, L; Martinotti, G | 2 |
| Gournellis, R; Lykouras, L; Rizos, E | 1 |
| Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD | 1 |
| Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
| Bourgeois, JA; Kahn, D | 1 |
| Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W | 1 |
| Li, JF; Liu, AX; Nian, YF; Shen, JS; Xia, GX | 1 |
| Flood, DG; Gasior, M; Marino, MJ | 1 |
| Sahoo, S | 1 |
| Assis, LC; Barbosa, LM; Grandi, E; Quevedo, J; Rezin, GT; Streck, EL | 1 |
| Konarski, JZ; McIntyre, RS; Miranda, A; Soczynska, JK; Woldeyohannes, HO; Yasgur, BS | 1 |
| Inoue, T; Kurokawa, K; Nakamura, A; Narita, M; Shiokawa, M; Suzuki, T | 1 |
| Choi, SH; Hong, JP; Kim, CY; Park, S; Wang, HR; Yoo, HK | 1 |
| Correa, H; da Rocha, FF | 1 |
| Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y | 1 |
| Adelbrecht, C; Allain, H; Bernardo, M; Janssen, F; Laughton, J; Lublin, H; Maier, W; Millar, H; Pans, M; Salokangas, RK; Smeraldi, E; Werner, C; Wolf, J | 1 |
| Wooten, J | 1 |
| Lafollette, J; Lea, JW; Stoner, SC | 1 |
| Kessler, RM | 1 |
| Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH | 1 |
| Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM | 1 |
| Evcimen, H; Evcimen, YA; Holland, J | 1 |
| Constant, EL; Emmanuel, H; Hermans, E; Jean-Jean, A; Koener, B; Maloteaux, JM | 1 |
| Castiglioni T, C; Miranda C, M | 1 |
| Bottlender, R; O'Donnell, M | 1 |
| Deng, C; Han, M; Huang, XF; Newell, K; Zavitsanou, K | 1 |
| Aleardi, M; Biederman, J; Doyle, R; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Spencer, T; Wozniak, J | 1 |
| Hendset, M; Hermann, M; Lunde, H; Molden, E; Refsum, H | 1 |
| Bhatia, SC; List, D; Padala, PR; Petty, F | 1 |
| Chiclana, C; Gonzalez, R; Lopez-Garcia, P | 1 |
| Burchardt, C; Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Piel, M | 1 |
| Chen, CH; Chen, CY; Cheng, MC; Hsiung, CA; Liao, DL; Liao, YC | 1 |
| Chen, CH; Huang, MC; Lu, ML | 2 |
| Lorenz, RA; Weinstein, B | 1 |
| Hurtig, HI; Weintraub, D | 1 |
| Carlson, B; Eudicone, J; McQuade, R; Pikalov, A; Suppes, T | 1 |
| Crandall, DT; Gaulin, BD; Gutierrez-Esteinou, R; Marcus, RN; McQuade, RD; Pikalov, A; Pultz, JA; Sachs, GS; Sanchez, R | 1 |
| Barnas, C; Fischer, P; Kapusta, ND; Mossaheb, N | 1 |
| Loebel, A; Siu, C; Warrington, L; Yang, R; Zimbroff, D | 1 |
| de Souza, CK; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP | 1 |
| Allen, MH; Nordstrom, K | 1 |
| Burrows, G; Jefferys, D | 1 |
| Jain, R; Skale, TG | 1 |
| Calabrese, JR; Carlson, BX; Carson, WH; Eudicone, JM; Keck, PE; Marcus, RN; McIntyre, RS; McQuade, RD; Sanchez, R | 1 |
| Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN | 1 |
| Arnold, KK; Yager, J | 1 |
| Berges, A; Dahmen, MM; Petry, WM; Stoner, SC | 1 |
| Azuma, J; Fukuda, T; Koue, T; Kubo, M; Maune, H | 1 |
| Atkinson, J; Fischetti, C; Jones, S; Sparshatt, A; Taylor, D | 1 |
| Breder, CD; Forbes, A; Marcus, RN; McQuade, RD; Mintzer, JE; Swanink, R; Tune, LE | 1 |
| Lu, JS; Pierre, JM | 1 |
| Azuma, J; Fukuda, T; Funaki, T; Hashimoto, Y; Kayano, Y; Koue, T; Kubo, M; Takaai, M | 1 |
| Delgado, SV; Strawn, JR | 1 |
| Aragona, M | 1 |
| Cortez, AM; Crawford, CA; Iñiguez, SD; McDougall, SA | 1 |
| Gardner, TJ; Kosten, TR | 1 |
| Lile, JA; Lofwall, MR; Rush, CR; Stoops, WW | 1 |
| Cooper, T; Usubiaga, H; Winsberg, B | 1 |
| Rai, A; Spiegel, D; Urbano, M | 1 |
| Avorn, J; Brookhart, MA; Choudhry, NK; Mogun, H; Patrick, A; Schneeweiss, S; Setoguchi, S; Wang, PS | 1 |
| Bachmann, CJ; de Lange, D; Nicksch, B; Remschmidt, H; Theisen, FM | 1 |
| Guimarães, FS; Leite, JV; Moreira, FA | 1 |
| Höppner, J; Kumbier, E | 1 |
| Chou, YH; Su, TP; Yang, KC | 1 |
| Araki, H; Hirose, T; Kikuchi, T; Mori, T; Nakai, S; Stark, A | 1 |
| Perlis, RH | 1 |
| Keating, GM; Sanford, M | 2 |
| Bushe, CJ; Leonard, BE | 1 |
| Rosenheck, RA | 1 |
| Hettema, JM; Ross, DE | 1 |
| Nickel, MK | 1 |
| Lee, C; Lee, CU; Lim, HK; Pae, CU | 1 |
| Freichel, C; Künnecke, B; Maco, M; Moreau, JL; Nordquist, RE; Riemer, C; Risterucci, C; Spooren, W; von Kienlin, M | 1 |
| Callahan, JL; Cohen, SJ; Hawkins, KA; Mathalon, DH; McGlashan, TH; Miller, TJ; Tully, EM; Walsh, BC; Woods, SW | 1 |
| Ben Djebara, M; Hartmann, A; Schüpbach, M; Worbe, Y | 1 |
| Thone, J | 1 |
| Citrome, L | 4 |
| Eudicone, JM; Kim, E; Miller, DD; Pikalov, A | 1 |
| Arnaout, B; Batchelder, S; Coram, L; Corpuz, V; Hellerstein, DJ; Hyler, S; Weiss, G | 1 |
| Chou, SY; Chung, PC; Su, JA; Tsang, HY | 1 |
| Amoretti, A; Di Lorenzo, R; Fiorini, F; Forghieri, M; Genedani, S; Rigatelli, M | 1 |
| Faruqui, RA; Zaidi, SH | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Cho, JY; Jang, IJ; Jo, HJ; Kang, DH; Kang, WJ; Kim, E; Kwon, JS; Lee, JM; Lee, JS; Shin, SG; Shin, YW; Yu, KS | 1 |
| Anton, RF; Breder, C; Carson, WH; Han, J; Kranzler, H; Marcus, RN | 1 |
| Bowden, CL; Carson, WH; Jonas, A; Khan, A; Marcus, RN; McQuade, RD; Owen, R; Thase, ME; Wu, X | 1 |
| Kikukawa, S | 1 |
| Sindø, I; Stenstrøm, AD | 1 |
| Neill, JC; Reynolds, GP; Snigdha, S; Thumbi, C | 1 |
| Aydemir, MC; Goka, E; Kisa, C; Yalcin, DO | 1 |
| Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
| Bhattacharjee, J; El-Sayeh, HG | 2 |
| Arias, AJ; Chan, G; Covault, J; Douglas, K; Kranzler, HR; Oncken, C; Pierucci-Lagha, A | 1 |
| Gonidakis, F; Papadimitriou, G; Ploubidis, D | 1 |
| Klein, J; Krüger, S; Sarkar, R | 1 |
| Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA | 1 |
| Desseilles, M; Mathot, F | 1 |
| Gray, R; Jones, M | 1 |
| Aitchison, KJ; McAllister, V; Mir, A; O'Keane, V; Shivakumar, K; Williamson, RJ | 1 |
| Bashir, M; Macrae, A; Shajahan, P; Taylor, M | 1 |
| Dimopoulos, NP; Mitsonis, CI; Psarra, VV | 1 |
| Hughes, D; Morcos, M | 1 |
| Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M | 1 |
| Hazra, M; Mamo, DC; Remington, G | 1 |
| Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Bauman, JN; Cox, LM; Frederick, KS; Kalgutkar, AS; Obach, RS; Sawant, A; Walsky, RL | 1 |
| Sanford, M; Scott, LJ | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Gregoriou, S; Karagiorga, T; Kontochristopoulos, G; Rigopoulos, D; Stratigos, A; Volonakis, K | 1 |
| Carlson, BX; Eudicone, J; Frye, MA; Marcus, RN; McQuade, RD; Pikalov, A | 1 |
| Dale, R; Varkula, M | 1 |
| Andersen, SE; Johansson, M; Manniche, C | 1 |
| Brovedani, S; Djebrani, K; Kraoul, L; Lancelin, F; Paubel, P; Piketty, ML; Tabaouti, K | 1 |
| Burne, TH; Deng, C; Han, M; Huang, XF; Newell, KA | 1 |
| Boncompagni, G; Kenndler, E; Musenga, A; Raggi, MA; Rizzato, E; Saracino, MA; Spinelli, D | 1 |
| Jerlhag, E | 1 |
| Lo, B; Pizon, A | 1 |
| Bianchi, F; Di Lorenzo, G; Leo, R; Razzini, C; Romeo, F; Siracusano, A; Tesauro, M; Zanasi, M | 1 |
| Dal-Pizzol, F; Gomes, KM; Martins, MR; Petronilho, FC; Quevedo, J; Streck, EL | 1 |
| Ahn, YM; Chang, JS; Kang, UG; Kim, SH; Kim, YS; Lee, KY; Park, HJ | 1 |
| Carlson, BX; Eudicone, JM; Marcus, RN; McQuade, RD; Momah, C; Muzina, DJ; Pikalov, A; Sanchez, R | 1 |
| Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD | 1 |
| Boy, C; Bröcheler, A; Fellows, C; Gründer, G; Hellmann, S; Hiemke, C; Janouschek, H; Kirschbaum, KM; Rösch, F; Schaefer, WM; Spreckelmeyer, KM; Vernaleken, I; Veselinovic, T | 1 |
| Carson, WH; Marcus, RN; McQuade, RD; Nameche, L; Owen, R; Sanchez, R; T'joen, C; Vieta, E | 1 |
| Masand, PS; Pae, CU; Patkar, AA; Serretti, A | 1 |
| Araki, H; Kawasaki, H; Kohnomi, S; Suemaru, K | 1 |
| Englisch, S; Zink, M | 1 |
| Abi-Dargham, A; Alvarez, B; Bae, SA; Frankle, WG; Gil, R; Gonzales, R; Hackett, E; Kegeles, LS; Kim, JH; Laruelle, M; Slifstein, M; Xu, X | 1 |
| Hanssens, L; L'Italien, G; Loze, JY; Marcus, RN; Pans, M; Taylor, D | 1 |
| Hashioka, S; Horikawa, H; Iwaki, T; Kanba, S; Kato, T; Mizoguchi, Y; Monji, A; Seki, Y; Suzuki, SO | 1 |
| Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD | 1 |
| Bai, DS; Sea, HS; Seo, WS; Sung, HM | 1 |
| Neill, JC; Snigdha, S | 1 |
| Campanella, LM; Lartey, R; Shih, R | 1 |
| Strange, PG | 1 |
| Mago, R | 1 |
| Hwang, MY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
| Dorado, P; Llerena, A; López-Torres, E; Peñas-Lledó, E; Salomón, J; Vicario, F | 1 |
| Kelly, DL; Shim, JC; You, YS | 1 |
| Brennum, LT; Fink-Jensen, A; Hee Bengtsen, C; Petersen, JH; Sager, TN; Sørensen, G; Thomsen, M; Thøgersen, P; Woldbye, DP; Wörtwein, G | 1 |
| Andreazza, AC; Kapczinski, F; Quevedo, J; Rosa, MI; Stertz, L; Streck, EL; Valvassori, SS | 1 |
| Dhamija, R; Verma, R | 1 |
| Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Glikman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
| Arnt, J; Dahan, L; Haddjeri, N; Hertel, P; Husum, H; Mnie-Filali, O | 1 |
| Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G | 1 |
| Abbasian, C; Power, P | 1 |
| Chang, KD | 1 |
| Findling, RL | 1 |
| Erickson, CA; McDougle, CJ; Posey, DJ; Stigler, KA | 2 |
| Sikich, L | 1 |
| Bagchus, J | 1 |
| Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM | 1 |
| Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A | 1 |
| Nelson, R; Pumariega, AJ; Rotenberg, L | 1 |
| Delong, HR; Hoge, EA; Kaufman, RE; Pollack, MH; Simon, NM; Worthington, JJ | 1 |
| Croarkin, PE; Emslie, GJ; Mayes, TL | 1 |
| Collins, J; Mervak, B; Valenstein, M | 1 |
| Endo, T; Miyake, N; Miyamoto, S; Ogino, S; Yamaguchi, N | 1 |
| Breder, CD; Carson, WH; Marcus, R; McQuade, R; Porsteinsson, AP; Streim, JE; Swanink, R | 1 |
| Tsai, AC | 2 |
| Bastiaens, L | 1 |
| Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
| Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M | 1 |
| Nahata, T; Saini, TR | 1 |
| Andrade, C; Duggal, H; Mendhekar, D | 1 |
| Boulton, DW; Bramer, SL; Mallikaarjun, S; Shoaf, SE | 1 |
| Caine, SB; Fink-Jensen, A; Holm, R; Pepe, LM; Sager, TN; Thomsen, M; Woldbye, DP; Wörtwein, G | 1 |
| Boulton, DW; Carson, WH; Findling, RL; Forbes, RA; Kauffman, RE; Mallikaarjun, S; Nyilas, M; Pikalov, A; Sallee, FR; Shoaf, SE | 1 |
| Heinz, A; Kupsch, A; Ströhle, A; Winter, C | 1 |
| Anderson, SJ; Brady, KT; McRae, AL; Tolliver, BK; Verduin, ML | 1 |
| Franklin, DL; Maguire, GA; Riley, GD; Tran, NL | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Bachmann, CJ; Heinzel-Gutenbrunner, M; Hiemke, C; Remschmidt, H; Rieger-Gies, A; Theisen, FM | 1 |
| Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R | 1 |
| Gründer, G; Sheldrick, AJ | 1 |
| Abad, A; Anderson, A; Condos, R; De La Garza, R; Elkashef, A; Halkitis, PN; Li, SH; Mahoney, JJ; Mojisak, J; Newton, TF; Palamar, J; Reid, MS | 1 |
| Carlson, BX; Eudicone, J; Marcus, RN; Masand, PS; McQuade, RD; Pikalov, A; Vester-Blokland, E | 1 |
| Goff, DC | 1 |
| Furukawa, H; Kamei, H; Matsui, K; Murai, R; Nabeshima, T; Nagai, T; Noda, Y | 1 |
| Rybakowski, JK | 1 |
| Hamamura, T; Harada, T; Kodama, M | 1 |
| Gripeos, D; Sokolski, KN | 1 |
| Carlat, D | 1 |
| Ghaemi, SN; Rakofsky, JJ | 1 |
| Bogeski, M; Gogos, A; van den Buuse, M | 1 |
| Barbero, JD; Benito, N; Cobo Gómez, JV; Coronas, R; Domenech, C; Fuste, G; García-Parés, G; Gómez, JV | 1 |
| Ayache, L; Buysschaert, M; Fagnart, O; Feys, JL; Gruson, D; Hermans, MP; Jamart, J; Luts, A; Mertens de Wilmars, S; Misson, A; Oriot, P | 1 |
| Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W | 1 |
| Fagiolini, A | 1 |
| Shen, YC | 1 |
| Wang, SJ; Yang, TT | 1 |
| Ibe, AI; Lee, JH; Makhzoumi, ZH; McLean, LP | 1 |
| Ashfaq, M; Haddad, PM; Narayan, V | 1 |
| Demeter, CA; Findling, RL; Leskovec, T; McNamara, NK; Short, EJ; Stansbrey, RJ; Townsend, LD | 1 |
| Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A | 1 |
| Chou, YH; Lin, WC | 1 |
| Libiger, J; Masopust, J; Tůma, I | 1 |
| Bastiampillai, T; Dhillon, R | 1 |
| Arsura, E; Sethi, NK; Torgovnick, J | 1 |
| Anton, R; Myrick, H; Randall, P; Voronin, K | 1 |
| Choi, JS; Jang, IJ; Kang, DH; Kim, E; Kwon, JS; Shin, SG; Yu, KS | 1 |
| Lyseng-Williamson, KA; Scott, LJ; Weber, J | 1 |
| Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Kane, JM; Pikalov, A; Whitehead, R | 1 |
| Seeman, P | 1 |
| Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA | 1 |
| Kashima, H; Kikuchi, T; Manki, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 1 |
| Langosch, JM; Schlachetzki, JC | 1 |
| Bellais, L; Keijzer, L; Lépine, JP; Vorspan, F | 1 |
| Perini, GI; Pigato, G; Toffanin, T | 1 |
| Azzoni, A; Raja, M | 1 |
| Calabrese, JR; Kemp, DE | 1 |
| Forbes, RA; Kikuchi, T; McQuade, RD; Tadori, Y | 4 |
| Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K | 1 |
| Cretaz, E; Diniz, BS; Forlenza, OV | 1 |
| Carson, WH; Cutler, AJ; Keck, PE; Marcus, RN; McQuade, RD; Orsulak, PJ; Sanchez, R; Torbeyns, A | 1 |
| Kawohl, W; Neuner, I; Schneider, F; Vernaleken, I | 2 |
| Montero, I; Ruiz, I; Talavera, M | 1 |
| Bellino, S; Bogetto, F; Paradiso, E | 1 |
| Nakaya, M; Ohmori, K | 1 |
| Chen, CH; Lu, ML; Shen, WW | 1 |
| Hays, LR; Lile, JA; Rush, CR; Stoops, WW | 1 |
| Chen, CH; Chen, SF; Chen, SJ; Chen, YJ; Lin, CC; Luu, SU; Shen, YC | 1 |
| Khan, A | 1 |
| Budman, C; Coffey, BJ; Schrock, M; Shechter, R; Simon, E; Spirgel, A; Wieland, N | 1 |
| Coffey, BJ; Groff, K | 1 |
| Kovalick, LJ; McQuade, RD; Naringrekar, VH; Ni, N; Pikalov, AA | 1 |
| Baardewijk, Mv; Davies, A; L'italien, GJ; Loze, JY; Sennfalt, K; Vardeva, K | 1 |
| Terao, T | 1 |
| Katsigiannopoulos, K; Kouvelas, D; Papazisis, G; Saitis, M | 1 |
| Amano, T; Asato, M; Hashimoto, K; Ikegami, D; Kuzumaki, N; Matsushima, Y; Nakamura, A; Narita, M; Niikura, K; Shiokawa, M; Suzuki, T; Takagi, S; Takei, D; Tsurukawa, Y | 1 |
| Caykoylu, A; Deniz, O; Ekinci, O; Kuloglu, M | 1 |
| Bria, P; Janiri, L; Mazza, M; Pecora, RD; Squillacioti, MR | 2 |
| Baker, RA; Carson, WH; Crandall, DT; Eudicone, JM; L'italien, G; Marcus, RN; McQuade, RD; Meyer, JM; Newcomer, JW; Pikalov, A; Vester-Blokland, E | 1 |
| Marshall, PB; Mellman, TA; Nguyen, SX | 1 |
| Madhusoodanan, S; Shah, P | 1 |
| Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R | 1 |
| Kamei, A; Kamei, J; Miyata, S; Ohsawa, M; Shimada, M; Sunohara, T | 1 |
| Braun, DE; Gelbrich, T; Griesser, UJ; Kahlenberg, V; Tessadri, R; Wieser, J | 1 |
| Aitchison, KJ; Bienroth, M; Cookson, J; Goodwin, GM; Gray, R; Haddad, PM; Moore, B; Ratna, L; Sullivan, G; Taylor, D; Taylor, M | 1 |
| Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL | 1 |
| Apfeldorf, WJ; Cullen, CE; Eide, CE; Lu, BY; Williams, CC | 1 |
| Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R | 1 |
| Glick, ID; Ivanova, O; Koran, LM; Poyurovsky, M | 1 |
| Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Bahk, WM; Cho, JY; Jang, IJ; Kang, DH; Kim, JR; Kim, YK; Kwon, JS; Seo, HB; Shin, SG; Yu, KS | 1 |
| Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R | 1 |
| Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W | 1 |
| Goodman, M | 1 |
| Gambini, O; Muffatti, R; Scarone, S | 1 |
| Bledowski, J; Kahn, DA; Pandurangi, A; Trutia, A | 1 |
| Mathew, SJ | 1 |
| Bao, YP; Beveridge, TJ; Di, XL; Li, SX; Liu, Y; Lu, L; Sun, HQ; Yang, FD | 2 |
| Hang, T; Song, M; Wen, A; Xu, X; Yang, L | 1 |
| Bergman, J | 1 |
| Haffejee, S; Santosh, PJ | 1 |
| Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M | 1 |
| Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Rappaport, SA | 1 |
| Carson, WH; Lowy, A; Marcus, RN; McQuade, RD; Oren, DA; Sanchez, R; Spiller, NH; Torbeyns, AF; Young, AH | 1 |
| Hauser, D; Ladds, B; Mejia, C; Thomas, P | 1 |
| Balch, AH; Benson, J; Boulton, DW; Carlson, BX; Croop, R; Mallikaarjun, S; Schieber, FC | 1 |
| Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO | 1 |
| Carroll, BJ | 1 |
| Jong-Yih, L | 1 |
| Christensen, H; Hermann, M; Refsum, H; Rudberg, I; Waade, RB | 1 |
| Costa, MC; Fiks, JP; Mello, MF; Schoedl, AF | 1 |
| Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY | 1 |
| Jana, AK; Praharaj, SK; Sinha, VK | 1 |
| Chang, CC; Chen, SH; Hsu, WY | 1 |
| Bernardi, G; Brusa, L; Iani, C; Mercuri, NB; Moschella, V; Orlacchio, A | 1 |
| Bies, R; Devlin, B; Dew, MA; Driscoll, HC; Lenze, EJ; Lotrich, F; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Kyomen, HH; Whitfield, TH | 1 |
| Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
| Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD | 1 |
| Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H | 1 |
| Cho, HY; Choi, SM; Ha, EK; Kim, YH; Lee, JG; Park, SW; Seo, MK | 1 |
| Deng, C; Han, M; Huang, XF | 1 |
| Brown, MW; Durkalski, VL; Hamner, MB; Robert, S; Ulmer, HG | 1 |
| Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Cho, DY; Lindenmayer, JP | 1 |
| Akhtar, J; Jameson, A; Katz, K; Melhem, S; Shellenbarger, D | 1 |
| Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV | 1 |
| Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR | 1 |
| Devane, CL; Donovan, JL; Geesey, ME; Markowitz, JS; Wang, JS; Yuan, HJ; Zhu, HJ | 1 |
| Adan-Manes, J; Garcia-Parajua, P | 1 |
| Costentin, J | 2 |
| Barnett, AH; Knapp, M; L'Italien, GJ; Loze, JY; Millar, HL; van Baardewijk, M | 1 |
| Bashir, M; Keith, S; MacRae, A; Majjiga, C; Murphy, J; Shajahan, P; Taylor, M | 1 |
| Bogers, JP; Starrenburg, FC | 1 |
| Chen, CH; Chen, SF; Shen, YC | 2 |
| Caykoylu, A; Ekinci, O; Yilmaz, E | 1 |
| Khalid, I; Khalid, TJ; Rana, L; Roehrs, T | 1 |
| Corey-Lisle, PK; Guo, Z; Kim, E; Lennox, RD; Pikalov, A; Trivedi, MH | 1 |
| Breier, A; Kane, JM; Kryzhanovskaya, LA; Osuntokun, O; Stauffer, VL; Watson, SB; Xu, W | 1 |
| Aguilar-Shea, AL; Gallardo-Mayo, C; Palomero-Juan, I; Sierra Santos, L | 1 |
| Carlström, EL; Jazin, E; Jiang, L; Saetre, P | 1 |
| Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V | 1 |
| Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM | 1 |
| Chen, CK; Ree, SC; Wang, LJ | 1 |
| Pae, CU | 3 |
| Chiesa, A; De Ronchi, D; Mandelli, L; Pae, CU; Serretti, A | 2 |
| Li, SX; Liu, LJ; Lu, L; Wu, P; Zou, Y | 1 |
| Smith, EJ | 1 |
| Choudhary, PP; Munda, S; Pattojoshi, A; Prakash, R | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Alsina, M; Bennàssar, A; Guilabert, A; Mascaró, JM; Pintor, L | 1 |
| Ketzer, CR; Narvaez, J; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP | 1 |
| Adson, D; Berman, RM; Carson, WH; Fava, M; Hazel, J; Marcus, RN; McQuade, RD; Swanink, R; Taylor, L; Thase, ME; Trivedi, MH | 1 |
| Fang, XL; Sha, XY; Wu, J | 1 |
| Cummings, TS; Noordsy, DL | 1 |
| Kalapatapu, RK; Schimming, C | 1 |
| Bopp, K; Petti, TA; Stern, RG; Tobia, A | 1 |
| Harada, T; Ishigooka, J; Sakamoto, K; Yamada, K | 1 |
| Chiesa, A; De Ronchi, D; Kim, J; Lee, C; Mandelli, L; Pae, CU; Paik, IH; Serretti, A | 1 |
| Price, LH | 1 |
| Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S | 1 |
| Arnt, J; Bétry, C; Etievant, A; Haddjeri, N | 1 |
| Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS | 1 |
| Bergmann, F; Ebrecht, M; Kungel, M; Modell, S; Nass, A; Spevakné-Göröcs, T; Urban, R; Werner, C; Zacher, A | 1 |
| Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C | 1 |
| Evenden, J; Jonak, G; Ross, L; Zhou, J | 1 |
| Preskorn, SH | 1 |
| Chiu, NY; Hsu, WY; Kahn, DA; Lee, CI | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Inada, K; Ishigooka, J; Oshibuchi, H; Sugawara, H | 1 |
| Cosenza, A; Masi, G; Millepiedi, S; Muratori, F; Pari, C; Salvadori, F | 1 |
| Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R | 1 |
| Heard, K; Hoppe, J; Tan, HH | 1 |
| Arvilommi, P; Isometsä, E; Leppämäki, S; Mantere, O; Suominen, K; Valtonen, HM | 1 |
| Schwankhaus, J; Singh, S | 1 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B | 1 |
| Aia, PG; Esper, CD; Factor, SA; Lungu, C; Shih, LC; Tarsy, D | 1 |
| Bourin, M; Chenu, F; Hascoët, M; Prica, C | 1 |
| Diener, JT; Erickson, CA; Kohn, AE; Li, L; McDougle, CJ; Posey, DJ; Stigler, KA | 1 |
| Kalapatapu, RK | 1 |
| Gebicke-Härter, PJ; Schmitt, A; Segnitz, N; Zink, M | 1 |
| DeLorenze, G; L'Italien, G; McQuade, R; Newcomer, J; Oliveria, SA; Quesenberry, CP; Tsai, AL; Willey, VJ; Yood, MU | 1 |
| Jing, Y; Kim, E; Pikalov, A; Tran, QV; You, M | 1 |
| Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N | 1 |
| Kenna, GA; Leggio, L; Swift, RM | 1 |
| Cohen, D; Correll, CU | 1 |
| Maurer, I | 1 |
| Chen, CK; Wu, JH | 1 |
| Bachmann, CJ; Lehr, D; Preiss, M; Theisen, FM | 1 |
| Englisch, S; Inta, D; Weinbrenner, A; Zink, M | 1 |
| Cantrell, FL; Clark, RF; Shah, N; Young, MC | 1 |
| Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H | 1 |
| Kashima, H; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 2 |
| Albert, U; Bogetto, F; Maina, G; Pessina, E | 1 |
| Huang, YC; Lee, Y; Lin, PY | 1 |
| Cruz, N; Goikolea, JM; Sanchez-Moreno, J; Torres, F; Valentí, M; Vieta, E | 1 |
| Blier, P; Chernoloz, O; El Mansari, M | 1 |
| Bian, QT; Chen, JX; Haile, C; Kosten, TR; Liu, YH; Su, YA; Wang, N; Wang, SL; Yang, FD; Zhang, XY | 1 |
| Baker, RA; Berman, RM; Carlson, BX; Eudicone, JM; Mankoski, R; Nelson, JC; Pikalov, A; Tran, QV | 1 |
| Carlson, BX; Chen, CC; Guo, Z; Kan, HJ; Kim, E; Pikalov, A; Tran, QV; Wisniewski, SR | 1 |
| Foltz, R; Lamm, L; Lin, SN; Moody, DE; Newton, TF; Reid, MS | 1 |
| Christodoulou, C; Douzenis, A; Gournellis, R; Lykouras, LP; Rizos, E | 1 |
| Mace, S; Taylor, D | 1 |
| Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Suzuki, T | 1 |
| Assuncao-Talbott, S; Blumer, J; Boulton, DW; Findling, RL; Iwamoto, T; Kauffman, R; Kollia, G; Kornhauser, DM; Mallikaarjun, S; McQuade, RD; Sahasrabudhe, V; Salazar, DE; Sallee, FR; Vachharajani, NN | 1 |
| Bengtson, M; Edge, PJ; Murphy, TK; Mutch, PJ; Reid, JM; Storch, EA; Yang, M | 1 |
| Lai, CH | 6 |
| Bates, JA; Guo, Z; Kan, HJ; Kane, JM; Kim, E; Pikalov, A; Whitehead, R | 1 |
| Capote, HA; Gengo, FM; Rainka, MM; Ross, CA | 1 |
| Kashima, H; Kobayashi, H; Koshikawa, H; Mizuno, M; Morita, K; Takeshi, K; Yamazawa, R | 1 |
| De León, OA; Garza, VM; Shepherd, J | 1 |
| Brunetto, M; Casamassima, F; Cassano, GB; Danese, A; Lattanzi, L; Litta, A; Longobardi, A; Schiavi, E; Stange, JP; Tatulli, A | 1 |
| Chiu, CC; Hsiao, SH; Tsai, PC | 1 |
| Avenet, P; Bergis, O; Boulay, D; Griebel, G | 1 |
| de Haan, L; Peters, B | 1 |
| Chandler, GM; Fava, M; Iosifescu, DV; Pollack, MH; Targum, SD | 1 |
| Shan, JC; Tseng, MC | 1 |
| Chen, YJ; Hsueh, WC; Liao, KC; Lin, KH; Lin, YT; Lu, CL; Yen, MH | 1 |
| Deng, C; du Bois, TM; Han, M; Huang, XF | 1 |
| Do, PH; Feltenstein, MW; See, RE | 1 |
| Pesek, MB | 1 |
| Aman, MG; Carson, WH; Kamen, L; Manos, G; Marcus, RN; McQuade, RD; Owen, R | 1 |
| Dom, G; Komen, G; Van Den Eede, F | 1 |
| El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Agüera-Ortiz, L; Hurtado de Mendoza, A; Osorio, RS; Palomo, T; Ramos, I | 1 |
| Beckett, VL; Belin, D; Besson, M; Castel, A; Crittenden, BM; Dalley, JW; Everitt, BJ; McNamara, R; Newman, AH; Robbins, TW; Theobald, DE | 1 |
| Germain, C; Pasquier de Franclieu, S; Petitjean, F | 1 |
| Correll, CU; Kane, JM; Malhotra, AK; Manu, P; Napolitano, B; Olshanskiy, V | 1 |
| Ketzer, CR; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP | 1 |
| Gagliano, A; Masi, G | 1 |
| Bat-Pitault, F; Delorme, R | 1 |
| Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E | 1 |
| Wagner, KD | 1 |
| Carson, WH; Chang, K; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; McQuade, RD; Nyilas, M | 1 |
| Mailman, RB; Murthy, V | 1 |
| Coskun, M; Oztürk, M | 1 |
| Agarwal, P; Griffith, A; Hall, DA; Seeberger, LC; Segro, V | 1 |
| Hamamura, T; Kodama, M | 1 |
| Fekete, S; Herold, R; Kovacs, A; Osvath, P; Simon, M; Tenyi, T; Voros, V | 1 |
| Callen, EC; Church, CO | 1 |
| Leckband, SG; Meyer, JM; Strack, DK | 1 |
| Kim, JJ; Kim, SI; Ku, J; Park, IH; Park, JY; Park, KM | 1 |
| Carson, WH; Corey-Lisle, P; Findling, RL; Manos, G; Marcus, RN; McQuade, RD; Owen, R; Sikich, L | 1 |
| Carbray, MJ; McGuinness, T | 1 |
| Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV | 1 |
| Coffey, BJ; Goldman, R; Hirsch, S; Jummani, R; Lyon, GJ; Samar, S; Spirgel, A | 1 |
| Mavrikaki, M; Nomikos, GG; Panagis, G | 1 |
| Barnett, RJ; Cauble, S; McLaren, JL | 1 |
| Chen, ST; Hsiao, YL | 1 |
| Dassa, D; Drai-Moog, D; Samuelian, JC | 1 |
| Hashimoto, K; Ishii, D; Iyo, M; Kanahara, N; Kohno, M; Matsuda, S; Matsuzawa, D; Nakazawa, K; Ohtsuka, H; Shimizu, E; Sutoh, C | 1 |
| Adham, N; Agai-Csongor, E; Bugovics, G; Domány, G; Fazekas, K; Gyertyán, I; Hornok, K; Horváth, A; Kiss, B; Laszlovszky, I; Némethy, Z; Orosz, S; Schmidt, E; Szombathelyi, Z; Tihanyi, K | 1 |
| Hedlund, PB; Roberts, AJ; Sarkisyan, G | 1 |
| Appel, DI; Markowitz, JS; Peterson, YK; Wang, Z; Zhu, HJ | 1 |
| Conley, Y; Davies, MA; Roth, BL | 1 |
| Rocha, FF | 1 |
| Kim, CE; Lee, MJ | 1 |
| Helm, ME; Henderson, C; Martin, BC; Pathak, P; West, D | 1 |
| McIntyre, RS | 3 |
| Stip, E; Tourjman, V | 1 |
| Chiesa, A; Gibiino, S; Mandelli, L; Pae, CU; Patkar, AA; Serretti, A | 1 |
| Ansseau, M; Pitchot, W | 1 |
| Ali, M; Assunção-Talbott, S; Carson, WH; Forbes, RA; Iwamoto, T; Nyilas, M; Pikalov, A; Robb, AS; Whitehead, R | 1 |
| Chou, JC | 1 |
| Kokaçya, H; Savas, HA; Selek, S; Virit, O | 1 |
| Aitchison, KJ; McAllister, VD; McCrone, P; Mir, A; O'Keane, V; Shivakumar, K | 1 |
| Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T | 1 |
| Albayrak, Y; Caykoylu, A; Ekinci, O; Kuloglu, M | 1 |
| Roxanas, MG | 1 |
| Hanatani, T; Ikejiri, Y; Kondo, M; Sumi, N | 1 |
| Duvvuri, V; Kaye, WH; Schwartz, TA; Trunko, ME | 1 |
| Beck, A; Dembler, T; Dinges, M; Friedel, E; Gallinat, J; Heinz, A; Juckel, G; Sarkar, R; Schlagenhauf, F; Wrase, J; Wüstenberg, T | 1 |
| Anghelescu, I; Born, C; Langosch, J; Luborzewski, A; Quante, A; Schommer, N; Wolf, J; Zeugmann, S | 1 |
| Audino, B; Curtis, J; Donohue, AM; Filymer, DM; Finkel, N; Josiassen, RC; Kacso, M; Shaughnessy, RA; Skuban, N | 1 |
| Anton, RF; Vergne, DE | 1 |
| Chen, HK; Shao, CH; Wu, BJ | 1 |
| Barth, KS; Garner, A; Phan, SV; Snarr, BS; VandenBerg, AM | 1 |
| Ebrecht, M; Kungel, M; Messer, T; Modell, S; Schmauss, M; Spevakne-Goeroecs, T; Werner, C | 1 |
| Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C | 1 |
| Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Chen, VC; Chou, JY; Hsieh, MH; Yeh, CC | 1 |
| Radics, J | 1 |
| Benedetti, AM; Frazee, LA; Leung, JG; Myers, N | 1 |
| Cerovecki, A; Dehning, S; Engel, RR; Matz, J; Möller, HJ; Müller, N; Musil, R; Obermeier, M; Opgen-Rhein, M; Riedel, M; Schennach-Wolff, R; Seemüller, F; Severus, E; Spellmann, I | 1 |
| Charntikov, S; Crawford, CA; Der-Ghazarian, T; McDougall, SA; Varela, FA | 1 |
| Deng, C; Huang, XF; Lian, J; Pai, N | 1 |
| Kitamura, H; Someya, T; Yokoyama, Y | 1 |
| Friedman, JH | 2 |
| Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW | 1 |
| Fujino, J; Tabushi, K; Tanaka, H; Taniguchi, N | 1 |
| Manoj, P; Skopek, M | 1 |
| Baudelet, C; Marcus, RN; McQuade, RD; Owen, R; Sanchez, R; Vieta, E | 1 |
| Hwu, HG; Lai, MC; Liu, CC; Sheu, YH; Wu, SY | 1 |
| Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP | 1 |
| Akaike, A; Izumi, Y; Kume, T; Matsuo, T; Sawada, H; Takada-Takatori, Y; Wakita, S | 1 |
| Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K | 1 |
| Chiesa, A; Pae, CU; Serretti, A | 1 |
| Berman, RM; Carlson, BX; Eudicone, JM; Marchant, BK; Marcus, RN; Martin, ML; Pikalov, A; Reimherr, FW; Tran, QV | 1 |
| Inada, K; Ishigooka, J; Oshibuchi, H | 1 |
| Baker, RA; Calabrese, JR; Eudicone, JM; Kemp, DE; Pikalov, A; Tran, QV | 1 |
| Chi, CH; Hsieh, PH; Hwang, KS; Lin, CE; Tzeng, NS | 1 |
| Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
| Fleischhacker, WW; Hoertnagl, C; Hofer, A; Pfaffenberger, N | 1 |
| Remington, G | 1 |
| Arand, J; Farger, G; Hiemke, C; Lutz, UC; Wiatr, G; Wildgruber, D | 1 |
| Guirguis-Blake, J | 1 |
| Hamidin, A; Normala, I | 1 |
| Chen, H; Chen, YH; Liu, YY; Liu, ZS | 1 |
| Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD | 1 |
| Hara, C; Ramos, MG; Rocha, FL | 1 |
| Akiyama, S; Forbes, A; Futamura, T; Kikuchi, T; McQuade, RD; Sugino, H | 1 |
| Kozumplik, O; Sedić, B; Uzun, S | 1 |
| Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Voronin, K | 1 |
| Chiang, CP; Tzeng, NS | 1 |
| Cohen, J; Gavaudan, G; Lançon, C; Léonetti, G; Magalon, D; Pélissier-Alicot, AL | 1 |
| Carter, WG; Lauterbach, EC; Norris, BK; Shillcutt, SD | 1 |
| Kapur, S; Patel, MX; Sparshatt, A; Taylor, D | 1 |
| Kibbey, KJ; Nicholson, GC; Roberts, AM | 1 |
| Hiemke, C; Holthoewer, D; Kirschbaum, KM; Namendorf, C; Pietrzik, C; Schmitt, U; Uhr, M | 1 |
| Campanella, D; De Berardis, D; Di Giannantonio, M; Marasco, V; Moschetta, FS; Serroni, N | 1 |
| Akaike, A; Izumi, Y; Kume, T; Matsuo, T; Sawada, H; Takada-Takatori, Y | 1 |
| Andoh, H; Kato, K; Matsumoto, H | 1 |
| Kovács, G | 1 |
| Tényi, T; Vörös, V | 1 |
| Banaschewski, T; Frölich, J; Lehmkuhl, G; Starck, M | 1 |
| Chen, VC; Chou, JY; Robson, D; Yu, SH | 1 |
| Lazarus, A; Quon, P; Tafesse, E; Woodward, TC | 1 |
| Chen, J; Deng, C; Hu, C; Huang, XF | 1 |
| Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 2 |
| Brunetti, L; Patel, MK | 1 |
| Chang, CC; Chen, SH; Hwang, PL; Ko, JY; Wei, SY; Yeh, HH | 1 |
| Abler, B; Gahr, M; Orth, M | 1 |
| Konstantakopoulos, G; Kouzoupis, AV; Mourikis, I; Oulis, P; Papageorgiou, SG | 1 |
| Kaneko, YS; Mori, K; Nagatsu, T; Nakashima, A; Ota, A; Ota, M; Takami, G | 1 |
| Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Biojone, C; Casarotto, PC; Guimarães, FS; Moreira, FA; Resstel, LB; Zangrossi, H | 1 |
| Ozdemir, B; Uzun, O | 1 |
| Carson, WH; El Mallakh, RS; Marcus, R; McQuade, R; Rollin, L; Vieta, E | 1 |
| Chen, CK; Hsiao, CC; Huang, YS; Ree, SC | 1 |
| Jackson, CW; Lorenz, RA; Saitz, M | 1 |
| Cui, YH; Li, J; Liu, J; Yang, YP; Zheng, Y | 1 |
| Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N | 1 |
| Berman, RM; Carlson, BX; Eudicone, JM; Khan, A; Pikalov, A; Tran, QV; Trivedi, MH; Weisler, RH; Yang, H | 1 |
| Jankovic, J; Peña, MS; Yaltho, TC | 1 |
| Andersson, C; Berman, RM; Carlson, BX; Eudicone, JM; Forbes, RA; Nelson, JC; Steffens, DC; Tran, QV; Yang, H | 1 |
| Chiesa, A; Mandelli, L; Pae, CU; Serretti, A | 1 |
| Chen, CH; Cheng, MC; Hsu, SH | 1 |
| Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y | 1 |
| Baker, RA; Chambers, JS; Eudicone, JM; Kemp, DE; McQuade, RD | 1 |
| Hori, H; Nakamura, J; Okamoto, T; Umene-Nakano, W; Yoshimura, R | 1 |
| Janicak, PG; Rado, J | 1 |
| Chou, YH; Wang, SJ; Wu, CL; Yang, KC | 1 |
| Greenway, LL; Kuppuswamy, PS; Lauterbach, EC | 1 |
| Kirino, E | 2 |
| De Fazio, P; Girardi, P; Maina, G; Mauri, M; Mauri, MC; Monteleone, P; Perini, GI; Perugi, G; Rossi, A | 1 |
| Carson, W; Cziraky, MJ; Delorenze, G; Niemcryk, SJ; Oliveria, SA; Phillips, S; Quesenberry, CP; Skovron, ML; Tsai, AL; Ulcickas Yood, M; Wells, K; Willey, VJ | 1 |
| Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M | 1 |
| Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW | 1 |
| Atallah, AN; Melnik, T; Puga, ME; Soares, BG | 1 |
| Chen, CH; Chiu, YH; Lu, ML | 1 |
| Aman, MG; Kasper, W; Mankoski, R; Manos, G; Marcus, R; Mathew, S; Owen, R | 1 |
| Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG | 1 |
| Gialloreti, LE; Guida, S; Pardini, M | 1 |
| Fountoulakis, KN; Schmidt, F; Vieta, E | 1 |
| Fukui, N; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Gen, K; Inoue, Y; Suzuki, H | 1 |
| Akamine, Y; Inoue, Y; Kojima, M; Uno, T; Yasui-Furukori, N | 1 |
| Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R | 1 |
| Calabrese, JR; Carlson, BX; Eudicone, JM; Ganocy, S; Kemp, DE; Marcus, RN; McQuade, RD; Owen, R; Tran, QV; Vester-Blokland, E | 1 |
| Ardizzone, I; Carratelli, TI; Ferrara, M; Marconi, A; Nardecchia, F | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| Bastiampillai, T; Lander, M | 1 |
| Calas, AG; Goursaud, S; Hermans, E; Jeanjean, AP; Koener, B; Maloteaux, JM; Van De Stadt, M | 1 |
| Enoksen, TB; Hendset, M; Hermann, M; Molden, E; Refsum, H | 1 |
| Brecher, M; Calabrese, JR; Carlson, BX; Edwards, S; Eudicone, JM; Evoniuk, G; Ganocy, SJ; Jansen, W; Kemp, DE; Leon, AC; Minkwitz, M; Pikalov, A; Stassen, HH; Szegedi, A; Tohen, M; Van Willigenburg, AP | 1 |
| Chen, J; Gao, K; Kemp, DE | 1 |
| Fernalld, R; Jordan, S; Kambayashi, J; Kikuchi, T; Koprivica, V; Murphy, JJ; Regardie, K; Wolff, C | 1 |
| Bolaños-Vergaray, J; Echeverri, C; Gonzalez, R; Obaya, JC; Piquer, P | 1 |
| Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL | 1 |
| Berloffa, S; Masi, G; Millepiedi, S; Pfanner, C | 1 |
| Guerdjikova, A; Keck, PE; McElroy, SL; Mori, N | 1 |
| Christopher, EJ; Gagliardi, JP; Kahn, DA; Muzyk, AJ | 1 |
| Ascher-Svanum, H; Faries, DE; Kane, JM; Osuntokun, OO; Peng, X; Stauffer, VL; Stensland, MD | 1 |
| Chang, CH; Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Bhutani, T; Busse, KL; Koo, JY; Ladizinski, B | 1 |
| McKinney, C; Renk, K | 1 |
| Ramaswamy, S; Selvaraj, V; Sharma, A; Wilson, D | 1 |
| Ekinci, O; Sabuncuoglu, O | 1 |
| Correll, CU | 1 |
| Lee, SY; Pae, CU; Park, MH; Patkar, AA | 1 |
| Cohn, T; Faulkner, G; Mukundan, A; Remington, G | 1 |
| Depping, AM; Gaudchau, A; Kissling, W; Komossa, K; Leucht, S | 1 |
| Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T; Uno, T | 1 |
| Leinonen, E; Valtonen, HM; Viikki, M | 1 |
| Bäckström, P; Etelälahti, TJ; Hyytiä, P | 1 |
| Lee, J; Ng, KW; Swapna, V | 1 |
| Kan, HJ; King, D; Knapp, M; Loze, JY; Razzouk, D; Thomas, P; van Baardewijk, M | 1 |
| Gupta, S; Jesudasan, J; Solomon, S | 1 |
| Choi, SH; Hong, JP; Kim, JE; Lee, JS; Paik, KW; Yoo, HK; Yoon, SJ | 1 |
| Arends, J; Cohen, D; van Kooten, M | 1 |
| Chiang, CL; Liu, CC | 1 |
| Albayrak, Y; Caykoylu, A; Ekinci, O; Ugurlu, GK | 1 |
| Katzman, MA | 1 |
| Yatham, LN | 1 |
| Blier, P; Blondeau, C | 1 |
| Kim, LW; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Shin, BS | 1 |
| Gumus, S; Kamberyan, K; Saatcioglu, O; Yanik, M | 1 |
| Boyer, L; Christophe, L; Cohen, J; Magalon, D; Simon, N | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Forbes, A; Pae, CU; Patkar, AA | 1 |
| Casamassima, F; Fagiolini, A; Forgione, RN; Marra, FS; Nitti, M | 1 |
| Bruno, A; Di Nardo, F; Micò, U; Muscatello, MR; Pandolfo, G; Santoro, V; Scimeca, G; Spina, E; Zoccali, RA | 1 |
| Chen, CY; Lin, TY; Shuai, HA; Wang, CC | 1 |
| Leelahanaj, T | 1 |
| Aman, MG; Farmer, CA | 1 |
| Frost, M; Marcus, RM; McQuade, RD; Sanchez, R | 1 |
| Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M | 1 |
| Atli, A; Aydin, A; Besiroglu, L; Ozdemir, O; Ozdemir, P; Selvi, Y | 1 |
| Erickson, CA; Kohn, A; McDougle, CJ; Mullett, JE; Posey, DJ; Stigler, KA; Wink, LK | 1 |
| Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI | 1 |
| Gründer, G; Klomp, M; Schiffl, K; Schorn, H; Vernaleken, IB; Veselinović, T | 1 |
| Bruno, A; Micò, U; Muscatello, MR; Pandolfo, G; Romeo, VM; Santoro, V; Scimeca, G; Settineri, S; Spina, E; Zoccali, RA | 1 |
| Kobayashi, T | 1 |
| Chen, CM; Frankle, WG; Himes, M; Keating, P; Laruelle, M; Mason, NS; Mathis, CA; May, MA; Narendran, R; Rabiner, EA | 1 |
| Atli, A; Aydin, A; Selvi, Y; Yener, HI | 1 |
| Foltin, RW; Haney, M; Rubin, E | 1 |
| Bernagie, C; De Hert, M; Dockx, L; Leucht, S; Peuskens, B; Peuskens, J; Sweers, K; Tack, J; Van de Straete, S; Wampers, M | 1 |
| Hashimoto, K; Iyo, M; Kanahara, N; Okamura, N; Sekine, Y; Tadokoro, S | 1 |
| Hackett, LP; Ilett, K; Nguyen, T; Teoh, S | 1 |
| Ikawa, M; Imai, N | 1 |
| Aleman, A; Bous, J; Hollander, K; Knegtering, H; Liemburg, E | 1 |
| Ak, M; Bozkurt, A; Bulut, SD; Ozsahin, A | 1 |
| Carson, W; Khan, A; Marcus, R; Morris, B; Rollin, L; Sanchez, R; Timko, K | 1 |
| De Risio, A; Gentile, B; Giannarelli, D; Pancheri, A; Simonetti, G; Stefanutto, L | 1 |
| Bruzek, JL; Jerome, RN; Krishnaswami, S; McPheeters, ML; Sathe, N; Veenstra-Vanderweele, J; Warren, Z | 1 |
| Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M | 1 |
| Caccia, S | 1 |
| Ferbert, T; Gass, P; Gebicke-Haerter, PJ; Schmitt, A; Segnitz, N; Zink, M | 1 |
| Han, YH; Hashioka, S; Hirata, E; Horikawa, H; Inoguchi, T; Kanba, S; Kasai, M; Kato, TA; Maeda, Y; Mizoguchi, Y; Monji, A; Seki, Y; Sonoda, N; Utsumi, H; Yasukawa, K | 1 |
| Curran, MP | 2 |
| Imamura, Y; Makihara, Y; Yamada, K | 1 |
| Larose-Pierre, M; Lewis, K; Rappa, L; Sherwood-Jachimowicz, DA | 1 |
| Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A | 1 |
| Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY | 1 |
| Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D | 1 |
| Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Yu, KS | 1 |
| Ameglio, M; Biasci, L; Cecconi, D; Cellesi, V; Forgione, RN; Meini, M; Moncini, M; Pellegrini, M; Rucci, P; Simoni, G | 1 |
| Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA | 1 |
| Fagiolini, A; Frieri, T; Villari, V | 1 |
| Chiang, KT; Huang, LC | 1 |
| Kasahara, M; Murashima, A; Nakajima, K; Nakamura, T; Sugibayashi, R; Watanabe, N; Watanabe, O | 1 |
| Carlsson, A; Carlsson, ML; Johansson, AM; Rung, E; Rung, JP; Svensson, K | 1 |
| Bearden, M; Cui, J; Luedtke, RR; Mach, RH; Taylor, M; Vangveravong, S; Wang, W; Xu, J; Zhang, Z | 1 |
| Bouckaert, F; De Schutter, P; Peuskens, J | 1 |
| Alexander, J; Lecamwasam, DL | 1 |
| Chiu, NY; Hsu, WY; Lee, BS; Liao, YC; Lin, TW | 1 |
| Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M | 1 |
| Healy, D; Jureidini, JN; Parry, PI; Rosenlicht, NZ; Spielmans, GI; Tsai, AC | 1 |
| Boettger, S; Breitbart, W; Friedlander, M; Passik, S | 1 |
| Fikretoglu, D; Liu, A; McIntosh, D; Richardson, JD | 1 |
| Bang, L; Harris, TB; Mian, A; Muscal, E | 1 |
| Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K | 1 |
| Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N | 1 |
| Chan, CH; Chiu, HJ; Lan, TH; Loh, el-W; Tsai, CJ; Wang, JT; Yu, YH | 1 |
| Gründer, G; Gur, R; Hiemke, C; Schiffl, K; Schorn, H; Vernaleken, I; Veselinović, T; Zernig, G | 1 |
| De Carolis, L; Milella, MS; Nencini, P; Schepisi, C | 1 |
| Aman, MG; Carson, WH; Corey-Lisle, PK; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R | 1 |
| Hou, YC; Lai, CH | 2 |
| Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R | 1 |
| Glaser, PE; Hays, LR; Rush, CR; Sevak, RJ; Stoops, WW; Vansickel, AR | 1 |
| Koran, LM; White, MP | 1 |
| Fitzgerald, ME; Fodstad, JC; Matson, JL; Sipes, M | 1 |
| Chen, CC; Liu, HC | 1 |
| Bous, J; de Boer, MK; Hamamura, T; Knegtering, H; Sytema, S; van der Moolen, AE; Wiersma, D; Wilffert, B | 1 |
| Fukui, N; Ono, S; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Alexopoulos, GS; Avari, J; Mahgoub, N | 1 |
| Bellantuono, C; Gentile, S; Tofani, S | 1 |
| Gagliardi, JP; Jiang, W; Muzyk, AJ; Revollo, JY; Rivelli, SK | 1 |
| Calì, PV; Cavanna, AE; Eddy, C; Gulisano, M; Rickards, H; Rizzo, R | 1 |
| Bertani, S; Carboni, L; Cavanni, P; Fratte, SD; Michielin, F; Negri, M; Oliosi, B | 1 |
| Azuma, J; Fujiwara, T; Hara, S; Hasunuma, T; Higashi, K; Katano, T; Kitahara, S; Koue, T; Kubo, M; Miyatake, M | 1 |
| Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C | 1 |
| Catapano, F; Esposito, G; Fabrazzo, M; Maj, M; Monteleone, P; Perris, F | 1 |
| Chang, JP; Chen, YT; Su, KP | 1 |
| Bowden-Jones, H; Kitchenham, N; Smith, N | 1 |
| Ivanova, A; Qaqish, B; Schoenfeld, DA | 1 |
| de Arce Cordón, R; Eding, E; Marques-Teixeira, J; Milanova, V; Rancans, E; Schreiner, A | 1 |
| Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R | 1 |
| Carson, WH; Forbes, RA; Mankoski, R; Mathew, SJ; Zhao, J | 1 |
| Calabrese, JR; Demeter, CA; Findling, RL; Frazier, TW; Lingler, J; McNamara, NK; Otto, BD; Rowles, BM; Stansbrey, RJ; Youngstrom, EA | 1 |
| Cavanna, AE; Eddy, CM; Luoni, C; Rickards, H; Selvini, C; Termine, C | 1 |
| Biswas, J; Gandhi, RA; George, RJ; Nair, AG | 1 |
| Belgamwar, RB; El-Sayeh, HG | 2 |
| Chou, J; Chung, MT; Lin, CH; Ma, H | 1 |
| Bagalman, E; Carls, GS; Curkendall, SM; Forbes, RA; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Camacho, LR; Celso, F; Da Rosa, KM; Da Silva, TG; Dos Santos, Bde J; Freitas, TM; Monteiro, JD; Pereira, P; Picada, JN; Pontes, VM; Vieira, LR | 1 |
| Berge, RK; Diéguez, C; Fernø, J; Fjær, S; López, M; Lunder, N; Pavlin, T; Skrede, S; Steen, VM; Vázquez, MJ; Vidal-Puig, A | 1 |
| Bechdolf, A; Brüne, M; de Millas, W; Gaebel, W; Heinz, A; Janssen, B; Klosterkötter, J; Krüger-Özgürdal, S; Lambert, M; Lautenschlager, M; Maier, W; Michel, TM; Müller, H; Naber, D; Riedel, M; Schneider, F; Stützer, H; Wagner, M; Wobrock, T | 1 |
| Kurokawa, K; Ohkuma, S; Shibasaki, M | 1 |
| Jang, FL; Lin, CH; Lin, SH | 1 |
| Bosier, B; Focant, MC; Hermans, E; Koener, B; Maloteaux, JM | 1 |
| Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z | 1 |
| Weiden, PJ | 1 |
| Bauer, LK; Januzzi, JL; Leskov, I; Mukherji, EH; Tanev, KS | 1 |
| Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK | 1 |
| Babu, GN; Chandra, P; Kumar, R; Saddichha, S | 1 |
| Bervoets, C; Constant, E; de Patoul, A; Delatte, B; Gillain, B; Halkin, V; Kok, F; Loze, JY; Peuskens, J; Touquet, G; Vansteelandt, K | 1 |
| Motomura, E; Nakagawa, M; Okada, M; Tanahashi, S; Yamamura, S | 1 |
| Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
| Fava, M; Hsieh, WH; Levy, M; Mischoulon, D; Papakostas, GI; Pencina, MJ; Pet, LR; Pollack, MH; Ward, S; Witte, J | 1 |
| Chang, KY; Wu, YF | 1 |
| Body, S; Bradshaw, CM; de Bruin, N; den Boon, FS; Hampson, CL; Szabadi, E | 1 |
| Bastiampillai, T; Dhillon, R; Goh, T | 1 |
| Akyol Ardic, U; Ardıc, UA; Ercan, E; Ercan, ES; Uysal, T | 1 |
| Burda, K; Czubak, A; Kus, K; Nowakowska, E; Ratajczak, P; Zin, J | 1 |
| Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T | 1 |
| Ishitobi, M; Kosaka, H; Murata, T; Oonuma, M; Takahashi, T; Wada, Y | 1 |
| Fleischhacker, WW; Han, C; Lee, SJ; Masand, PS; Pae, CU; Park, MH; Patkar, AA | 1 |
| Abbar, M; Ågren, H; Altamura, AC; Bellivier, F; Fountoulakis, KN; Goodwin, GM; Grunze, H; Holsboer-Trachsler, E; Licht, RW; Pitchot, W; Schlaepfer, TE; Vieta, E | 1 |
| Chen, CK; Lin, SK; Liu, YL | 1 |
| Endo, T; Fukui, N; Ono, S; Shindo, M; Someya, T; Sugai, T; Suzuki, Y | 1 |
| Christoffersen, RK; Høimark, L; Vesterby, A; Vestergård, LD | 1 |
| Ahmed, SU; Hossain, MA; Plakogiannis, FM | 1 |
| Barnett, M; Calarge, C; Holman, T; Kolar, A; Kuperman, S; Perry, P | 1 |
| Capote, E; Ezequiel, U; Paez, R; Wix-Ramos, RJ | 1 |
| Chen, YH; Liao, JX; Liu, ZS; Sun, D; Wang, DB; Wang, H; Zhong, YQ; Zou, LP | 1 |
| Boettger, S; Breitbart, W | 1 |
| Bundgaard, C; Garmer, M; Jensen, CJ | 1 |
| Hayashida, K; Kiriike, N; Maebayashi, K; Matsunaga, H; Mito, H | 1 |
| Ahn, YM; Bahk, WM; Chung, MY; Chung, SK; Kim, DH; Kim, JG; Lee, JH; Lee, KH; Paik, KC; Woo, YS; Yoon, BH | 1 |
| Karadağ, F; Tan, D; Unal, F | 1 |
| Hartmann, A; Lehéricy, S; Palminteri, S; Pessiglione, M; Vidailhet, M; Worbe, Y | 1 |
| Adegbite, C; Calabrese, JR; Demeter, CA; Findling, RL; Frazier, TW; McNamara, NK; Rowles, BM; Stansbrey, RJ; Wynbrandt, JL; Youngstrom, EA | 1 |
| Cavanna, AE; Rickards, H; Worrall, R | 1 |
| Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, BH; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Turkheimer, FE | 1 |
| Bschor, T; Erbe, S; Gutwinski, S | 1 |
| Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB | 2 |
| Dhillon, S | 1 |
| Dalton, ED; Dording, CM; Fava, M; Mischoulon, D; Pencina, MJ | 1 |
| Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Mori, A; Niwa, S; Numata, Y; Takeuchi, S; Yang, Q | 1 |
| Baudelet, C; Carson, WH; El-Mallakh, RS; Marcus, R; McQuade, R; Owen, R | 1 |
| Brotzge, K; El-Mallakh, RS; Manshadi, M | 1 |
| Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H | 1 |
| Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R | 1 |
| Baker, RA; Berman, RM; Camacho, TA; Chambers, JS; Eudicone, JM; Forbes, RA; Muzina, DJ | 1 |
| Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U | 1 |
| Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
| Jaśkowska, J; Kowalski, P | 1 |
| Arakawa, R; Fujiwara, H; Ito, H; Kato, M; Kimura, Y; Kodaka, F; Mimura, M; Nagashima, T; Nogami, T; Sasaki, T; Shimada, H; Suhara, T; Suzuki, M; Takahata, K; Takano, H | 1 |
| Chung, YC; Huang, GB; Lee, KH; Park, CH; Park, MS; Park, TW; Tong, Z; Yang, JC | 1 |
| Asano, M; Hiratani, M; Ishitobi, M; Kosaka, H; Mizuno, T; Murata, T; Takahashi, T; Tomoda, A; Wada, Y | 1 |
| Akiyoshi, J; Hanada, H; Higuma, H; Ishitobi, Y; Isogawa, K; Kanehisa, M; Kodama, K; Maruyama, Y; Tanaka, Y; Tsuru, J | 1 |
| Bartlett, MG; Liang, F; Terry, AV | 1 |
| Tomba, E | 1 |
| Bou Khalil, R; Dahdah, P; Kahn, DA; Richa, S | 1 |
| Fava, M; Flynn, M; Harper, L; Iosifescu, D; Levy, M; Mischoulon, D; Pencina, M; Pollack, M; Rickels, K; Witte, J | 1 |
| Paille, F | 1 |
| Kurokawa, K; Mizuno, K; Ohkuma, S; Shibasaki, M | 1 |
| Croxtall, JD | 1 |
| Bowden, CL; Carlson, BX; Eudicone, JM; Marcus, R; McQuade, RD; Nashat, M; Thase, ME | 1 |
| Goto, S; Terao, T; Tomita, M; Uchimura, N | 1 |
| Caloro, M; Casolla, B; Cuomo, I; De Filippis, S; De Persis, S; Girardi, P; Kotzalidis, GD; Lionetto, L; Pucci, D; Sciarretta, A; Simmaco, M; Simonetti, A | 1 |
| Carlson, BX; Ketter, TA; Marcus, R; McQuade, RD; Sanchez, R; Sun, W; Timko, K; Vester-Blokland, E | 1 |
| Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C | 1 |
| Jindal, KC; Munjal, V; Singh, GP | 1 |
| Ahlbrand, R; Bronson, SL; Grainger, M; Horn, P; McNamara, RK; Richtand, NM; Tambyraja, R | 1 |
| Andrade, C; Chittaranjan, AC; Mendhekar, DN | 1 |
| Berloffa, S; Calarese, T; Cedro, C; Gagliano, A; Ilardo, G; Magazù, A; Masi, G; Pfanner, C; Siracusano, R | 1 |
| Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T | 5 |
| Hashimoto, N; Ito, K; Koyama, T; Kusumi, I; Matsuda, N | 1 |
| Itoh, M; Kaneko, YS; Kondo, K; Mori, K; Nagasaki, H; Nagatsu, T; Nakashima, A; Ota, A; Ota, M; Takayanagi, T | 1 |
| Hon, A | 1 |
| Doey, T | 1 |
| Han, C; Jeong, HG; Joe, SH; Ko, YH; Lee, HY; Lee, MS | 1 |
| Johnsen, E; Kroken, RA | 1 |
| Chang, LR; Huang, WL | 2 |
| Ammerman, DK; Carson, WH; Corey-Lisle, PK; Guo, Z; Handen, BL; Mankoski, R; Manos, G; Marcus, RN; Mathew, S; McQuade, RD; Owen, R; Varni, JW | 1 |
| Miranda C, M; Retamal C, P | 1 |
| Rittmannsberger, H; Werl, R | 1 |
| Knoepflmacher, D; Shapley, L; Turner, EH | 1 |
| Pomeraniec, F; Primeau, M; Wallace, DM | 1 |
| Alsop, DC; Dazzan, P; Handley, R; Johnston, A; Kapur, S; Marques, TR; McGuire, P; Mehta, MA; O'Gorman, R; Pariante, CM; Reinders, AA; Taylor, H; Williams, S; Zelaya, FO | 1 |
| Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
| Baker, RA; Bellocchio, EE; Berman, RM; Eudicone, JM; Marcus, RN; McQuade, RD; Nelson, JC; Rollin, LM; Thase, ME | 1 |
| Brittain, HG | 1 |
| Bradford, DW; Butterfield, MI; Hertzberg, MA; Kilts, JD; Marx, CE; Naylor, JC; Strauss, JL; Youssef, NA; Zinn, S | 1 |
| Dunn, G; French, P; Hutton, P; Morrison, AP; Taylor, PJ; Yung, AR | 1 |
| Gill, JS; Guan, NC; Hussein, HM; Said, MA; Sulaiman, AH; Zainal, NZ | 1 |
| Cottencin, O; Geoffroy, PA; Goddefroy, G; Rolland, B | 1 |
| Chadman, KK; Guariglia, SR; Yoo, JH | 1 |
| Anandarajan, T; Bastiampillai, T; Dhillon, R; Tibrewal, P | 1 |
| Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D | 1 |
| Catani, M; Craig, M; Jordan, I; Murphy, D; Robertson, D | 1 |
| Djuric, Z; Graovac, A; Ibric, S; Kachrimanis, K; Mihajlovic, T | 1 |
| Bivas, R; Chahal, L; Fung, LK; Hardan, AY; Libove, RA | 1 |
| Ishigooka, J; Kanba, S; Kawasaki, H; Kinoshita, T; Kuroki, T; Sakamoto, K | 1 |
| Meltzer, HY; Porter, JH; Vunck, SA; Wiebelhaus, JM | 1 |
| Das, S; Ganguly, A; Ghosh, A; Kumar Das, A; Mondal, S; Saha, I | 1 |
| Baker, RA; Forbes, RA; Jing, Y; Oster, G; Papakostas, GI; Taneja, C | 1 |
| Kikuchi, T; Tadori, Y | 1 |
| Lowry, JP; O'Connor, JJ | 1 |
| Ching, H; Pringsheim, T | 1 |
| Hofer, A; Widschwendter, CG | 1 |
| Harrison, C | 1 |
| Baggio, R; Freire, E; Polla, G | 2 |
| Khemiri, L; Moreira, T; Runeson, L | 1 |
| Magno Zito, J; Safer, AM; Safer, DJ | 1 |
| Jean-Baptiste, M; Mukai, Y; Two, A | 1 |
| Calì, PV; Gulisano, M; Rizzo, R | 1 |
| Carson, WH; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Sanchez, R | 1 |
| Kawohl, W; Neuner, I; Nordt, C; Schneider, F | 1 |
| Abdallah, CG; Hong, X; Huang, H; Huang, Q; Jiang, L; Liang, C; Liu, Y; Wan, X; Wang, J; Wu, R; Xu, C; Zhang, J | 1 |
| Nasti, JJ | 1 |
| Fleischhacker, WW; Uchida, H | 1 |
| Bokemeyer, S; Kleimann, A; Müller-Vahl, KR; Wenzel, C | 1 |
| Isogai, S; Kasai, E; Mori, N; Morimoto, S; Nakasato, K; Suzuki, K; Takagai, S | 1 |
| Citraro, R; Davoli, A; De Sarro, G; Di Paola, ED; Gallelli, L; Russo, E | 1 |
| Cottencin, O; Geoffroy, PA; Guardia, D; Rolland, B; Warembourg, F | 1 |
| Di Rosa, G; Imbesi, D; Magaudda, A | 1 |
| Ghanizadeh, A | 2 |
| Bobmanuel, S; Davies, W; Dratcu, L; Farmer, A; George, M; Rana, T; Singh, M; Turner, M | 1 |
| Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
| Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB | 1 |
| Kollias, K; Konstantakopoulos, G; Nathanailidis, E; Oulis, P; Tsiamoura, M | 1 |
| Caramelli, P; Oliveira, LC; Rocha, FL | 1 |
| Bradshaw, B; Henry, J; Macedo, LR; Marino, J | 1 |
| Bai, X; Chen, M; Chen, X; Frye, SV; Jin, J; Roth, BL; Sassano, MF; Setola, V; Wetsel, WC; Zheng, L | 1 |
| Iwatsubo, T; Kawamura, A; Nagasaka, Y; Oda, K; Usui, T | 1 |
| Caldwell, RL; Erickson, CA; Ho, JG; McDougle, CJ; Orsagh-Yentis, DK; Posey, DJ; Stigler, KA | 1 |
| Alvir, JM; Berger, A; Edelsberg, J; Mychaskiw, MA; Oster, G; Sanders, KN | 1 |
| Moteshafi, H; Stip, E | 1 |
| Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP | 1 |
| Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K | 1 |
| Boostani, H; Ghaffari, SM; Hoseini, A; Sayyah, M | 1 |
| Borba, CP; Copeland, P; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC | 1 |
| Boulton, DW; Kollia, GD; Kornhauser, DM; Mallikaarjun, S | 1 |
| de Bartolomeis, A; Perugi, G | 1 |
| Gebicke-Haerter, PJ; Peselmann, N; Schmitt, A; Zink, M | 1 |
| Chaumartin, N; Lachaux, B; Monville, M | 1 |
| Lian, R; Liu, X; Lu, Y; Wu, W; Xu, Y; Yin, Z; Zheng, S | 1 |
| Alexander, J; Bickerstaff, S | 1 |
| Nightingale, S | 1 |
| Yui, K | 1 |
| Bervoets, C; Constant, E; de Patoul, A; Halkin, V; Kok, F; Morrens, M; Peuskens, J; Pitsi, D; Sabbe, B; Vansteelandt, K | 1 |
| Kato, M; Kinoshita, T; Nishida, K; Okugawa, G; Sakai, S; Suwa, A; Takekita, Y; Wakeno, M | 1 |
| Ahn, ES; Pidcock, FS; Sanz, JH; Slomine, BS; Wachtel, LE; Yap, JL | 1 |
| Bauer, MS; Kilbourne, AM; Lai, Z; Mohr, DC; Penfold, RB; Seibert, MN | 1 |
| Arakawa, R; Ito, H; Kodaka, F; Nogami, T; Suhara, T; Suzuki, M; Takahashi, H; Takahata, K; Takano, H | 1 |
| Motomura, E; Nakagawa, M; Okada, M; Shiroyama, T; Tanii, H; Yamamura, S | 1 |
| Dimitrakopoulos, S; Kollias, K; Konstantakopoulos, G; Oulis, P; Tsaltas, E | 1 |
| Higuchi, H; Sato, K; Yoshida, K | 1 |
| Andersson, C; Findling, RL; Mankoski, R; Marcus, R; McQuade, R; Youngstrom, EA; Zhao, J | 1 |
| Hashimoto, K; Ishima, T; Iyo, M | 2 |
| Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T | 1 |
| Coffey, DB; John, N; Potter, PO | 1 |
| Akhtar, U; Ambrosini, PJ; Lobach, L; Oluwabusi, OO; Youngman, B | 1 |
| Stern, AP; Trieu, ML | 1 |
| Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
| Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E | 1 |
| de Andrés, F; de la Rubia, A; Dorado, P; González, AP; González, I; Llerena, A; Naranjo, ME; Peñas-Lledó, EM | 1 |
| Attademo, L; Moretti, P; Quartesan, R | 1 |
| Aman, MG; Arnold, LE; Butter, E; Handen, B; Humphries, K; Lecavalier, L; Li, X; McDougle, CJ; Scahill, L; Stigler, KA; Swiezy, NB; Wilson, K | 1 |
| Brunetti, M; Dezi, S; Di Tizio, L; Grandinetti, P; Martinotti, G; Pozzi, G | 1 |
| Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Gründer, G; Gur, R; Hiemke, C; Schorn, H; Vernaleken, IB; Veselinovic, T; Zernig, G | 1 |
| Blagojević, D; Lečić-Toševski, D; Miljević, Č; Niketić, V; Nikolić, M; Nikolić-Kokić, A; Spasić, MB | 1 |
| Calí, P; Cavanna, AE; Eddy, CM; Gulisano, M; Rizzo, R | 1 |
| Chung, YC; Huang, GB; Kim, MG; Oh, KY; Park, TW; Yang, JC; Zhao, T | 1 |
| Lin, CC; Lin, HY; Liu, CC | 1 |
| Goga, JK; Kaplan, D; Khushalani, S; Seidel, L; Walters, JK | 1 |
| Landowski, J; Wichowicz, H; Wilkowska, A | 1 |
| Eisenstein, M | 1 |
| Hartmann, A; Worbe, Y | 1 |
| Gyertyán, I; Kiss, B; Román, V; Sághy, K; Szombathelyi, Z | 1 |
| Adams, CE; Jones, H; Powney, MJ | 1 |
| Aguiar, DC; Almeida-Santos, AF; Moreira, FA; Viana, TG | 1 |
| Hiranyatheb, T; Ittasakul, P; Ketter, TA; Srivastava, S | 1 |
| Coffin, PO; Colfax, GN; Das, M; Gasper, J; Huffaker, S; Matheson, T; Santos, DM; Santos, GM; Vittinghoff, E | 1 |
| Caron, MG; Jacobsen, JP; Peterson, SM; Snyder, JC; Urs, NM | 1 |
| Czoty, PW; Nader, MA | 1 |
| Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA | 1 |
| Aulisa, AG; Bocchino, L; Marzetti, E; Scudieri, G; Teramo, S | 1 |
| Chang, HC; Chang, LR; Huang, WL; Liu, CM; Tsai, YF | 1 |
| Cho, AR; Kang, WS; Park, JK | 1 |
| Plotnikoff, GA | 1 |
| Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z | 1 |
| Forbes, RA; Guo, Z; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, BH; Kim, E; Kim, JW; Kwon, JS; Lee, JS; Shin, SG; Turkheimer, FE | 1 |
| Bouvard, S; Ciumas, C; d'Amato, T; Daléry, J; Lerond, J; Lothe, A; Poulet, E; Ryvlin, P; Saoud, M | 1 |
| Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Liu, CC; Liu, CM | 1 |
| Bojarski, AJ; Duszyńska, B; Grychowska, K; Jastrzębska-Więsek, M; Lenda, T; Marciniec, K; Maślankiewicz, A; Nowak, G; Partyka, A; Pawłowski, M; Satała, G; Siwek, A; Wesołowska, A; Wróbel, D; Zajdel, P | 1 |
| Anttila, E; Lahti, A; Räsänen, P; Riala, K | 1 |
| Perry, CL; Reeves, RR | 1 |
| Ammerman, D; Baker, RA; Carlson, BX; Fountoulakis, KN; Fyans, P; Marler, SV; Rahman, Z; Yatham, LN | 1 |
| Chen, L; Zhou, Z; Zhu, H | 1 |
| Bienroth, M; Curtis, V; Debenham, M; George, M; Gonzalez, D; Jones, S; Pitsi, D | 1 |
| Choi, JE; Han, DH; Kim, SM; Min, KJ; Renshaw, PF | 1 |
| Bader, M; Klingerman, CM; Lynch, CJ; Stipanovic, ME | 1 |
| Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W | 1 |
| Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S | 1 |
| Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M | 1 |
| De Deyn, PP; Drenth, AF; Kremer, BP; Oude Voshaar, RC; Van Dam, D | 1 |
| Almeida, JR; Axelson, DA; Birmaher, B; Diler, RS; Ladouceur, CD; Pan, LA; Phillips, ML; Segreti, A | 1 |
| Doros, G; Fava, M; Meisner, A; Pencina, M; Rybin, D | 1 |
| Campistol, J; Darling, A; Perez-Duenas, B; Poo, P | 1 |
| Leung, JG; Nelson, S | 1 |
| Honaker, J; Lohr, WD | 1 |
| Florek, E; Gomółka, E; Piekoszewski, W; Synowiec, A; Zieba, A; Zyss, T | 1 |
| Abraham, R; Bhyrapuneni, G; Jayarajan, P; Kandikere, V; Muddana, N; Nirogi, R; Saralaya, R | 1 |
| Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Valdizan, EM; Vazquez-Barquero, JL | 1 |
| Chen, MH; Liou, YJ | 1 |
| Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS | 1 |
| Chang, HC; Choi, G; Choy, JH; Choy, YB; Lee, HJ; Oh, YJ; Park, JH; Park, JW; Yoon, YJ | 1 |
| Carlson, GA; Carson, WH; Correll, CU; Findling, RL; Forbes, RA; Ivanova, S; Jin, N; Mankoski, R; McQuade, RD; Nyilas, M | 1 |
| DelBello, MP; Welge, JA | 1 |
| Emslie, GJ | 1 |
| Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y | 1 |
| El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S | 1 |
| Ambavaram, VB; Gajulapalle, M; Kalluru, GR; Nandigam, V; Vemula, M | 1 |
| Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R | 1 |
| Pitchot, W | 1 |
| Couchman, L; Fisher, DS; Flanagan, RJ; Handley, SA; Morgan, PE; Partridge, SJ | 1 |
| Carson, W; Findling, RL; Forbes, RA; Mankoski, R; Marcus, RM; McQuade, R; Youngstrom, E; Zhao, J | 1 |
| Wang, YC | 1 |
| Dell'Osso, L; Marazziti, D; Moroni, I; Piccinni, A; Veltri, A | 1 |
| Li, W; Lv, L; Wang, S; Wang, X; Yang, G; Yang, Y; Zhang, H; Zhao, J | 2 |
| Golla, H; Perrar, KM; Voltz, R | 1 |
| Caccia, F; Caloro, M; Cuomo, I; De Filippis, S; De Persis, S; Gentile, G; Girardi, P; Janiri, D; Kotzalidis, GD; Lionetto, L; Piazzi, G; Sciarretta, A; Simmaco, M; Simonetti, A; Telesforo, CL | 1 |
| Patel, DP; Sanyal, M; Sharma, P; Shrivastav, PS | 1 |
| Aitchison, KJ; Almandil, NB; Besag, FM; Liu, Y; Murray, ML; Wong, IC | 1 |
| Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Begley, AE; Blumberger, D; Butters, M; Dew, MA; Joel, I; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF | 1 |
| Fisher, DS; Flanagan, RJ; Handley, SA; Partridge, SJ | 1 |
| Fraile, S; García, B; Hidalgo, FJ; Lopez, E | 1 |
| Medvedovici, A; Rădulescu, FŞ; Ranetti, AE; Voicu, V | 1 |
| Tang, J; Xie, Q; Xu, Y; Zeng, HL | 1 |
| Baker, RA; Carson, W; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, B; Kane, JM; McQuade, R; Sanchez, R | 1 |
| Falkai, P; Schmitt, A | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Mata, I; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM; Vázquez-Barquero, JL | 1 |
| Aggarwal, A; Gopalakrishna, G; Lauriello, J | 1 |
| Calarge, CA; Safer, AM; Safer, DJ | 1 |
| Edlinger, M; Fleischhacker, W; Hofer, A; Seppi, K | 1 |
| Baker, RA; Duca, AR; Eramo, A; Johnson, BR; Kane, JM; McQuade, RD; Peters-Strickland, T; Sanchez, R; Zhao, J | 1 |
| Brovedani, P; Masi, G; Pfanner, C | 1 |
| Ardiana, F; Indrayanto, G; Lestari, ML | 1 |
| Amano, N; Hanihara, T; Takahashi, T; Takahashi, Y; Washizuka, S; Yasaki, T | 1 |
| An, SK; Chang, JG; Cho, HS; Jung, YC; Kim, CH; Roh, D | 1 |
| Tadokoro, S | 1 |
| De Berardis, D; Di Giannantonio, M; Martinotti, G; Moschetta, FS; Serroni, N | 1 |
| Alnıak, İ; Ulusoy, S; Yavuz, KF | 1 |
| Gangadhar, BN; Rao, MG; Raveendranathan, D; Shiva, L; Varambally, S; Venkatasubramanian, G | 1 |
| Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP | 1 |
| Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
| Abdelbary, AA; El-Nabarawi, M; Elassasy, A; Jasti, B; Li, X | 1 |
| Remington, G; Takeuchi, H | 1 |
| Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U | 1 |
| Aubin, HJ; Daeppen, JB | 1 |
| Chen, TY; Tzeng, NS | 1 |
| Tsukarzi, EE | 1 |
| Cassiello, C; Dording, C; Fava, M; King, F; Mischoulon, D; Pencina, M | 1 |
| Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M | 1 |
| Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M | 1 |
| Jalenques, I; Kernisant, M; Legrand, G; May, R; Richard, B | 1 |
| Elpern, DJ; Ladizinski, B | 1 |
| Carson, W; Correll, CU; Forbes, RA; Mankoski, R; Marcus, R; McQuade, R; Zhao, J | 1 |
| Berk, M; Ghanizadeh, A; Sahraeizadeh, A | 1 |
| Bio, DS; Costa, LF; David, DP; Demétrio, FN; Fernandes, F; Missio, G; Moreno, DH; Moreno, RA; Rodrigues dos Santos, D; Soeiro-de-Souza, MG | 1 |
| Dowben, JS; Keller, DM; Keltner, NL; Myhre, KE | 1 |
| Baker, RA; Bricmont, P; Eramo, A; Kasper, W; Mallikaarjun, S; McQuade, R; Peters-Strickland, T; Potkin, SG; Raoufinia, A; Sanchez, R | 1 |
| Fuller, C; Grudziak, J; Nguyen, HL; Rickels, K; Rickels, MR; Teff, KL | 1 |
| Ahn, JH; Chen, BH; Cho, JH; Kim, IH; Kim, SK; Lee, B; Lee, DH; Lee, JC; Lee, YL; Park, JH; Won, MH; Yan, BC | 1 |
| Coley, KC; Fabian, TJ; Haskett, R; Kreys, TJ; Saul, MI | 1 |
| Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ | 1 |
| Argilli, E; Bonci, A; Madhavan, A; Whistler, JL | 1 |
| Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R | 1 |
| Agbaba, D; Filijović, ND; Maričić, B; Nikolic, K | 1 |
| Hashiguchi, M; Kunitomi, T; Mochizuki, M | 1 |
| Chiu, NC; Ho, CS; Huang, YL; Tseng, CF | 1 |
| Sebestyén, Z; Szabó, B; Szepesi, K | 1 |
| Hamada, Y; Itoh, M; Kaneko, YS; Kodani, Y; Kondo, K; Nagasaki, H; Nagatsu, T; Nakashima, A; Ota, A; Ota, M; Takayanagi, T | 1 |
| Li, X; Tang, Y; Wang, C | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; de la Foz, VO; Martinez-Garcia, O; Mata, I; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM | 1 |
| Buchanan, RW; Dickerson, FB; Earl, AK; Feldman, S; Fischer, BA; Keller, WR; Kelly, DL; McMahon, RP; Shim, JC; Sullivan, KM; Warfel, D; Wehring, HJ | 1 |
| Cho, DH; Chung, YC; Hahn, SW; Jeong, B; Kim, JH; Kim, SW; Koo, MS; Lee, SH; Lee, SJ; Lee, YH; Park, JI; Rho, SH | 1 |
| Bennett, JA; Lile, JA; Rush, CR; Sevak, RJ; Stoops, WW | 1 |
| Cho, SC; Joung, YS; Kim, BN; Kim, JW; Lee, JS; Lee, YS; Song, DH; Yoo, HK | 1 |
| Altamura, AC; Buoli, M; Serati, M | 1 |
| Charntikov, S; Crawford, CA; Der-Ghazarian, T; Lee, RJ; McDougall, SA; Varela, FA | 1 |
| Higuchi, T; Ishigooka, J; Kamijima, K; Kanba, S; Kinoshita, T; Koyama, T; Ohmori, T; Ozaki, N | 1 |
| Ishigooka, J; Iwata, N; Nakagome, K; Ohmori, T | 1 |
| Kearns, B; Ren, S; Stevenson, M; Uttley, L | 1 |
| Horikawa, H; Kanba, S; Kato, TA; Mizoguchi, Y; Monji, A; Sato-Kasai, M; Seki, Y; Yoshiga, D | 1 |
| Lawlor, BA; Sweeney, EB | 1 |
| Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM | 1 |
| Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD | 1 |
| Forbes, RA; Mankoski, R; Manos, G; Marcus, R; Marler, S; McQuade, R; Stockton, G | 1 |
| Poncin, YB; Stubbe, DE; Webb, JE; Webb, JR | 1 |
| Singh, KP; Tripathi, N | 1 |
| Lord, C; Moyal, WN; Walkup, JT | 1 |
| Diberto, JF; Fish, EW; Krouse, MC; Malanga, CJ; Robinson, JE; Stringfield, SJ | 1 |
| Calabrò, MP; D'Amico, G; Gagliano, A; Germanò, E; Guerriero, L; Ingrassia, M; Italiano, D; Lamberti, M; Privitera, C; Siracusano, R; Spina, E | 1 |
| Bleickardt, CJ; Hodgson, RA; Hunter, JC; Jones, NT; Kazdoba, TM | 1 |
| Burda-Malarz, K; Czubak, A; Hardyk, S; Kus, K; Nowakowska, E; Ratajczak, P | 1 |
| Banerjee, R; Liu, JJ; Minhas, HM | 1 |
| Ameis, SH; Cole, L; Corbett-Dick, P; Correll, CU | 1 |
| Hendset, M; Hermann, M; Knape, M; Molden, E | 1 |
| Arnoldy, R; Curtis, J; Samaras, K | 1 |
| Jackson, EA; Kwan, BK; Yam, FK | 1 |
| Han, C; Jeon, HJ; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Seo, HJ; Wang, SM | 1 |
| Au, RW; Chiu, HF; Dickerson, F; Kreyenbuhl, J; Lai, KY; Man, D; Shum, D; Tang, WK; Ungvari, GS; Wang, CY; Xiang, YT; Yu, X; Zhou, FC; Zhou, JJ; Zhou, Y | 1 |
| Fumagalli, F; Luoni, A; Racagni, G; Riva, MA | 1 |
| Dore, J; Hill, SJ; Hooshmand, F; Ketter, TA; Miller, S; Portillo, N; Wang, PW | 1 |
| Allain-Veyrac, G; Gaboriau, L; Gérardin, M; Grall-Bronnec, M; Jolliet-Evin, P; Victorri-Vigneau, C | 1 |
| Buchanan, RW; Newcomer, JW; Weiden, PJ | 1 |
| Ghanizadeh, A; Haghighi, A | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Santos, R; Wuo-Silva, R | 1 |
| Brown, R; Geddes, J; Taylor, MJ | 1 |
| Alcera, E; Coffey, DB; Patel, S; Tosyali, PM; Varas, DB | 1 |
| Bojarski, AJ; Marciniec, K; Partyka, A; Pawlowski, M; Wesolowska, A; Zajdel, P | 1 |
| Abdoli, N; Aghaei, A; Bajoghli, H; Brand, S; Farnia, V; Juibari, TA; Shakeri, J; Tatari, F; Yazdchi, K | 1 |
| Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Girinelli, G; Iasevoli, F; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Serroni, N; Valchera, A | 1 |
| El-Sayeh, HG; Khanna, P; Komossa, K; Leucht, S; Ma, H; Rummel-Kluge, C; Suo, T; Xia, J | 1 |
| Hasebe, S; Kawamoto, N; Kikuta, M; Ogita, K; Shiba, T; Shuto, M; Yamaguchi, T; Yoneyama, M | 1 |
| McKeage, K | 1 |
| Arshad, E; Deb, S; Deb, T; Farmah, BK; Roy, M; Unwin, GL | 1 |
| Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ | 1 |
| Correll, CU; Iwata, N; Kishi, T; Matsuda, Y | 1 |
| Charpeaud, T; Llorca, PM; Samalin, L | 1 |
| Dai, G; Zhang, Y | 1 |
| Campbell, C; Lofwall, MR; Nuzzo, PA; Walsh, SL | 1 |
| Chibnall, JT; Conway, CR; Cornell, ME; Cumming, P; Gangwani, S; Gebara, MA; McConathy, JE; Mintun, MA; Perantie, DC; Price, JL; Sheline, YI | 1 |
| Anagnostou, E; Baribeau, DA | 1 |
| Amatniek, J; Eudicone, JM; Findling, RL; Lears, K; Mankoski, R; Marcus, RN; McCartney, T; McQuade, RD; Sheehan, JJ; Timko, K | 1 |
| Anzai, N; Furukawa, S; Hatsuse, N; Ikebuchi, E; Iwata, K; Kishimoto, T; Matsuda, Y; Sato, S; Watanabe, Y | 1 |
| Yalcin, O | 1 |
| Chen, TT; Huang, WL; Tsai, CH | 1 |
| Brede, WR; Gjerdalen, G; Michelsen, LS; Nordeng, H; Spigset, O | 1 |
| Fukui, K; Nagoshi, Y; Tominaga, T | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Belletti, A; Cilia, R; Marotta, G; Pezzoli, G; Siri, C | 1 |
| Gallego, JA; Ikuta, T; Kane, J; Malhotra, AK; Peters, BD; Robinson, DG; Szeszko, PR | 1 |
| Malcolm, P; Pereira, A; Sugiharto-Winarno, A; Sundram, S; Zhang, B | 1 |
| Almarsson, O; Dawit, H; Deaver, DR; Hickey, MB; Merisko-Liversidge, E; Paquette, SM | 1 |
| Awad, G; Hassan, M; Hsu, J; Loebel, A; Pikalov, A; Rajagopalan, K | 1 |
| Early, M; Erickson, CA; Horn, P; McDougle, CJ; Pottenger, A; Schaefer, T; Wink, LK | 1 |
| Adler, BA; Early, M; Erickson, CA; McDougle, CJ; Minshawi, N; Shaffer, R; Wink, LK | 1 |
| Goetz, M; Surman, CB | 1 |
| Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Andrews, G; Boulton, M; Michael, S | 1 |
| Eun, SC; Hong, JM | 1 |
| Baker, RA; Berman, RM; Eudicone, JM; Laubmeier, KK; Marcus, RN; McQuade, RD; Nelson, JC; Rahman, Z; Sheehan, JJ | 1 |
| Chennoufi, L; Cheour, M; Ouanes, S | 1 |
| Bahramzi, M; Campillo, A; Minassian, A; Vilke, GM; Wilson, MP | 1 |
| Baker, RA; Citrome, L; Hebden, T; Kalsekar, I | 1 |
| Kawamura, A; Nagasaka, Y; Oda, K; Sano, T; Usui, T | 1 |
| Bergman, J; Pashinian, A; Poyurovsky, M; Weizman, A | 1 |
| Eleméry, M; Faludi, G; Kovács, G; Szegő, A | 1 |
| Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M | 1 |
| Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C | 1 |
| Eatt, J; Varghese, ST | 1 |
| Berman, RM; Hatch, A; Largay, K; Marler, SV; Nelson, JC; Sheehan, JJ; Stewart, TD | 1 |
| Crayton, J; Nasr, S; Popli, A; Wendt, B | 1 |
| Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
| Garg, A; Jyrwa, S; Sinha, P | 1 |
| Danilov, DS | 1 |
| Brawman-Mintzer, O; Gros, DF; Hershenberg, R | 1 |
| Csomor, PA; Geyer, MA; Huber, T; Preller, KH; Studerus, E; Vollenweider, FX | 1 |
| Bruno, A; Muscatello, MR; Pandolfo, G; Romeo, VM; Scimeca, G; Zoccali, RA | 1 |
| Frazier, J; Maloney, A; Mick, EO | 1 |
| Burda-Malarz, K; Czubak, A; Jędrzejewski, L; Kus, K; Nowakowska, E; Ratajczak, P; Sadowski, C | 1 |
| Cichocki, M; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Lozano, R; Marin, R; Santacruz, MJ | 1 |
| Hu, JY; Huang, A; Liu, YY; Liu, ZL; Wang, LM; Wen, XJ | 1 |
| Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Walling, D | 1 |
| Clark, T; Gmeiner, P; Kling, RC; Lanig, H; Tschammer, N | 1 |
| De Santis, M; Deng, C; Huang, XF; Lian, J; Pan, B | 1 |
| Philip, NS | 1 |
| Higuchi, T; Kamijima, K; Kato, M; Ono, H; Otsubo, T; Ozaki, N | 1 |
| Bagney, A; Caballero, M; Jiménez-Arriero, MA; Rodríguez-Jiménez, R; Torio, I | 1 |
| Perry, CM; Shirley, M | 1 |
| Makkos, Z | 1 |
| Himle, M; Schrock, L; Shprecher, DR | 1 |
| Hiraoka, S; Namiki, N; Uchida, S | 1 |
| Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W | 1 |
| Eryilmaz, G; Gül, IG; Hizli Sayar, G; Karamustafalioğlu, O; Özten, E; Yorbik, Ö | 1 |
| Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JR; Juul, K; Klauber, DG; Lauritsen, MB; Madsen, S; Nyvang, L; Pagsberg, AK; Paludan, J; Pedersen, J; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Thomsen, PH; Vernal, DL; Werge, TM; Wetterslev, J; Winge, K | 1 |
| Upadhyay, A | 1 |
| Budman, CL | 1 |
| Arunagiri, P; Balamurugan, E; Rajeshwaran, K; Shanthakumar, J; Tamilselvan, T | 1 |
| Pawelczyk, A; Pawelczyk, T; Rabe-Jablonska, J | 1 |
| Baker, RA; Berman, RM; Cain, ZJ; Clayton, AH; Forbes, RA; Marcus, R; Marler, SV; Sheehan, JJ; Thase, ME | 1 |
| Adham, N; Gruca, P; Gyertyán, I; Kiss, B; Lasoń-Tyburkiewicz, M; Papp, M | 1 |
| Gagne, JJ; Maclure, M; Schneeweiss, S; Wang, SV | 1 |
| Lu, CL; Shen, YC | 1 |
| Takaki, M | 1 |
| Leung, JG; Schak, KM; Silverman, MA | 1 |
| Gentile, S | 1 |
| Chan, HY; Tan, HK; Wu, WY | 1 |
| Amado, JA; Ayesa-Arriola, R; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez García, O; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Baker, RA; Carson, WH; Eramo, A; Gara, M; Hertel, P; Jin, N; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R | 1 |
| Bourgeois, JA; Hategan, A | 1 |
| Goyal, P; Kumar, D; Prakash, O; Tripathi, P | 1 |
| Aguiar, DC; Almeida-Santos, AF; Duarte, ID; Ferreira, RC; Gobira, PH; Moreira, FA; Romero, TR; Souza, DP | 1 |
| Sharma, V; Sommerdyk, C; Xie, B | 1 |
| Du, Y; Ehrich, EW; Hard, M; Risinger, R; Turncliff, R | 1 |
| Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M | 1 |
| Baker, RA; Dunlop, BW; Eudicone, JM; McCabe, B; Sheehan, JJ | 1 |
| Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Tsai, LF | 1 |
| Cornelius, V; Smith, L; Taylor, DM; Young, AH | 1 |
| Chiou, CC; Lane, HY; Lin, CY; Tsai, GE; Wang, HS; Wu, VY; Wu, YH | 1 |
| Carta, MG; Moro, MF | 1 |
| Glenmullen, J; Mattison, DR; Moore, TJ | 1 |
| Buckley, P; Corwin, MJ; Dretchen, K; McEvoy, J; Millet, RA; Morris, AA | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Okabe, N; Takaki, M | 1 |
| Argyelan, M; Gallego, JA; Ikuta, T; Kane, JM; Karlsgodt, K; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR | 1 |
| Ghezai, H; Goldacre, B; Hodsoll, J; Miles, S; Smallcombe, N; Veale, D | 1 |
| Brust, TF; Hayes, MP; Roman, DL; Watts, VJ | 1 |
| Stroup, TS | 1 |
| Heres, S | 1 |
| Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP | 1 |
| Cakıcı, M; Celik, M; Cetin, M; Polat, M; Suner, A | 1 |
| Kobayashi, H; Tadori, Y | 1 |
| Algaidi, SA; Attia, GM; Soliman, HM; Wagih, HM | 1 |
| Malempati, RN | 1 |
| Deng, C; Han, M; Hu, CH; Huang, XF; Pan, B | 1 |
| Abrial, E; Bétourné, A; Etiévant, A; Haddjeri, N; Lambás-Señas, L; Lucas, G; Scarna, H | 1 |
| Baker, RA; Eramo, A; Kostic, D; Landsberg, W; Larsen, F; Nylander, AG; Raoufinia, A | 1 |
| Lanzarotta, A | 1 |
| Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T | 1 |
| Liu, J; Meng, X; Xia, SY; Yu, H; Zhang, P; Zhang, YR | 1 |
| Brugnoli, R; De Filippis, S; Di Sciascio, G; Fagiolini, A; Maina, G | 1 |
| Futamura, T; Hashimoto, K; Ishima, T; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Aksoy-Poyraz, C; Duran, A; Öcek, T; Sakalli Kani, A; Turan, S | 1 |
| Arao, T; Kuno, F; Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Audo, I; Faure, C; Letessier, JB; Robert, MP; Zeitz, C | 1 |
| Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK | 1 |
| Huh, L; Lee, BJ | 1 |
| Bilgiç, A; Yılmaz, E; Yılmaz, S | 1 |
| Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R | 1 |
| Percinel, I; Yazici, KU | 1 |
| Baker, RA; Citrome, L; Nagamizu, K; Ota, A; Perry, P; Weiller, E | 1 |
| Badran, IA; Correll, CU; Curran, RL; DelBello, MP; Pedapati, EV; Peppers, V | 1 |
| Ishigooka, J; Nishiyama, K; Noda, T; Shima, T; Tadori, Y; Tamaru, N; Yamasaki, Y | 1 |
| Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E | 1 |
| Castle, D; Hope, J; Keks, NA | 1 |
| Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J | 1 |
| Champika, L; Chandradasa, M | 1 |
| Abad-Santos, F; Belmonte, C; Koller, D; Ochoa, D; Román, M; Ruiz-Nuño, A; Wojnicz, A | 1 |
| Aladeen, T; Capote, H; Lee, Y; McIntyre, RS; Rainka, M; Rong, C; Westphal, E | 1 |
| Goldnik, A; Mach, A; Malek, G; Marszalek, D; Pawinski, T; Somogi, A | 1 |
| Burudpakdee, C; Greene, M; Hartry, A; Seetasith, A | 1 |
| Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P | 1 |
| Frampton, JE | 1 |
| Limandri, BJ | 1 |
| Amore, M; Belvederi Murri, M; Cervetti, A; Monacelli, F; Piccinini, G; Pompili, M; Serafini, G; Visimberga, S | 1 |
| Citrome, LL; Manning, JS; McIntosh, D; McIntyre, RS | 1 |
| Abad-Santos, F; Belmonte, C; Koller, D; Ochoa, D; Román, M; Saiz-Rodríguez, M; Zubiaur, P | 1 |
| Correll, CU; Høiseth, G; Molden, E; Smith, RL; Tveito, M | 1 |
| Cummings, OT; Enders, JR; Feng, S; McIntire, G; McIntire, T; Strickland, EC | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T | 1 |
| Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K | 1 |
| Antoun Reyad, A; Girgis, E; Mishriky, R | 1 |
| Dinnissen, M; Hoekstra, PJ; Popma, A; Reijnen, S; Reurts, EE; Troost, PW | 1 |
| Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D | 1 |
| Boku, S; Fujiyama, H; Fukuhara, R; Kanno, T; Kawahara, K; Sugawara, H; Takebayashi, M; Tanaka, H | 1 |
| Banner, J; Johansen, SS; Linnet, K; Rygaard, K | 1 |
| Mishra, VC; Swami, MK | 1 |
| Espay, AJ; Gupta, HV; Sharma, VD | 1 |
| Aoki, K; Inada, K; Ishigooka, J; Iwashita, S; Kojima, Y; Niidome, K; Yamada, S | 1 |
| Alefishat, E; Aloum, L; Baltatu, OC; Petroianu, GA | 1 |
| Futamura, T; Hirose, T; Kikuchi, T; Maeda, K; McQuade, RD; Suzuki, M | 1 |
| Aguirre, C; Garcia, M; Lertxundi, U; Morera-Herreras, T; Zazu, L | 1 |
| Abad-Santos, F; Hempel, G; Kneller, LA; Koller, D; Zubiaur, P | 1 |
| Arıkan, MK; Günver, G; İlhan, R; Metin, B; Öksüz, Ö | 1 |
| Dehaen, W; Juza, R; Kobrlova, T; Korabecny, J; Mecava, M; Mezeiova, E; Muckova, L; Musilek, K; Petrasek, T; Prchal, L; Pulkrabkova, L; Randakova, A; Soukup, O; Stefkova, K; Vojtechova, I | 1 |
| Alaghmand, A; Ayatollahi, ZS; Jamilian, H; Shayganfard, M | 1 |
| Baymeeva, NV; Kaleda, VG; Miroshnichenko, II; Platova, AI; Tikhonov, DV | 1 |
| Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z | 1 |
| Bellagamba, S; Orsolini, L; Salvi, V; Volpe, U | 1 |
| De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R | 1 |
| De Ronchi, D; Fabbri, C; Fanelli, G; Lippi, M; Serretti, A | 1 |
| Hsu, TW; Liang, CS; Tsou, HL | 1 |
| Hernández-Díaz, S; Huybrechts, KF; Straub, L | 1 |
| Heming, SM; Olsen, KE | 1 |
| Chang, CC; Hsieh, MH; Ju, PC; Wang, WF; Yang, TC | 1 |
| Dorozhenok, IY | 1 |
| Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y | 1 |
| Gaebler, AJ; Haen, E; Margraff, T; Neuner, I; Paulzen, M; Schoretsanitis, G | 1 |
| Funahashi, Y; Iga, JI; Kumon, H; Mori, H; Ochi, S; Ozaki, T; Ozaki, Y; Ueno, M; Ueno, SI; Yamazaki, K; Yoshino, Y | 1 |
| Juza, R; Kelemen, E; Korabecny, J; Petrasek, T; Soukup, O; Stuchlik, A; Tuckova, K; Vojtechova, I | 1 |
| Harada, T; Hosokawa, T; Kishi, Y; Miyaji, C; Nomura, A; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Washida, K; Yada, Y; Yamada, N; Yoshimura, Y | 1 |
243 review(s) available for aripiprazole and carbostyril
| Article | Year |
|---|---|
[How do antipsychotics exert their effects on dopamine receptor subtypes?].
Topics: Animals; Antipsychotic Agents; Aripiprazole; Haloperidol; Piperazines; Quinolones; Rats; Receptors, Dopamine; RNA, Messenger | 1998 |
Aripiprazole. Abilitat, OPC 14597.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2 | 2002 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Aripiprazole (Otsuka Pharmaceutical Co).
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Dopamine Antagonists; Humans; Piperazines; Quinolones; Schizophrenia; Technology, Pharmaceutical | 2002 |
Aripiprazole.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cognition; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2002 |
Aripiprazole: profile on efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Cardiovascular System; Clinical Trials as Topic; Digestive System; Dyskinesia, Drug-Induced; Humans; Mental Disorders; Piperazines; Quinolones; Schizophrenia | 2002 |
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2003 |
Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2003 |
Aripiprazole: a new atypical antipsychotic drug.
Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole: quite possibly a new type of antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
Treatment for mood and anxiety disorders: quetiapine and aripiprazole.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Dibenzothiazepines; Humans; Mood Disorders; Piperazines; Quetiapine Fumarate; Quinolones | 2003 |
Antipsychotic medication and seizures: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2003 |
Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Prolactin; Putamen; Quinolones; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed | 2003 |
Schizophrenia: from dopamine to glutamate and back.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia | 2004 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Focus on aripiprazole.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2004 |
Dopamine partial agonists: a new class of antipsychotic.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin; Treatment Outcome | 2004 |
Aripiprazole: in acute mania associated with bipolar I disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Evaluation; Drug Tolerance; Humans; Piperazines; Practice Guidelines as Topic; Quinolones | 2004 |
Aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2004 |
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome | 2004 |
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2004 |
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Schizophrenia; Tissue Distribution; Treatment Outcome | 2004 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Treatment Outcome | 2004 |
[Aripiprazole: a new atypical antipsychotic drug].
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2.
Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Pharmacogenetics; Piperazines; Quinolones; Topiramate | 2004 |
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Risperidone; Schizophrenia; Time Factors | 2004 |
Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones | 2004 |
Partial agonism and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Brain; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2005 |
Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Mood Disorders; Piperazines; Quinolones; Schizophrenia | 2005 |
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Double-Blind Method; Humans; Lithium; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2005 |
[Psychiatry].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Humans; Lamotrigine; Mental Disorders; Methylphenidate; Piperazines; Quinolones; Risperidone; Triazines | 2005 |
The treatment of mixed states and the risk of switching to depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Electroconvulsive Therapy; Haloperidol; Health Education; Humans; Lithium Carbonate; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2005 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
[A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Metabolic Syndrome; Piperazines; Quinolones; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2004 |
Partial dopamine agonists in schizophrenia.
Topics: Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Aripiprazole: pharmacology, efficacy, safety and tolerability.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia | 2005 |
A typical mood stabilizers: a "typical role for atypical antipsychotics.
Topics: Affect; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Secondary Prevention; Sulpiride; Thiazoles | 2005 |
Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2005 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2005 |
Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Molecular Structure; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2005 |
Aripiprazole: an overview of a novel antipsychotic.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Brain; Clinical Trials as Topic; Half-Life; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Treatment Outcome | 2005 |
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2006 |
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Dibenzothiazepines; Double-Blind Method; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic | 2006 |
Aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2006 |
Haloperidol alone or in combination for acute mania.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride; Valproic Acid | 2006 |
Long-term use of atypical antipsychotics in bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Administration Schedule; Drug Costs; Humans; Olanzapine; Piperazines; Practice Guidelines as Topic; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; United States | 2006 |
Aripiprazole for schizophrenia. Systematic review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Patient Compliance; Piperazines; Prolactin; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Treatment Outcome | 2006 |
Maintenance treatment of bipolar disorder: Applying research to clinical practice.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Evidence-Based Medicine; Humans; Lamotrigine; Lithium Carbonate; Olanzapine; Piperazines; Quinolones; Triazines; Valproic Acid | 2006 |
[The antipsychotic drug aripiprazole (ABILIFY)].
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
Role of aripiprazole in treating mood disorders.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Humans; Mood Disorders; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinolones; Treatment Outcome | 2006 |
Unique pharmacological profile of aripiprazole as the phasic component buster.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Dopamine; Dopamine Agents; Humans; Neurons; Piperazines; Quinolones; Receptors, Dopamine D2; Synaptic Transmission | 2007 |
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Aripiprazole: pharmacology and evidence in bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Humans; Piperazines; Quinolones | 2007 |
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2 | 2007 |
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Haloperidol; Humans; Longitudinal Studies; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome | 2007 |
Maintenance treatment in bipolar disorder: a focus on aripiprazole.
Topics: Antidepressive Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Time | 2007 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Cholinesterase Inhibitors; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones | 2007 |
Managing the acutely agitated and psychotic patient.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
Aripiprazole: in adolescents with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2007 |
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia | 2007 |
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Aripiprazole versus typicals for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Injections, Intramuscular; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia | 2008 |
Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.
Topics: Animals; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Depressive Disorder; Humans; Piperazines; Quinolones | 2008 |
Combined antipsychotic treatment involving clozapine and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Weight Loss | 2008 |
Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Inverse Agonism; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Signal Transduction | 2008 |
Proposed strategies for successful clinical management with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mental Disorders; Piperazines; Practice Guidelines as Topic; Quinolones; Titrimetry; Treatment Outcome | 2008 |
Aripiprazole in adolescents with schizophrenia: profile report.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2008 |
[Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2008 |
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Comorbidity; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Weight Gain | 2008 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Dibenzothiazepines; Disorders of Excessive Somnolence; Headache; Humans; Methylphenidate; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2008 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Clozapine; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2008 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Thiazoles | 2008 |
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome | 2008 |
Aripiprazole versus typical antipsychotic drugs for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Aripiprazole: in major depressive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Disability Evaluation; Drug Tolerance; Humans; Piperazines; Quinolones | 2008 |
The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
A clinical paradigm of delusions of parasitosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders | 2008 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, Vascular; Dibenzothiazepines; Double-Blind Method; Evidence-Based Medicine; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2008 |
Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sex Distribution; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Current evidence for aripiprazole as augmentation therapy in major depressive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol; Cholesterol, HDL; Endpoint Determination; Female; Humans; Lipoproteins; Male; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2008 |
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug Therapy; Humans; Lobeline; Methamphetamine; Methylphenidate; Narcotic Antagonists; Nicotinic Agonists; Piperazines; Prevalence; Quinolones; Recurrence; Substance-Related Disorders | 2008 |
Treatment-resistant depression: recent developments and future directions.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Combined Modality Therapy; Deep Brain Stimulation; Depressive Disorder, Major; Drug Resistance; Electroconvulsive Therapy; Humans; Piperazines; Prognosis; Quinolones; Tetrahydrofolates; Transcranial Magnetic Stimulation; Treatment Outcome; Vagus Nerve Stimulation | 2008 |
Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Dopamine Agonists; Drug Evaluation, Preclinical; Haplorhini; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Self Administration; Substance-Related Disorders | 2008 |
Incomplete response in late-life depression: getting to remission.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones; Treatment Outcome | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2009 |
[A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Neurons; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Synaptic Transmission | 2009 |
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.
Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain | 2009 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Treatment options for the patient who does not respond well to initial antidepressant therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Drug Approval; Drug Resistance; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Piperazines; Psychotropic Drugs; Quinolones; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Vagus Nerve Stimulation | 2009 |
A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cardiovascular System; Dibenzothiazepines; Drug Overdose; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2009 |
A review of the safety and tolerability of aripiprazole.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2009 |
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult | 2009 |
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2009 |
[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Design; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2009 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2009 |
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Drug Discovery; Drug Partial Agonism; Drugs, Investigational; Humans; Models, Neurological; Molecular Structure; Piperazines; Quinolones; Receptors, Dopamine D2; Serotonin Antagonists; Signal Transduction; Terminology as Topic | 2010 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult | 2010 |
Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Metabolic Diseases; Obesity; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
Mixed episodes with psychotic features.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Hospitalization; Humans; Male; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Treatment Outcome; Valproic Acid | 2009 |
Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Antipsychotic Agents; Aripiprazole; Brain Chemistry; Frontal Lobe; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Serotonin; Reward | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2010 |
[Action of amygdala dopamine and effect of antipsychotics].
Topics: Amygdala; Animals; Antipsychotic Agents; Aripiprazole; Catecholamines; Conditioning, Classical; Dopamine; Fear; Haloperidol; Humans; Piperazines; Quinolones; Rats; Schizophrenia; Schizophrenic Psychology; Stress, Psychological | 2010 |
A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Quinolones; Receptors, Dopamine; Treatment Outcome | 2010 |
Aripiprazole in autism spectrum disorders and fragile X syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Fragile X Syndrome; Humans; Piperazines; Quinolones | 2010 |
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biostatistics; Clinical Trials as Topic; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Epidemiologic Measurements; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Drug Resistance; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2010 |
Aripiprazole for late-life schizophrenia.
Topics: Aged; Aging; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2010 |
Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.
Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Italy; Medication Adherence; Piperazines; Quinolones; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; Paliperidone Palmitate; Piperazines; Placebos; Pyrimidines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Review Literature as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depression; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Drug Resistance; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2010 |
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Male; Multicenter Studies as Topic; Olanzapine; Patient Selection; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Sulpiride | 2011 |
Therapeutic potential of new second generation antipsychotics for major depressive disorder.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic | 2010 |
Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Humans; Olanzapine; Piperazines; Practice Guidelines as Topic; Quinolones; Risperidone; Treatment Outcome | 2011 |
Switching and combining antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2010 |
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain | 2010 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dysthymic Disorder; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride | 2010 |
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Anxiety Disorders; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones | 2011 |
A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compounds; Piperazines; Quinolones; Secondary Prevention | 2011 |
Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2011 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2011 |
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Drug Interactions; Humans; Piperazines; Quinolones | 2011 |
Aripiprazole for the treatment of bipolar disorder: a review of current evidence.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Injections, Intramuscular; Piperazines; Quinolones | 2011 |
Aripiprazole for the treatment of irritability associated with autism.
Topics: Antipsychotic Agents; Aripiprazole; Autistic Disorder; Humans; Irritable Mood; Piperazines; Quinolones; Risperidone | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Fluoxetine; Humans; Male; Patient Compliance; Piperazines; Prognosis; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Serotonin Antagonists; Severity of Illness Index; Treatment Outcome | 2011 |
Pharmacokinetics and metabolism update for some recent antipsychotics.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Drug Interactions; Humans; Inactivation, Metabolic; Isoindoles; Lurasidone Hydrochloride; Piperazines; Quinolones; Thiazoles | 2011 |
Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.
Topics: Aripiprazole; Autistic Disorder; Child; Clinical Trials as Topic; Drug Dosage Calculations; Humans; Irritable Mood; Piperazines; Quinolones; Time Factors | 2011 |
Aripiprazole for the treatment of adolescent Tourette's syndrome: a case report.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Tics; Tourette Syndrome; Treatment Outcome; Young Adult | 2010 |
Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Evidence-Based Medicine; Humans; Lithium; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2011 |
Issues in the management of challenging behaviours of adults with autism spectrum disorder.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Behavior Therapy; Child; Child Development Disorders, Pervasive; Combined Modality Therapy; Humans; Piperazines; Quinolones; Risperidone | 2011 |
Adding aripiprazole to clozapine worsened delusions and hallucinations: a case report.
Topics: Aripiprazole; Clozapine; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia, Paranoid | 2011 |
Aripiprazole and pregnancy: a case report and literature review.
Topics: Adult; Aripiprazole; Female; Humans; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications; Quinolones; Schizophrenia, Paranoid | 2011 |
Aripiprazole versus placebo for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2011 |
[Functional homology between alcohol dependence and mood disorder].
Topics: Alcoholism; Animals; Antipsychotic Agents; Aripiprazole; Hypothalamo-Hypophyseal System; Mice; Mood Disorders; Piperazines; Pituitary-Adrenal System; Quinolones; Receptors, Serotonin; Serotonin Plasma Membrane Transport Proteins | 2011 |
Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia | 2011 |
Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Hypnotics and Sedatives; Male; Piperazines; Practice Guidelines as Topic; Quinolones | 2011 |
Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sex Characteristics; Treatment Outcome; Young Adult | 2012 |
[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Treatment-Resistant; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Humans; Lithium Carbonate; Olanzapine; Patient Compliance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2012 |
Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Lycanthropy as a culture-bound syndrome: a case report and review of the literature.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior Control; Citalopram; Cultural Characteristics; Culture; Delusions; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethnopsychology; Female; Humans; Lebanon; Middle Aged; Mythology; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2012 |
Aripiprazole: a review of its use in the management of schizophrenia in adults.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2012 |
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2012 |
Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Is rational antipsychotic polytherapy feasible? A selective review.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Piperazines; Prolactin; Quinolones; Schizophrenia | 2012 |
Efficacy and safety of aripiprazole in child and adolescent patients.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Bipolar Disorder; Child; Humans; Piperazines; Quinolones; Schizophrenia | 2012 |
Aripiprazole vs placebo for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2012 |
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Topics: Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2012 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Child; Child Behavior; Child Development Disorders, Pervasive; Child, Preschool; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Discovery; GluK2 Kainate Receptor; Glutamic Acid; Humans; Methylphenidate; Mice; Mice, Inbred C57BL; Oxytocin; Piperazines; Quinolones; Rats; Receptors, Kainic Acid; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2012 |
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2012 |
Oral aripiprazole-induced severe hypoglycemia.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Humans; Hypoglycemia; Male; Piperazines; Quinolones; Severity of Illness Index | 2012 |
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Topics: Antipsychotic Agents; Aripiprazole; Cells, Cultured; Colforsin; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia | 2012 |
Aripiprazole for autism spectrum disorders (ASD).
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Female; Humans; Hyperkinesis; Irritable Mood; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic | 2012 |
Age-grouped differences in bipolar mania.
Topics: Adolescent; Adult; Age Factors; Aggression; Anger; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Child; Clinical Trials as Topic; Comorbidity; Defense Mechanisms; Female; Humans; Irritable Mood; Male; Middle Aged; Motor Activity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Sexual Behavior; Thinking; Young Adult | 2012 |
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Humans; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Schizophrenia | 2014 |
Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Aripiprazole; Behavior, Animal; Cognition; Cognition Disorders; Depression; Disease Models, Animal; Epilepsy, Absence; Nootropic Agents; Piperazines; Quinolones; Rats; Rats, Inbred Strains | 2013 |
Systemic review of aripiprazole for the treatment of children and adolescents with tic disorders.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Databases, Factual; Humans; Pediatrics; Piperazines; Quinolones; Tic Disorders | 2012 |
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Hypercholesterolemia; Incidence; Pharmacovigilance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2012 |
Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compounds; Piperazines; Quinolones; Valproic Acid | 2012 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Industry; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Support as Topic; Risperidone; Thiazoles | 2013 |
Aripiprazole, alcohol and substance abuse: a review.
Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Humans; Piperazines; Quinolones; Substance-Related Disorders; Tobacco Use Disorder | 2012 |
Pharmacological treatment of Gilles de la Tourette syndrome.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Botulinum Toxins; Cognitive Behavioral Therapy; Humans; Piperazines; Quinolones; Tourette Syndrome | 2013 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles | 2012 |
Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Torticollis; Young Adult | 2012 |
Aripiprazole in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Meta-Analysis as Topic; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine; Serotonin 5-HT2 Receptor Antagonists | 2013 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Child, Preschool; Dopamine; Dopamine Antagonists; Down Syndrome; Dyskinesia, Drug-Induced; Dystonic Disorders; Electroencephalography; Epilepsy; Female; Fragile X Syndrome; Humans; Intellectual Disability; Isoxazoles; Male; Methotrimeprazine; Ocular Motility Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Risperidone; Substance Withdrawal Syndrome; Translocation, Genetic; Valproic Acid | 2013 |
Atypical antipsychotics for the treatment of disruptive behavior.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Olanzapine; Pediatrics; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2013 |
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Delirium; Evidence-Based Medicine; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Olanzapine; Palliative Care; Piperazines; Quinolones; Risk Factors | 2013 |
Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Weight Gain | 2013 |
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Blood-Brain Barrier; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Prolactin; Pyrimidines; Quinolones; Receptors, Dopamine D2; Risperidone; Stress, Psychological; Sulpiride; Xenobiotics | 2013 |
Long-acting injectable aripiprazole: how might it fit in our tool box?
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States | 2013 |
Prolactin serum concentrations during aripiprazole treatment in youth.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones | 2013 |
Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Piperazines; Quinolones; Spectrum Analysis | 2013 |
[Aripiprazole as "dopamine sensitivity stabilizer"].
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia | 2013 |
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Practice Guidelines as Topic; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2013 |
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate | 2013 |
[Efficacy of aripiprazole (amdoal) in the long-term treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Follow-Up Studies; Humans; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2013 |
Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Time Factors | 2013 |
[Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antiemetics; Antifungal Agents; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Humans; Hungary; Multiple Myeloma; Oligopeptides; Piperazines; Pyrimidines; Quinolones; Quinuclidines; Solubility; Thiazoles; Triazoles; Voriconazole | 2013 |
Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Humans; Long-Term Care; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2014 |
Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Piperazines; Precision Medicine; Quinolones | 2013 |
Atypical antipsychotics for psychosis in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2013 |
Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Humans; Piperazines; Quinolones | 2013 |
Quality of life in children and adolescents with autism spectrum disorders: what is known about the effects of pharmacotherapy?
Topics: Adolescent; Aripiprazole; Child; Child Development Disorders, Pervasive; Comorbidity; Humans; Oxytocin; Piperazines; Psychopharmacology; Psychotropic Drugs; Quality of Life; Quinolones | 2014 |
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2013 |
Aripiprazole alone or in combination for acute mania.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Lithium Compounds; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Valproic Acid | 2013 |
Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?
Topics: Antipsychotic Agents; Aripiprazole; Humans; Isoquinolines; Piperazines; Protein Binding; Quinolines; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Sulfonamides | 2014 |
Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Drug Partial Agonism; Drug Therapy, Combination; Humans; Hyperprolactinemia; Patents as Topic; Piperazines; Quinolones; Receptors, Dopamine D2 | 2014 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia | 2014 |
Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; European Union; Humans; Medication Adherence; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic | 2014 |
The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review.
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Child Development Disorders, Pervasive; Developmental Disabilities; Humans; Intellectual Disability; Mental Disorders; Piperazines; Quinolones; Self-Injurious Behavior; Treatment Outcome | 2014 |
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dopamine; Dopamine Uptake Inhibitors; Humans; Methamphetamine; Olanzapine; Outcome Assessment, Health Care; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Substance Withdrawal Syndrome; Synaptic Transmission; Treatment Outcome | 2013 |
[Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
Topics: Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Hostility; Humans; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2014 |
An update on medication management of behavioral disorders in autism.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Humans; Piperazines; Propylamines; Quinolones; Risperidone | 2014 |
An update on the treatment of mixed bipolar states: what is new in 2013?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Calcitonin; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2014 |
A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbohydrate Metabolism; Diabetes Mellitus; Glucose Metabolism Disorders; Humans; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Overweight; Piperazines; Quinolones; Weight Gain | 2014 |
Role of atypical antipsychotics in the treatment of generalized anxiety disorder.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Generalization, Psychological; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Treatment Outcome | 2014 |
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Synergism; Humans; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Treatment Outcome; Young Adult | 2014 |
Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2014 |
Neurobehavioral aspects, pathophysiology, and management of Tourette syndrome.
Topics: Alcohol Oxidoreductases; Aripiprazole; Benzazepines; Cerebellar Nuclei; Disease Management; Dopamine Antagonists; Humans; Mental Disorders; Mutation; Piperazines; Quinolones; Tourette Syndrome | 2014 |
The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Isoxazoles; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Risperidone; Tourette Syndrome; Treatment Outcome | 2014 |
A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Postpartum Period; Pregnancy; Psychotic Disorders; Quinolones; Schizophrenia | 2014 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Isoindoles; Lamotrigine; Lithium Compounds; Lurasidone Hydrochloride; Monoamine Oxidase Inhibitors; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles; Treatment Outcome; Triazines; Valproic Acid | 2014 |
Evaluating aripiprazole as a potential bipolar disorder therapy for adults.
Topics: Adult; Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Treatment Outcome | 2014 |
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clomipramine; Dibenzothiazepines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Humans; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2014 |
[In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Cricetulus; Depression; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Synaptic Transmission | 2014 |
Initiation of aripiprazole once-monthly in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomedical Research; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2015 |
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2015 |
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine | 2016 |
Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes | 2018 |
Brexpiprazole: A Review in Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Approval; Humans; Japan; Quinolones; Schizophrenia; Serotonin Receptor Agonists; Thiophenes; United States | 2019 |
Aripiprazole-induced persistent hiccup: a case report and review of the literature.
Topics: Antipsychotic Agents; Aripiprazole; Hiccup; Humans; Piperazines; Quinolones | 2019 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Network Meta-Analysis; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2020 |
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2020 |
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiophenes | 2020 |
The action of aripiprazole and brexpiprazole at the receptor level in
Topics: Aripiprazole; Hiccup; Humans; Neurotransmitter Agents; Quinolones; Thiophenes | 2021 |
Discovery research and development history of the dopamine D
Topics: Aripiprazole; Depressive Disorder, Major; Dopamine; Dopamine Agonists; Humans; Quinolones; Research; Thiophenes; United States | 2021 |
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Humans; Polypharmacy; Psychotic Disorders; Quinolones; Thiophenes | 2022 |
325 trial(s) available for aripiprazole and carbostyril
| Article | Year |
|---|---|
Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Electroencephalography; Humans; Male; Piperazines; Quinolones; Schizophrenia | 1998 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2003 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Piperazines; Placebos; Quinolones; Treatment Outcome | 2003 |
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2003 |
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Fasting; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Piperazines; Quinolones | 2004 |
Aripiprazole, a novel atypical antipsychotic drug.
Topics: Antipsychotic Agents; Aripiprazole; Forecasting; Humans; Piperazines; Psychotic Disorders; Quinolones | 2004 |
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain | 2004 |
Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Depressive Disorder; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Nausea; Obesity; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Weight Gain | 2005 |
Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Comorbidity; Depressive Disorder; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Dopamine Agonists; Female; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substance-Related Disorders; Treatment Outcome | 2005 |
Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans.
Topics: Adult; Amphetamines; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Interactions; Female; Heart Rate; Humans; Male; Piperazines; Psychological Tests; Quinolones; Surveys and Questionnaires | 2005 |
Aripiprazole in schizophrenia with cocaine dependence: a pilot study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2005 |
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2005 |
Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones | 2005 |
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2005 |
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones | 2006 |
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2006 |
Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
Topics: Activities of Daily Living; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Body Mass Index; Denmark; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Primary Health Care; Prospective Studies; Psychiatry; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Schizophrenia; Time Factors | 2006 |
Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
Topics: Aggression; Anger; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Double-Blind Method; Female; Humans; Male; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Suicide; Surveys and Questionnaires; Treatment Outcome | 2006 |
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cross-Cultural Comparison; Double-Blind Method; Female; Humans; International Cooperation; Male; Pain; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Secondary Prevention; Time Factors; Treatment Outcome | 2006 |
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Cognition; Female; Humans; Learning; Male; Memory; Middle Aged; Olanzapine; Piperazines; Quinolones | 2006 |
[Clinical observations with aripiprazole in schizophrenia].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Single-Blind Method; Treatment Outcome | 2006 |
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2006 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment | 2006 |
A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome; United Kingdom | 2006 |
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides | 2006 |
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Time Factors | 2007 |
Clozapine augmented with aripiprazole in 5 patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2006 |
A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Aripiprazole; Female; Humans; Male; Methylphenidate; Piperazines; Placebos; Quinolones; Severity of Illness Index; Substance Abuse Detection; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Treatment Outcome | 2007 |
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up.
Topics: Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Research Design; Time Factors; Treatment Outcome | 2007 |
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Drug Resistance; Female; Humans; Male; Perphenazine; Piperazines; Prolactin; Quality of Life; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Bupropion; Dizziness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Pilot Projects; Piperazines; Quality of Life; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Headache; Humans; Injections, Intramuscular; Lorazepam; Male; Nausea; Patient Dropouts; Piperazines; Psychomotor Agitation; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Vomiting | 2007 |
Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Neurologic Examination; Personality Inventory; Piperazines; Quinolones | 2007 |
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2007 |
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2007 |
Aripiprazole for treatment of behavioural psychological symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Dementia; Humans; Piperazines; Prospective Studies; Psychomotor Disorders; Quinolones; Social Behavior | 2007 |
Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Combat Disorders; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Personality Assessment; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2007 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia | 2007 |
[Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Phytotherapy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Blood Glucose; Community Mental Health Services; Female; Humans; Lipoproteins; Male; Middle Aged; Patient Care; Piperazines; Prolactin; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Weight Gain | 2007 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Pilot Projects; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
Efficacy and safety of aripiprazole in alcohol dependence.
Topics: Adult; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Motivation; Pain Measurement; Piperazines; Quinolones; Temperance | 2007 |
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2007 |
An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Severity of Illness Index; Tic Disorders; Treatment Outcome | 2007 |
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).
Topics: Antipsychotic Agents; Aripiprazole; Europe; Humans; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Surveys and Questionnaires; Treatment Outcome | 2007 |
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Placebos; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome | 2007 |
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome | 2007 |
An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brief Psychiatric Rating Scale; Child; Drug Tolerance; Female; Humans; Male; Piperazines; Quinolones; Surveys and Questionnaires | 2007 |
Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Diagnosis, Dual (Psychiatry); Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Quinolones; Secondary Prevention; Temperance | 2007 |
Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.
Topics: Acute Disease; Adolescent; Adult; Age Distribution; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2008 |
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Electrocardiography; Fasting; Humans; Lipids; Nausea; Piperazines; Prolactin; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Weight Loss | 2007 |
Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Double-Blind Method; Female; Humans; Male; Piperazines; Quinolones | 2007 |
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; GABA Modulators; Humans; Lorazepam; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Remission Induction; Secondary Prevention; Severity of Illness Index; Surveys and Questionnaires | 2007 |
Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Asian People; Biotransformation; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Homozygote; Humans; Japan; Phenotype; Piperazines; Polymorphism, Genetic; Quinolones; Reference Values; Tablets | 2007 |
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Institutionalization; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance.
Topics: Administration, Intranasal; Adult; Antipsychotic Agents; Aripiprazole; Blood Pressure; Cocaine; Cocaine-Related Disorders; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Male; Piperazines; Quinolones; Surveys and Questionnaires | 2007 |
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Blood Glucose; Body Mass Index; Child; Chlorpromazine; Fasting; Female; Ghrelin; Glucose; Glucose Tolerance Test; Humans; Insulin; Leptin; Male; Piperazines; Quinolones; Risperidone; Sex Factors; Time Factors; Weight Gain | 2007 |
Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition; Drug Administration Schedule; Female; Humans; Male; Neuropsychological Tests; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizotypal Personality Disorder; Treatment Outcome | 2007 |
Aripiprazole as an adjunctive treatment for refractory unipolar depression.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Social Behavior; Time Factors; Treatment Outcome | 2008 |
Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Base Sequence; Brain; Cross-Over Studies; DNA Primers; Humans; Male; Piperazines; Placebos; Polymorphism, Genetic; Quinolones; Receptors, Dopamine D2; Reference Values; Single-Blind Method; Taq Polymerase | 2008 |
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence.
Topics: Adult; Aged; Alcoholism; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Temperance; Treatment Outcome | 2008 |
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2008 |
Effects of aripiprazole on subjective and physiological responses to alcohol.
Topics: Adult; Alcohol Drinking; Aripiprazole; Blood Pressure; Breath Tests; Double-Blind Method; Ethanol; Female; Heart Rate; Humans; Male; Middle Aged; Piperazines; Quinolones | 2008 |
A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Lorazepam; Male; Middle Aged; Nausea; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2008 |
Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Female; Humans; Interview, Psychological; Lamotrigine; Lithium Carbonate; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Quinolones; Triazines; Valproic Acid | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Treatment Outcome | 2008 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment | 2008 |
Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Valproic Acid | 2008 |
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Choice Behavior; Community Mental Health Services; Consumer Behavior; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy; Female; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires | 2008 |
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.
Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia | 2008 |
Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Tics; Tourette Syndrome; Treatment Outcome | 2008 |
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.
Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Piperazines; Quinolones; Secondary Prevention; Substance Withdrawal Syndrome | 2009 |
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Biological Availability; Biotransformation; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult | 2008 |
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Behavioral Symptoms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nursing Homes; Piperazines; Psychotic Disorders; Quinolones; United States | 2008 |
A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Child; Community Mental Health Centers; Female; Humans; Male; Piperazines; Quinolones; Thiazoles; Treatment Outcome | 2009 |
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2008 |
Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Area Under Curve; Aripiprazole; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Piperazines; Protein Binding; Quinolones; Severity of Illness Index | 2008 |
Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers.
Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Area Under Curve; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Cues; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Male; Methamphetamine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Socioeconomic Factors | 2008 |
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence | 2008 |
Aripiprazole in children with attention-deficit/hyperactivity disorder.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Dose-Response Relationship, Drug; Female; Headache; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Treatment Outcome | 2008 |
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Impulsive Behavior; Male; Models, Theoretical; Piperazines; Quinolones; Sleep; Social Control, Informal | 2008 |
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult | 2008 |
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2008 |
An open-label study of aripiprazole in nonschizophrenic crack-dependent patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Crack Cocaine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Substance Abuse Treatment Centers | 2008 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2008 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Quinolones; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2010 |
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Follow-Up Studies; Headache; Humans; Lithium Compounds; Male; Middle Aged; Nausea; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Treatment Outcome; Weight Gain | 2009 |
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride; Young Adult | 2008 |
The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period.
Topics: Administration, Intranasal; Antipsychotic Agents; Aripiprazole; Blood Pressure; Cocaine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Heart Rate; Humans; Male; Patient Acceptance of Health Care; Piperazines; Quinolones | 2008 |
Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quinolones | 2009 |
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia | 2009 |
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Dopamine Antagonists; Double-Blind Method; Female; Hospitalization; Humans; Lorazepam; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Triglycerides; United States; Young Adult | 2008 |
Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2008 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Interactions; Drug Monitoring; Female; Genotype; Humans; Male; Mental Disorders; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperazines; Polymorphism, Genetic; Quinolones; Young Adult | 2008 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult | 2009 |
Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Headache; Humans; Lorazepam; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Young Adult | 2008 |
Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention; Blood Pressure; China; Cognition; Cross-Over Studies; Cues; Data Interpretation, Statistical; Heart Rate; Humans; Male; Memory, Short-Term; Piperazines; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2009 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sexual Behavior; Treatment Outcome | 2008 |
A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dementia, Vascular; Double-Blind Method; Drug Tolerance; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Placebos; Psychomotor Agitation; Quinolones; United States | 2009 |
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Endpoint Determination; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome; Young Adult | 2009 |
A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Area Under Curve; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Lamotrigine; Male; Middle Aged; Piperazines; Quinolones; Sleep Initiation and Maintenance Disorders; Triazines | 2009 |
Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Stress Disorders, Post-Traumatic; Treatment Outcome | 2008 |
Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
Topics: Adult; Aged; Aripiprazole; Cross-Over Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Huntingtin Protein; Huntington Disease; Hyperkinesis; Male; Middle Aged; Nerve Tissue Proteins; Nuclear Proteins; Piperazines; Quinolones; Receptors, Dopamine D2; Tetrabenazine; Trinucleotide Repeats | 2009 |
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Body Weight; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Quinolones; Treatment Outcome | 2008 |
An open-label assessment of aripiprazole in the treatment of PTSD.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2009 |
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult | 2009 |
Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Female; Genotype; Glycine; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Restriction Fragment Length; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D3; Retrospective Studies; Schizophrenia; Serine; Time Factors; Treatment Outcome | 2009 |
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires | 2009 |
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome | 2009 |
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptor, Serotonin, 5-HT2A; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Young Adult | 2009 |
Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Humans; Pilot Projects; Piperazines; Quinolones; Surveys and Questionnaires | 2009 |
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Failure; Young Adult | 2009 |
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phobic Disorders; Piperazines; Prospective Studies; Psychometrics; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2009 |
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Protocols; Clozapine; Drug Resistance; Drug Therapy, Combination; Government Regulation; Haloperidol; Humans; Italy; Piperazines; Prospective Studies; Quinolones; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Severity of Illness Index | 2009 |
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Health Status; Humans; Male; Middle Aged; Outpatients; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quinolones; Risperidone; Schizophrenia; Sexuality; Treatment Outcome | 2009 |
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Triglycerides | 2009 |
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Body Mass Index; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Humans; Irritable Mood; Male; Pilot Projects; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Severity of Illness Index | 2009 |
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Pilot Projects; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Serotonin; Treatment Outcome | 2009 |
A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol.
Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Interactions; Female; Fructose; Humans; Male; Middle Aged; Neuroprotective Agents; Piperazines; Quinolones; Topiramate; Young Adult | 2009 |
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors; Treatment Failure | 2009 |
Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2010 |
Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.
Topics: Antimanic Agents; Aripiprazole; Carbamazepine; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2009 |
Open label aripiprazole in the treatment of youth with tic disorders.
Topics: Adolescent; Age Factors; Aripiprazole; Child; Female; Humans; Male; Mood Disorders; Piperazines; Quinolones; Tic Disorders; Treatment Outcome | 2009 |
Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state.
Topics: Adolescent; Adult; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Thinking; Treatment Outcome; Young Adult | 2009 |
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).
Topics: Antipsychotic Agents; Aripiprazole; Depression; Double-Blind Method; Female; Humans; Male; Massachusetts; Piperazines; Quinolones; Reproducibility of Results; Self Report; Surveys and Questionnaires | 2010 |
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Irritable Mood; Male; Personality Assessment; Piperazines; Psychomotor Agitation; Quinolones; Self-Injurious Behavior; Treatment Outcome | 2009 |
Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Piperazines; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index | 2009 |
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2009 |
Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2009 |
Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Diagnosis, Computer-Assisted; Female; Humans; Middle Aged; Pilot Projects; Piperazines; Quinolones; Risperidone; Schizophrenia, Paranoid; Schizophrenic Psychology; Severity of Illness Index; Social Behavior; User-Computer Interface; Young Adult | 2009 |
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Mood; Male; Personality Assessment; Piperazines; Quinolones; Treatment Outcome; Weight Gain | 2009 |
Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Weight; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Tics; Tourette Syndrome; Treatment Outcome; Young Adult | 2009 |
Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2010 |
Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
Topics: Administration, Oral; Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hostility; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Syndrome; Time Factors; Treatment Outcome | 2010 |
Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Quality of Life; Quinolones; Time Factors; Treatment Outcome; Young Adult | 2011 |
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antimanic Agents; Aripiprazole; Bipolar Disorder; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires | 2010 |
Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Time Factors | 2010 |
Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Germany; Humans; Male; Nausea; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Vomiting | 2010 |
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention; Cognition; Humans; Inpatients; Memory; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reaction Time; Schizophrenia; Time Factors; Treatment Outcome | 2010 |
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
Topics: Adult; Antimanic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome; Valproic Acid | 2010 |
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
Topics: Adolescent; Adult; Aged; Aripiprazole; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Physician's Role; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Young Adult | 2010 |
Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Argentina; Aripiprazole; Bipolar Disorder; Comorbidity; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Incidence; Long-Term Care; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2010 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
[A control study of aripiprazole and tiapride treatment for tic disorders in children].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Tiapamil Hydrochloride; Tic Disorders | 2010 |
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Social Behavior Disorders; Young Adult | 2010 |
The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Corpus Striatum; Cues; Dopamine; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Piperazines; Quinolones; Young Adult | 2010 |
Long-term treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Double-Blind Method; Female; Humans; Male; Pilot Projects; Piperazines; Postprandial Period; Quinolones; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Tobacco Use Disorder; Young Adult | 2010 |
A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007).
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Piperazines; Quinolones; Secondary Prevention; Treatment Outcome | 2010 |
Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Suicidal Ideation; Time Factors; Young Adult | 2011 |
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Young Adult | 2011 |
Aripiprazole versus haloperidol treatment in early-stage schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.
Topics: Adolescent; Affective Symptoms; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Checklist; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Self-Injurious Behavior; Treatment Outcome | 2010 |
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning | 2011 |
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Lamotrigine; Olanzapine; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome; Triazines | 2011 |
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain | 2010 |
Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2010 |
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Residence Characteristics; Schizophrenia; Standard of Care; Surveys and Questionnaires; Treatment Outcome | 2011 |
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Double-Blind Method; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors | 2011 |
Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological | 2011 |
The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Asian People; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Drug Therapy, Combination; Humans; Models, Economic; Outpatients; Piperazines; Quality-Adjusted Life Years; Quinolones; Thailand; Treatment Outcome | 2010 |
The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Risperidone; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome; Young Adult | 2011 |
A prospective open-label study of aripiprazole in fragile X syndrome.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Child; Female; Fragile X Syndrome; Humans; Male; Pilot Projects; Piperazines; Prospective Studies; Psychological Tests; Quinolones; Treatment Outcome; Young Adult | 2011 |
Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Receptors, Dopamine D2; Risperidone; Single-Blind Method; Young Adult | 2011 |
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Topics: Adult; Aged; Aripiprazole; Clomipramine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2011 |
[Efficacy of aripiprazole on patients with at-risk mental state and subjective well-being].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Personal Satisfaction; Piperazines; Psychotic Disorders; Quinolones; Risk; Young Adult | 2010 |
Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Carbon Radioisotopes; Cerebellum; Cerebral Cortex; Dopamine; Female; Humans; Male; Piperazines; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Salicylamides; Young Adult | 2011 |
Aripiprazole maintenance increases smoked cocaine self-administration in humans.
Topics: Adult; Aripiprazole; Blood Pressure; Cocaine; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Humans; Male; Piperazines; Quinolones; Reinforcement Schedule; Self Administration; Smoke; Token Economy | 2011 |
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Mood Disorders; Personal Satisfaction; Pilot Projects; Piperazines; Pleasure; Quinolones; Risperidone; Schizophrenia | 2011 |
Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Obsessive Behavior; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2011 |
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.
Topics: Adult; Antimanic Agents; Aripiprazole; Bipolar Disorder; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome; Valproic Acid | 2011 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cocaine; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Indoles; Linear Models; Male; Middle Aged; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Young Adult | 2011 |
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Olanzapine; Patient Selection; Piperazines; Proportional Hazards Models; Quinolones; Research Design; Schizophrenia; Time Factors | 2011 |
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone; Schizophrenia | 2012 |
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine; Female; Haloperidol; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reserpine; Single-Blind Method; Young Adult | 2011 |
Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Female; Follow-Up Studies; Humans; Irritable Mood; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2011 |
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2011 |
Open-label trial of aripiprazole in the treatment of trichotillomania.
Topics: Adult; Aripiprazole; Female; Humans; Middle Aged; Piperazines; Prospective Studies; Quinolones; Treatment Outcome; Trichotillomania; Young Adult | 2011 |
A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study).
Topics: Adult; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult | 2011 |
Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Blood Pressure; Cardiovascular System; Child; Electrocardiography; Female; Heart Rate; Humans; Longitudinal Studies; Male; Pimozide; Piperazines; Quinolones; Time Factors; Tourette Syndrome | 2011 |
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biotransformation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Genetic Association Studies; Half-Life; Humans; Japan; Male; Metabolic Clearance Rate; Paroxetine; Piperazines; Polymorphism, Genetic; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Young Adult | 2012 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2011 |
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clomipramine; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Secondary Prevention; Time Factors | 2012 |
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Topics: Adolescent; Aggression; Alanine Transaminase; Antipsychotic Agents; Aripiprazole; Aspartate Aminotransferases; Autistic Disorder; Basal Ganglia Diseases; Child; Drug Tolerance; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Weight Gain | 2011 |
Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Inpatients; Male; Outpatients; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome | 2011 |
An open-label study of aripiprazole in children with a bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Child, Preschool; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Outpatients; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Weight Gain | 2011 |
Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosi
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Early Medical Intervention; Female; Humans; Male; Piperazines; Placebos; Psychotic Disorders; Quinolones; Treatment Outcome; Young Adult | 2011 |
Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Treatment Outcome; Young Adult | 2011 |
A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2012 |
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2012 |
Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Drug Monitoring; Drug Resistance; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Turkey | 2012 |
Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome | 2011 |
An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Conduct Disorder; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2011 |
[A multicenter controlled study on aripiprazole treatment for children with Tourette syndrome in China].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Tiapamil Hydrochloride; Tourette Syndrome; Treatment Outcome | 2011 |
An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delirium; Female; Humans; Inpatients; Male; Middle Aged; Neoplasms; Piperazines; Prospective Studies; Quinolones; Severity of Illness Index; Statistics, Nonparametric | 2011 |
Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial.
Topics: Adult; Aripiprazole; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Time Factors; Treatment Outcome; Valproic Acid | 2011 |
Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Piperazines; Quinolones | 2012 |
Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Humans; Male; Models, Theoretical; Piperazines; Positron-Emission Tomography; Quinolones; Radiography; Receptors, Dopamine; Time Factors | 2012 |
Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Topics: Acute Disease; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Female; Genetic Carrier Screening; Genotype; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taq Polymerase; Treatment Outcome; Young Adult | 2012 |
A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Female; Follow-Up Studies; Humans; Lithium Compounds; Male; Middle Aged; Piperazines; Quinolones; Young Adult | 2012 |
Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Young Adult | 2012 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Carbon Radioisotopes; Corpus Striatum; Humans; Male; Piperazines; Positron-Emission Tomography; Pyrrolidines; Quinolones; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Salicylamides; Young Adult | 2012 |
No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dizziness; Double-Blind Method; Female; Haloperidol; Humans; Hypnotics and Sedatives; Male; Neurotoxicity Syndromes; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Severity of Illness Index; Sulpiride; Time Factors; Young Adult | 2012 |
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Constipation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Placebos; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United States; Weight Gain; Young Adult | 2012 |
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lamotrigine; Male; Middle Aged; Piperazines; Quinolones; Secondary Prevention; Treatment Outcome; Triazines | 2012 |
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; India; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2013 |
Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Logistic Models; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Severity of Illness Index; Tourette Syndrome; Treatment Outcome | 2012 |
Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Basal Ganglia Diseases; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Japan; Male; Mass Spectrometry; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Young Adult | 2012 |
Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.
Topics: Adolescent; Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Blood Pressure; Brain Mapping; Cerebrovascular Circulation; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Piperazines; Psychomotor Agitation; Quinolones; Receptors, Dopamine D2; Young Adult | 2013 |
An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Drug Resistance; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Stress Disorders, Post-Traumatic; Veterans | 2012 |
A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Double-Blind Method; Female; Humans; Male; Methamphetamine; Middle Aged; Patient Compliance; Piperazines; Psychoses, Substance-Induced; Quinolones | 2013 |
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study).
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Asia; Asian People; Bipolar Disorder; Double-Blind Method; Humans; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2014 |
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Proportional Hazards Models; Quinolones; Schizophrenia; Secondary Prevention | 2012 |
Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline | 2012 |
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.
Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology | 2013 |
The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Child; Child Development Disorders, Pervasive; Child, Preschool; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Irritable Mood; Male; Pilot Projects; Piperazines; Prospective Studies; Quinolones | 2012 |
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2012 |
Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2012 |
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.
Topics: Absorptiometry, Photon; Adult; Antipsychotic Agents; Aripiprazole; Body Composition; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose; Glucose Tolerance Test; Humans; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Piperazines; Quinolones; Schizophrenia | 2013 |
Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Memory; Middle Aged; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Semantics; Treatment Outcome; Verbal Learning; Young Adult | 2012 |
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome | 2013 |
Respondent and item level patterns of response of aripiprazole in the acute treatment of pediatric bipolar I disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Depression; Double-Blind Method; Female; Humans; Male; Parents; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2012 |
High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Limit of Detection; Male; Mental Disorders; Middle Aged; Piperazines; Quinolones; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2012 |
Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Child Development Disorders, Pervasive; Child, Preschool; Combined Modality Therapy; Comorbidity; Female; Follow-Up Studies; Humans; Male; Parents; Patient Education as Topic; Piperazines; Quinolones; Risperidone; Treatment Outcome | 2012 |
Effects of antipsychotic treatment on cognition in healthy subjects.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Attention; Brain; Cognition; Cognition Disorders; Dopamine Antagonists; Female; Haloperidol; Humans; Learning; Male; Middle Aged; Neurons; Piperazines; Quinolones; Reaction Time; Reserpine; Single-Blind Method; Young Adult | 2013 |
Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Hypnotics and Sedatives; Male; Piperazines; Psychomotor Performance; Quinolones; Risperidone; Sulpiride; Treatment Outcome; Young Adult | 2012 |
Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Amphetamine-Related Disorders; Aripiprazole; Combined Modality Therapy; Counseling; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Medication Adherence; Methamphetamine; Piperazines; Quinolones; Substance Abuse Detection; Treatment Failure | 2013 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States | 2013 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperazines; Quinolones; Time Factors; Treatment Outcome; Triazines; Valproic Acid | 2013 |
The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbon Radioisotopes; Cognition; Corpus Striatum; Fluorodeoxyglucose F18; Frontal Lobe; Humans; Male; Memory, Short-Term; Piperazines; Positron-Emission Tomography; Quinolones; Raclopride; Reaction Time; Receptors, Dopamine D2; Single-Blind Method; Young Adult | 2013 |
Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode.
Topics: Adult; Aripiprazole; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Longitudinal Studies; Male; Middle Aged; Piperazines; Quinolones; Secondary Prevention; Single-Blind Method; Tranquilizing Agents; Valproic Acid | 2013 |
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Functional Neuroimaging; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurons; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors | 2013 |
The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2012 |
Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Coronary Artery Disease; Dibenzothiazepines; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; United States | 2013 |
Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Female; Humans; Male; Parents; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reproducibility of Results; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2013 |
Intramuscular aripiprazole in the acute management of psychomotor agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Hospitals, University; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2013 |
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2013 |
Dynamic prediction of treatment response in late-life depression.
Topics: Age of Onset; Aged; Aged, 80 and over; Aripiprazole; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Remission Induction; Severity of Illness Index; Signal Detection, Psychological; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Incidence; Injections, Intramuscular; Maintenance Chemotherapy; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Weight Gain; Young Adult | 2013 |
Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Outcome Assessment, Health Care; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2013 |
Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Community Mental Health Services; Cross-Over Studies; Delayed-Action Preparations; Female; Hospitalization; Humans; Injections, Intramuscular; Male; North America; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index; Standard of Care | 2013 |
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Standard of Care; Treatment Outcome; Young Adult | 2013 |
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Hostility; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Young Adult | 2013 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Multivariate Analysis; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2013 |
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors; Treatment Outcome | 2013 |
Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Piperazines; Placebos; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2013 |
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Risperidone; Treatment Outcome | 2014 |
The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brazil; Clinical Protocols; Dibenzothiazepines; Drug Synergism; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Male; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Research Design; Time Factors; Treatment Outcome; Young Adult | 2013 |
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Sex Factors; Time Factors | 2013 |
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Humans; Insulin Resistance; Male; Mental Disorders; Olanzapine; Piperazines; Postprandial Period; Quinolones; Weight Gain; Young Adult | 2013 |
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Secondary Prevention; Treatment Outcome | 2013 |
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
Topics: Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors | 2013 |
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Protocols; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Research Design; Schizophrenia | 2013 |
The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Republic of Korea; Treatment Outcome; Young Adult | 2014 |
A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Female; Humans; Male; Neurologic Examination; Piperazines; Quinolones; Tourette Syndrome | 2013 |
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Asian People; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome | 2013 |
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Protocols; Female; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Remission Induction; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Treatment Outcome | 2013 |
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2014 |
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones | 2013 |
Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones | 2014 |
Predictive value of prospective memory for remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Memory, Episodic; Olanzapine; Piperazines; Prognosis; Quinolones; Remission Induction; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Female; Humans; Male; Piperazines; Quality of Life; Quinolones; Risperidone; Tic Disorders; Treatment Outcome | 2014 |
Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis.
Topics: Adolescent; Adult; Amphetamine; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Risperidone; Symptom Assessment; Treatment Outcome; Young Adult | 2014 |
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss | 2014 |
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.
Topics: Adult; Aripiprazole; Cocaine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Piperazines; Quinolones; Self Administration; Self Report; Smoking; Smoking Cessation; Treatment Outcome | 2014 |
Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.
Topics: Adult; Animals; Antidepressive Agents; Aripiprazole; Caudate Nucleus; Citalopram; Corpus Striatum; Depressive Disorder, Major; Dihydroxyphenylalanine; Dopamine; Dopamine Agonists; Drug Synergism; Female; Humans; Magnetic Resonance Imaging; Male; Piperazines; Positron-Emission Tomography; Quinolones; Sample Size; Single-Blind Method; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Double-Blind Method; Drug Administration Schedule; Female; Humans; Irritable Mood; Kaplan-Meier Estimate; Long-Term Care; Male; Piperazines; Placebos; Quinolones; Secondary Prevention; Treatment Outcome | 2014 |
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult | 2014 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
White matter changes associated with antipsychotic treatment in first-episode psychosis.
Topics: Anisotropy; Antipsychotic Agents; Aripiprazole; Brain; Diffusion Tensor Imaging; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipoproteins, LDL; Longitudinal Studies; Male; Nerve Fibers, Myelinated; Occipital Lobe; Parietal Lobe; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Young Adult | 2014 |
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Outpatients; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2014 |
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
Topics: Adult; Aripiprazole; Asian People; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Electrocardiography; Electroencephalography; Female; Genotype; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Piperazines; Quinolones | 2014 |
Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Odds Ratio; Piperazines; Psychomotor Agitation; Quinolones; Severity of Illness Index | 2014 |
[The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Obesity; Piperazines; Quinolones; Schizophrenia; Withholding Treatment | 2014 |
Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open-label, uncontrolled, preliminary study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Drug Administration Schedule; Drug Therapy, Combination; Female; Fructose; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Topiramate; Treatment Outcome; Young Adult | 2014 |
Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Treatment Outcome | 2014 |
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2015 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain | 2014 |
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Patient Selection; Piperazines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Quinolones; Sample Size; Schizophrenia | 2014 |
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Norepinephrine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior; Treatment Outcome | 2014 |
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sex Factors; Thiazoles; Weight Gain | 2014 |
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Placebos; Quinolones; Schizophrenia; Treatment Outcome | 2014 |
Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biological Availability; Buttocks; Delayed-Action Preparations; Deltoid Muscle; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult | 2014 |
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Self Care; Social Behavior; Treatment Outcome | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connectome; Corpus Striatum; Drug Monitoring; Episode of Care; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
The Chinese First-Episode Schizophrenia Trial: background and study design.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Quinolones; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
[Treatment of antipsychotic drug-induced phlegm dampness type amenorrhea by Wuji Powder and a small dose aripiprazole: a clinical study].
Topics: Aged; Amenorrhea; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Galactorrhea; Humans; Obesity; Piperazines; Quinolones; Waist-Hip Ratio | 2014 |
Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Benzhydryl Compounds; Cytochrome P-450 CYP3A Inducers; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Middle Aged; Modafinil; Piperazines; Quinolones; Wakefulness-Promoting Agents; Young Adult | 2015 |
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Weight Gain | 2016 |
[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult | 2016 |
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Sleep; Thiophenes; Treatment Outcome | 2017 |
Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nomograms; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2017 |
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult | 2018 |
Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2D6; Female; Humans; Ibuprofen; Male; Pharmacogenetics; Piperazines; Prolactin; Quinolones; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D3; Sex Factors; Young Adult | 2020 |
1032 other study(ies) available for aripiprazole and carbostyril
| Article | Year |
|---|---|
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Male; Mice; Mice, Inbred ICR; Motor Activity; Oxidopamine; Piperazines; Presynaptic Terminals; Quinolones; Radioligand Assay; Rats; Reserpine; Spiperone; Stereotyped Behavior; Synapses; Tritium | 1995 |
Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Autoreceptors; Behavior, Animal; Brain; Dopamine; Haloperidol; Male; Microdialysis; Neurons; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Time Factors | 1995 |
Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Azepines; Estradiol; Haloperidol; In Vitro Techniques; Male; Piperazines; Pituitary Gland, Anterior; Prolactin; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Reserpine | 1996 |
Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Azepines; Dopamine Agonists; Drug Synergism; Male; Oxidopamine; Piperazines; Piperidines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior; Sympathectomy, Chemical; Yawning | 1996 |
Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzazepines; Domperidone; Dopamine Antagonists; In Vitro Techniques; Male; Piperazines; Quinolones; Rats; Rats, Wistar; Ventral Tegmental Area | 1996 |
Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Clozapine; Corpus Striatum; Fluphenazine; Genes, fos; Haloperidol; In Situ Hybridization; Nucleus Accumbens; Piperazines; Prefrontal Cortex; Quinolones; Rats; RNA, Messenger; Septum Pellucidum; Sulpiride | 1996 |
Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agents; Electric Stimulation; In Vitro Techniques; Male; Neostriatum; Piperazines; Quinolones; Quinpirole; Rats; Rats, Wistar; Sulpiride | 1997 |
Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Dopamine Agonists; GTP Phosphohydrolases; Haloperidol; Male; Membranes; Neostriatum; Oligonucleotides, Antisense; Piperazines; Quinolones; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Up-Regulation | 1997 |
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine Antagonists; GABA Modulators; Male; Mice; Mice, Inbred ICR; Molecular Structure; Piperazines; Quinolones; Rats; Stereotyped Behavior; Structure-Activity Relationship | 1998 |
Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Cell Membrane; Gene Expression Regulation; Haloperidol; Male; Piperazines; Pituitary Gland; Prolactin; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Ribonucleases; RNA, Messenger; Spiperone | 1998 |
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Corpus Striatum; Cricetinae; Glioma; Piperazines; Quinolones; Rats; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Tumor Cells, Cultured | 1999 |
Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Domperidone; Dopamine; Dopamine Antagonists; Electric Stimulation; Electrophysiology; Evoked Potentials; Extracellular Space; Male; Microelectrodes; Neostriatum; Neurons; Piperazines; Quinolones; Rats; Rats, Wistar; Substantia Nigra | 1999 |
Aripiprazole. OPC 14597.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase II as Topic; Drugs, Investigational; Humans; Piperazines; Quinolones | 1999 |
Tandem sulfur-containing amino acids are epicritical determinants of dopamine D(2) receptor pharmacology.
Topics: Amino Acids, Sulfur; Animals; Aripiprazole; Aspartic Acid; Chlorocebus aethiops; COS Cells; Dopamine; Kinetics; Ligands; Piperazines; Point Mutation; Quinolones; Raclopride; Receptors, Dopamine D2 | 2000 |
In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Blood Pressure; Cardiac Output; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Haloperidol; Heart Rate; Hemodynamics; Piperazines; Quinolones; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure | 2001 |
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Corpus Striatum; Dopamine Agents; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substantia Nigra | 2001 |
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2001 |
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding Sites; Cricetinae; Dose-Response Relationship, Drug; Humans; Piperazines; Quinolones; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Receptor Agonists | 2002 |
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; GTP-Binding Proteins; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Signal Transduction; Spiperone | 2002 |
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Brain; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Neurons; Piperazines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Tomography, Emission-Computed | 2002 |
Synthetic study on the unique dimeric arylpiperazine: access to the minor contaminant of aripiprazole.
Topics: Amination; Antipsychotic Agents; Aripiprazole; Dimerization; Drug Contamination; Piperazines; Quinolones | 2003 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Aripiprazole (Abilify) for schizophrenia.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Dopamine Agonists; Drug Interactions; Fees, Pharmaceutical; Humans; Intestinal Absorption; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Therapeutic Equivalency | 2003 |
Aripiprazole. The newest antipsychotic agent for treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
Topics: Antipsychotic Agents; Aripiprazole; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Piperazines; Potassium Channels; Quinolones; Receptors, Dopamine; Receptors, Serotonin | 2003 |
Aripiprazole.
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Humans; Patents as Topic; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Piperazines; Quinolones | 2003 |
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Corpus Striatum; Dopamine; Haloperidol; Limbic System; Male; Mice; Mice, Inbred ICR; Piperazines; Quinolones; Risperidone; Time Factors | 2003 |
Aripiprazole in an adult with Asperger disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Humans; Male; Piperazines; Quinolones | 2003 |
Aripiprazole and extrapyramidal symptoms.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Drug Interactions; Male; Piperazines; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Tryptamines | 2004 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Biological Availability; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States | 2003 |
Medication developments in the treatment of mental illness.
Topics: Adolescent; Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Blood Glucose; Child; Depressive Disorder; Humans; Mental Disorders; Piperazines; Primary Health Care; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2003 |
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Microdialysis; Neostriatum; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin | 2004 |
Aripiprazole-induced improvement in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index | 2003 |
Aripiprazole and Parkinson's disease psychosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Quinolones | 2004 |
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
Topics: Anger; Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia | 2004 |
The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Mice; Piperazines; Prolactin; Protein Binding; Protein Isoforms; Quinolones; Rats; Receptors, Dopamine D2 | 2004 |
Aripirazole-olanzapine combination for treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
Excessive somnolence from aripiprazole in a child.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Disorders of Excessive Somnolence; Female; Humans; Piperazines; Quinolones | 2004 |
Aripiprazole possibly worsens psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2 | 2004 |
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Aripiprazole; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Haloperidol; Hippocampus; Male; Nucleus Accumbens; Piperazines; Prefrontal Cortex; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists | 2004 |
Worsening schizoaffective disorder with aripiprazole.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones | 2004 |
Aripiprazole-induced rabbit syndrome.
Topics: Adult; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Female; Humans; Piperazines; Quinolones; Syndrome | 2004 |
European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Anxiety; Aripiprazole; Dopamine Antagonists; Humans; Nicotinic Agonists; Piperazines; Psychotropic Drugs; Quinolones; Receptors, Metabotropic Glutamate; Receptors, Nicotinic; Schizophrenia | 2003 |
Aripiprazole and psychotherapy for delusional disorder, erotomanic type.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Female; Humans; Love; Obsessive Behavior; Piperazines; Psychotherapy; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2004 |
Chronic interictal psychosis responsive to aripiprazole.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Chronic Disease; Clonazepam; Delusions; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Epilepsy, Complex Partial; Epilepsy, Temporal Lobe; Female; Humans; Lamotrigine; Paranoid Disorders; Piperazines; Quinolones; Treatment Outcome; Triazines | 2004 |
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blepharoptosis; Catalepsy; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Head Movements; Male; Methoxydimethyltryptamines; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Prosencephalon; Quinolones; Rats; Rats, Wistar; Risperidone; Serotonin; Stereotyped Behavior | 2004 |
Possible increased efficacy of low-dose clozapine when combined with aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2004 |
Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Piperazines; Prolactin; Quinolones; Schizophrenia, Paranoid; Sexual Dysfunctions, Psychological; Thiazoles | 2004 |
The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Piperazines; Quality of Life; Quinolones; Risk Factors; Self-Injurious Behavior; Thiazoles | 2004 |
The use of the dopamine-receptor partial agonist aripiprazole in the treatment of restless legs syndrome.
Topics: Adult; Aripiprazole; Dopamine Agonists; Humans; Male; Piperazines; Quinolones; Restless Legs Syndrome | 2004 |
Aripiprazole for acute bipolar mania.
Topics: Acute Disease; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Multicenter Studies as Topic; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Treatment Outcome | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
Aripiprazole: novelty, adherence and understatement.
Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Therapeutic Equivalency | 2005 |
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazepines; Dose-Response Relationship, Drug; Histamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2004 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2004 |
[Expectation and development of atypical antipsychotic drugs].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2004 |
Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Down-Regulation; Humans; Models, Neurological; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia; Treatment Outcome | 2004 |
Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia | 2004 |
Aripiprazole and atypical neuroleptic malignant syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Time Factors | 2004 |
[Aripiprazol. An atypical neuroleptic with exceptional mechanisms of action] ].
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder; Dopamine Agonists; Humans; Piperazines; Quinolones | 2004 |
Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Child, Preschool; Humans; Male; Piperazines; Quinolones | 2004 |
Aripiprazole as an adjunctive treatment for refractory major depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones | 2004 |
Aripiprazole-associated dyskinesia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Valproic Acid | 2005 |
Treatment of tics in tourette syndrome with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Quinolones; Tics; Tourette Syndrome | 2005 |
[Aripiprazole and Tourette syndrome].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Tourette Syndrome | 2004 |
Aripiprazole for maladaptive behavior in pervasive developmental disorders.
Topics: Adolescent; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2004 |
Aripiprazole in the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Quinolones | 2004 |
The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome | 2004 |
Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2005 |
Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Treatment Outcome | 2005 |
Aripiprazole in a patient vulnerable to side effects.
Topics: Adult; Amenorrhea; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Piperazines; Quinolones; Sulpiride; Tourette Syndrome; Treatment Outcome | 2005 |
Aripiprazole and depression in schizoaffective disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Overdose of aripiprazole, a new type of antipsychotic.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Overdose; Emergency Medical Services; Female; Humans; Piperazines; Quinolones; Suicide, Attempted | 2005 |
Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Topics: Administration, Oral; Adult; Antifungal Agents; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Humans; Itraconazole; Male; Piperazines; Quinolones | 2005 |
Partial agonists in schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Up-Regulation | 2005 |
Aripiprazole-induced seizure.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Diagnosis, Differential; Epilepsy, Complex Partial; Humans; Male; Piperazines; Quinolones | 2005 |
Improvement in tardive dyskinesia with aripiprazole use.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Long-Term Care; Middle Aged; Piperazines; Quinolones; Risperidone; Valproic Acid | 2005 |
Aripiprazole in schizophrenia: consensus guidelines.
Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Case series on the use of aripiprazole for Tourette syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Tourette Syndrome | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; DNA, Complementary; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Humans; Lisuride; Piperazines; Piperidines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Risperidone; Transfection; Tritium | 2005 |
High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain Chemistry; Chromatography, High Pressure Liquid; Drug Stability; Freezing; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2005 |
Galactorrhea with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Piperazines; Quinolones; Receptors, Dopamine D2 | 2005 |
Aripiprazole reduces alcohol use.
Topics: Adult; Alcohol Drinking; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones | 2005 |
Atypical experience: a case series of pediatric aripiprazole exposures.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Drug Overdose; Female; Humans; Male; Pediatrics; Piperazines; Poison Control Centers; Quinolones; Suicide, Attempted; Treatment Outcome | 2005 |
Aripiprazole (abilify) overdose in a child.
Topics: Antipsychotic Agents; Aripiprazole; Child, Preschool; Drug Overdose; Female; Humans; Piperazines; Quinolones; Treatment Outcome; Unconsciousness | 2005 |
[Combining effectiveness and tolerance].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Female; Humans; Long-Term Care; Patient Compliance; Physician-Patient Relations; Piperazines; Prognosis; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
FDA warns antipsychotic drugs may be risky for elderly.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Drug Approval; Drug Labeling; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2005 |
The novel atypical antipsychotic aripiprazole as treatment for and prophylaxis against progressive multifocal leukoencephalopathy.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Leukoencephalopathy, Progressive Multifocal; Piperazines; Quinolones | 2005 |
An African patient with ziprasidone intolerance.
Topics: Africa; Antipsychotic Agents; Aripiprazole; Dystonia; Ethnicity; Germany; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome | 2005 |
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.
Topics: Animals; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Olanzapine; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Rats, Wistar; Weight Gain | 2005 |
[Aripiprazole in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma.
Topics: Aripiprazole; Chromatography, Liquid; Drug Stability; Humans; Mass Spectrometry; Piperazines; Quinolones; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dioxanes; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Antagonists; Haloperidol; Interpersonal Relations; Male; Phencyclidine; Piperazines; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Remoxipride; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles; Tropanes | 2005 |
Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; Male; Mice; Mice, Inbred C57BL; Microdialysis; Motor Activity; Norepinephrine; Piperazines; Prefrontal Cortex; Quinolones; Serotonin; Synaptic Transmission; Up-Regulation | 2005 |
TrkB partial agonists: potential treatment strategy for epilepsy, mania, and autism.
Topics: Aripiprazole; Autistic Disorder; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Epilepsy; Humans; Piperazines; Quinolones; Receptor, trkB; Signal Transduction | 2006 |
Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Brain; Dose-Response Relationship, Drug; Female; Maternal Behavior; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Sulpiride | 2005 |
One-year experience with aripiprazole exposures.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Drug Overdose; Emergency Medicine; Humans; Piperazines; Quinolones; Retrospective Studies; Suicide, Attempted; Treatment Outcome | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Clozapine; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Reversal of symptomatic hyperprolactinemia by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2005 |
['Awakening': a confusing improvement during treatment with atypical antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Humans; Piperazines; Quality of Life; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2005 |
Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Spectrophotometry, Ultraviolet | 2005 |
Aripiprazole in children and adolescents: clinical experience.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Child Behavior Disorders; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Treatment Outcome; Treatment Refusal | 2005 |
Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Anxiety Agents; Anti-HIV Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Lorazepam; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2005 |
Diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Female; Humans; Infusions, Intravenous; Insulin; Insulin, Isophane; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Aripiprazole in psychosis associated with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2005 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Synthesis of biologically active amines via rhodium-bisphosphite-catalyzed hydroaminomethylation.
Topics: Amination; Anti-Arrhythmia Agents; Antipsychotic Agents; Aripiprazole; Catalysis; Methylation; Molecular Structure; Phosphites; Piperazines; Quinolones; Rhodium; Stereoisomerism; Sulfonamides | 2005 |
Treatment of withdrawal dyskinesia.
Topics: Adolescent; Amino Acids, Branched-Chain; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Examination; Piperazines; Quinolones; Substance Withdrawal Syndrome; Treatment Outcome | 2005 |
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Suicide, Attempted; Thinking | 2005 |
Galactorrhea with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Second generation antipsychotics--aripiprazole revisited.
Topics: Antipsychotic Agents; Aripiprazole; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2005 |
Use of aripiprazole for psychosis and agitation in dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Female; Humans; Neuropsychological Tests; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Treatment Outcome | 2006 |
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania?
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Humans; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Quinolones; Research Design; Risperidone; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2005 |
Treatment-emergent psychosis with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones | 2005 |
Priapism associated with oxcarbazepine, aripiprazole, and lithium.
Topics: Adolescent; Affective Symptoms; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Carbamazepine; Child; Child Development Disorders, Pervasive; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Lithium Carbonate; Male; Oxcarbazepine; Penile Erection; Piperazines; Priapism; Quinolones | 2005 |
Atypical antipsychotics: special formulations for acute agitation.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Risperidone; Thiazoles | 2005 |
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Catalepsy; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Immunohistochemistry; Male; Motor Activity; Oncogene Proteins v-fos; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone | 2006 |
Hypertension and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Hypertension; Middle Aged; Piperazines; Quinolones; Schizophrenia, Paranoid | 2005 |
Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Calcium; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Female; Humans; Intracellular Space; Olanzapine; Piperazines; Protein Isoforms; Quinolones; Receptor, Serotonin, 5-HT2C; RNA Editing; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Transfection | 2006 |
[Determination of aripiprazole by nonaqueous reversed-phase high performance liquid chromatography].
Topics: Aripiprazole; Chromatography, High Pressure Liquid; Piperazines; Quinolones | 2005 |
Effect of aripiprazole for a patient with psychotic symptoms and parkinsonism associated with delayed-sequelae of carbon monoxide intoxication.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbon Monoxide Poisoning; Female; Humans; Mental Disorders; Parkinsonian Disorders; Piperazines; Quinolones | 2005 |
Aripiprazole-induced movement disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Syndrome | 2006 |
The patient with schizophrenia taking aripiprazole: case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Approval; Humans; Male; Outcome Assessment, Health Care; Patient Participation; Piperazines; Quality of Life; Quinolones; Schizophrenia | 2005 |
A case of Aripiprazole and extra pyramidal side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naive patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2006 |
Aripiprazole as a dopamine partial agonist: positive and negative effects.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists | 2006 |
Aripiprazole and suicidality.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia, Paranoid; Suicide, Attempted | 2006 |
Aripiprazole-induced parkinsonism.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Male; Middle Aged; Parkinsonian Disorders; Piperazines; Quinolones | 2006 |
Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diet; Epilepsy, Generalized; Female; Hallucinations; Humans; Hypnotics and Sedatives; Hypothyroidism; Lorazepam; Magnetic Resonance Imaging; Multiple Sclerosis; Paranoid Disorders; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Use of aripiprazole during late pregnancy in a woman with psychotic illness.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Pregnancy; Pregnancy Complications; Quinolones; Schizophrenia, Paranoid | 2006 |
Aripiprazole-induced extrapyramidal side effects in a patient with schizoaffective disorder.
Topics: Adult; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin Agents; Treatment Outcome | 2007 |
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Cricetinae; Cricetulus; Dioxanes; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Phosphorylation; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Signal Transduction; Transfection; Tropanes | 2006 |
[No rebound psychosis in a case of switching from clozapine to quetiapine].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brief Psychiatric Rating Scale; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Humans; Limbic System; Mesencephalon; Neural Pathways; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2006 |
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Piperazines; Psychotic Disorders; Quinolones; Sleep Wake Disorders; Suicide, Attempted | 2006 |
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quinolones; Sleep Wake Disorders; Suicide, Attempted | 2006 |
Effect of aripiprazole for a patient with psychotic symptoms and parkinsonism associated with delayed-sequelae of carbon monoxide intoxication.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Carbon Monoxide Poisoning; Female; Humans; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Quinolones; Treatment Outcome | 2006 |
Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combat Disorders; Female; Humans; Male; Piperazines; Quinolones; Stress Disorders, Post-Traumatic; Terrorism; Treatment Outcome; Veterans; Warfare | 2006 |
A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Piperazines; Quinolones; Substance-Related Disorders; Surveys and Questionnaires | 2006 |
The acutely psychotic patient--assessment and initial management.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Cyclohexanols; Female; Humans; Male; Physicians, Family; Piperazines; Practice Guidelines as Topic; Psychotic Disorders; Quinolones; Referral and Consultation; Risk Assessment; Venlafaxine Hydrochloride | 2006 |
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Binding, Competitive; Cell Line; Clozapine; Dioxanes; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Humans; Male; Piperazines; Prolactin; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Spodoptera; Sulfur Radioisotopes; Tropanes | 2006 |
Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
Topics: Analysis of Variance; Animals; Arachidonic Acid; Aripiprazole; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Guanosine Triphosphate; Mitogen-Activated Protein Kinases; Piperazines; Quinolones; Quinpirole; Receptors, Dopamine D2; Signal Transduction | 2007 |
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2006 |
Three cases of risperidone-induced enuresis.
Topics: Aripiprazole; Enuresis; Female; Humans; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2006 |
Acute dystonia with low-dosage aripiprazole in Tourette's disorder.
Topics: Acute Disease; Adolescent; Aripiprazole; Biperiden; Dystonia; Humans; Male; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome | 2006 |
Benefits of combining aripiprazole to clozapine: three case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia, Disorganized; Schizophrenia, Paranoid | 2006 |
High-dose aripiprazole in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Clozapine augmentation with aripiprazole for negative symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome | 2006 |
Aripiprazole in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Delirium; Female; Humans; Male; Neuropsychological Tests; Piperazines; Quinolones | 2005 |
Psychiatric decision making in the adoption of a new antipsychotic in Germany.
Topics: Antipsychotic Agents; Aripiprazole; Attitude of Health Personnel; Drug Utilization; Germany; Piperazines; Practice Patterns, Physicians'; Prospective Studies; Psychiatric Department, Hospital; Psychiatry; Quinolones | 2006 |
Aripiprazole and the neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2006 |
Aripiprazole in patients with Tourette syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Tics; Tourette Syndrome | 2006 |
Elevated lipase and diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Aripiprazole use in a pregnant schizoaffective woman.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Lactation; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quinolones | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
Neuroleptic malignant syndrome and aripiprazole.
Topics: Adolescent; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder; Female; Humans; Intellectual Disability; Lorazepam; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; United States | 2006 |
Aripiprazole pharmacotherapy of borderline personality disorder.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Personality Assessment; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones | 2006 |
Aripiprazole is effective in the treatment of Tourette's disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Tourette Syndrome | 2006 |
Aripiprazole-induced acute dystonia.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dystonia; Humans; Male; Muscarinic Antagonists; Piperazines; Quinolones; Torticollis; Trihexyphenidyl | 2006 |
[Pharmacology of antipsychotic drugs]].
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Norepinephrine; Piperazines; Quinolones; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology | 2006 |
Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Extinction, Psychological; Male; Motor Activity; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Secondary Prevention; Self Administration | 2007 |
Aripiprazole-related tardive dyskinesia.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quinolones | 2006 |
Aripiprazole associated with severe exacerbation of Parkinson's disease.
Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Pisa syndrome during aripiprazole treatment: a case report.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Dementia; Dibenzothiazepines; Dystonia; Female; Humans; Piperazines; Quetiapine Fumarate; Quinolones | 2007 |
Questionable advertising of psychotropic medications and disease mongering.
Topics: Advertising; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Industry; Humans; Piperazines; Psychotropic Drugs; Quinolones | 2006 |
Aripiprazole-associated seizure.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Schizophrenia; Seizures | 2006 |
Neuroleptic malignant syndrome with aripiprazole and lithium: a case report.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Lithium; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2006 |
A case of dose-dependent aripiprazole-induced conduction disturbance.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bundle-Branch Block; Dose-Response Relationship, Drug; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2006 |
Aripiprazole exposures reported to Texas poison control centers during 2002-2004.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Humans; Male; Piperazines; Poison Control Centers; Poisoning; Quinolones; Retrospective Studies; Texas | 2006 |
Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2006 |
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid | 2006 |
Aripiprazole in childhood and adolescence for Tourette syndrome.
Topics: Adolescent; Adolescent Behavior; Adult; Antipsychotic Agents; Aripiprazole; Attention; Body Weight; Child; Child Behavior; Cognition; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Psychomotor Agitation; Quinolones; Tourette Syndrome; Treatment Outcome | 2006 |
Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Binding, Competitive; Biotransformation; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Guanosine 5'-O-(3-Thiotriphosphate); HeLa Cells; Humans; Male; Motor Activity; Oxidopamine; Piperazines; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Species Specificity; Transfection | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
A case series: evaluation of the metabolic safety of aripiprazole.
Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome | 2007 |
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sulpiride; Treatment Failure | 2007 |
Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Agents; Dose-Response Relationship, Drug; Male; Motivation; Piperazines; Quinolones; Rats; Rats, Wistar; Reinforcement Schedule; Reward; Substance Withdrawal Syndrome | 2007 |
Advanced pediatric psychopharmacology.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cannabinoids; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Humans; Male; Marijuana Abuse; Mental Status Schedule; Neuroleptic Malignant Syndrome; Patient Readmission; Piperazines; Prognosis; Psychoses, Substance-Induced; Quinolones; Recurrence; Social Environment; Thiazoles; Treatment Refusal | 2006 |
A pilot study of aripiprazole in children and adolescents with Tourette's disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dose-Response Relationship, Drug; Humans; Korea; Neurologic Examination; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome | 2006 |
Neuroacanthocytosis: presenting with depression.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dystonia; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Risperidone; Schizophrenia, Paranoid; Treatment Outcome; Weight Gain | 2006 |
Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation.
Topics: Antipsychotic Agents; Aripiprazole; Cyclohexanols; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Skin; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Aripiprazole in chronic schizophrenia: experiences in daily practice.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors | 2006 |
Atypical neuroleptic malignant syndrome associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2006 |
Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study.
Topics: Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Cytochrome P-450 CYP2D6; Electroencephalography; Genotype; Half-Life; Humans; Male; Phenotype; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Severity of Illness Index; Time Factors | 2006 |
Recurrent priapism associated with use of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Priapism; Quinolones; Recurrence; Schizophrenia, Paranoid | 2006 |
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 recept
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzoxazoles; Clozapine; Discrimination Learning; Discrimination, Psychological; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Male; Oxazines; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2007 |
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology | 2007 |
Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Body Mass Index; Child; Child Behavior Disorders; Child, Preschool; Dose-Response Relationship, Drug; Drug Approval; Female; Follow-Up Studies; Humans; Impulsive Behavior; Intellectual Disability; Male; Mood Disorders; Piperazines; Quinolones; Reactive Attachment Disorder; Self-Injurious Behavior; Sleep Wake Disorders | 2006 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
[Endocrine side effects among psychiatric patients treated with antipsychotics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast; Dibenzothiazepines; Endocrine System; Female; Galactorrhea; Gynecomastia; Humans; Male; Olanzapine; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Schizophrenia; Sulpiride | 2006 |
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection | 2007 |
Urinary obstruction with citalopram and aripiprazole combination in an elderly patient.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Citalopram; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Urinary Retention | 2006 |
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine.
Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Area Under Curve; Aripiprazole; Central Nervous System Stimulants; Dextroamphetamine; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Humans; Piperazines; Psychomotor Performance; Quinolones | 2006 |
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation.
Topics: Adult; Aripiprazole; Clozapine; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6 Inhibitors; Drug Monitoring; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Quinolones | 2006 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; Catalepsy; Clozapine; Dopamine Agonists; Drug Evaluation, Preclinical; Haloperidol; Male; Piperazines; Prolactin; Proto-Oncogene Proteins c-fos; Psychotic Disorders; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Serotonin Antagonists; Treatment Outcome | 2007 |
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Italy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2007 |
Psychosis in a patient with Fabry's disease and treatment with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Fabry Disease; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Adjunctive aripiprazole in bipolar I depression.
Topics: Adult; Aged, 80 and over; Aripiprazole; Bipolar Disorder; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies | 2007 |
Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Hospitalization; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Retrospective Studies; Schizophrenia; Treatment Outcome | 2006 |
Diagnostic and therapeutic challenges in narcolepsy-related psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Hallucinations; Humans; Narcolepsy; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia | 2006 |
Manic episode during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Hyperglycemia in a 7-year-old child treated with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Humans; Hyperglycemia; Male; Piperazines; Quinolones | 2007 |
Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient.
Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Humans; Middle Aged; Mutation; Piperazines; Quinolones; Schizophrenia | 2007 |
Datapoints: The ups and downs of dosing second-generation antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles | 2007 |
Synthesis and bioactivity of aripiprazole derivatives.
Topics: Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Female; Indicators and Reagents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, Inbred ICR; Piperazines; Quinolones; Receptors, Dopamine; Sex Characteristics; Spectrophotometry, Infrared; Stereotyped Behavior | 2006 |
Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Dropouts; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones | 2007 |
Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Synergism; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2007 |
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia | 2007 |
Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Interactions; Electrophysiology; Hippocampus; Humans; Male; Neurons; Piperazines; Quinolones; Radioligand Assay; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists | 2007 |
Ultra-performance liquid chromatography-tandem mass spectrometry for the determination of atypical antipsychotics and some metabolites in in vitro samples.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Dibenzothiazepines; Indoles; Isoindoles; Piperazines; Quetiapine Fumarate; Quinolones; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazoles | 2007 |
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Topics: Action Potentials; Animals; Antipsychotic Agents; Aripiprazole; Autoreceptors; Brain; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Piperazines; Prefrontal Cortex; Quinolones; Raphe Nuclei; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Serotonin; Serotonin Receptor Agonists; Ventral Tegmental Area | 2007 |
Aripiprazole in delusional parasitosis: Case report.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Parasitic Diseases; Piperazines; Quinolones | 2007 |
Aripiprazole in human milk.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Milk, Human; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Clinical Trials as Topic; Female; Humans; Inpatients; Male; Mental Disorders; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Treatment Outcome | 2007 |
Aripiprazole-associated acute dystonia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Drug Interactions; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline | 2007 |
Acute dystonia associated with aripiprazole in a child.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Dystonia; Humans; Male; Piperazines; Quinolones; Receptors, Dopamine D2 | 2007 |
Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.
Topics: Amphetamine-Related Disorders; Animals; Antipsychotic Agents; Aripiprazole; Brain; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Drug Interactions; Male; Methamphetamine; Nucleus Accumbens; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Self Administration | 2007 |
A case of aripiprazole-induced mania.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dibenzothiazepines; Humans; Male; Mood Disorders; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia, Paranoid | 2007 |
Aripiprazole in a therapy-resistant patient with borderline personality and post-traumatic stress disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Drug Resistance; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Stress Disorders, Post-Traumatic | 2007 |
Indexing of reports on aripiprazole augmentation of clozapine.
Topics: Abstracting and Indexing; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Information Services; Information Storage and Retrieval; Piperazines; Quinolones; Schizophrenia | 2007 |
Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cognitive Behavioral Therapy; Combined Modality Therapy; Desensitization, Psychologic; Drug Therapy, Combination; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sertraline | 2008 |
An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.
Topics: Age of Onset; Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones | 2007 |
Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Weight Loss | 2007 |
Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Ascorbic Acid; beta Carotene; Brain; Calcium Channel Blockers; Citalopram; Glutathione; Glutathione Peroxidase; Lamotrigine; Lipid Peroxidation; Male; Neuroprotective Agents; Oxidative Stress; Piperazines; Quinolones; Random Allocation; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Triazines; Vitamin A | 2007 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Piperazines; Quinolones; Tranylcypromine; Treatment Outcome | 2007 |
Worsening of obsessive-compulsive symptoms after treatment with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Treatment Outcome | 2007 |
Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examination; Piperazines; Psychotic Disorders; Quinolones | 2007 |
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Clonazepam; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Patient Care Team; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Quinolones; Schizophrenia | 2007 |
Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Baclofen; Basal Ganglia Diseases; Citalopram; Diphenhydramine; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Hypnotics and Sedatives; Male; Mental Disorders; Oxazepam; Piperazines; Quinolones | 2007 |
Does aripiprazole have a role in treating cognitive impairment in Parkinson's disease?
Topics: Acetylcholine; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Administration Schedule; Humans; Male; Middle Aged; Parkinson Disease; Piperazines; Quinolones; Serotonin | 2007 |
Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia.
Topics: Affect; Aged; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Memantine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2007 |
Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Male; Parkinsonian Disorders; Piperazines; Quinolones; Schizophrenia | 2007 |
Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Blood Glucose; Dementia; Fluorodeoxyglucose F18; Follow-Up Studies; Frontal Lobe; Humans; Male; Mental Status Schedule; Piperazines; Positron-Emission Tomography; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2007 |
Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2007 |
Aripiprazole-induced hyponatremia: a case report.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyponatremia; Male; Piperazines; Quinolones | 2007 |
Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Treatment Outcome | 2007 |
Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Carbamazepine; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychotic Disorders; Quinolones; Trifluoperazine | 2007 |
Augmentation of clozapine treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2007 |
Aripiprazole and worsening of psychosis: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disease Progression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Recurrence | 2007 |
Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Lamotrigine; Piperazines; Quinolones; Schizophrenia; Stevens-Johnson Syndrome; Triazines | 2007 |
Violent behavior.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Commitment of Mentally Ill; Dangerous Behavior; Haloperidol; Humans; Male; Piperazines; Quinolones; Risk Factors; Students; Treatment Outcome; Universities; Violence; Virginia | 2007 |
Intramuscular aripiprazole in the control of agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzoxazoles; Carrier Proteins; Chlorocebus aethiops; Clozapine; COS Cells; Cricetinae; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Piperazines; Piperidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Transfection | 2007 |
Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Carbamazepine; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Valproic Acid | 2007 |
Relief from migraine headache with aripiprazole treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agents; Female; Humans; Migraine Disorders; Piperazines; Quinolones | 2007 |
Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; United Kingdom | 2007 |
Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clomipramine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Readmission; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Sensitivity and Specificity; Substance Withdrawal Syndrome; Survival Rate; Thiazoles | 2008 |
Aripiprazole--data on efficacy and associated mortality.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones | 2007 |
Aripiprazole--data on efficacy and associated mortality.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones | 2007 |
Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients.
Topics: Antipsychotic Agents; Aripiprazole; Gas Chromatography-Mass Spectrometry; Humans; Mental Disorders; Piperazines; Quinolones; Reference Standards; Sensitivity and Specificity | 2007 |
Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones | 2007 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.
Topics: Acute Disease; Acute Kidney Injury; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Diabetic Ketoacidosis; Humans; Male; Olanzapine; Pancreatitis; Piperazines; Quinolones; Schizophrenia | 2007 |
[Spectroscopic studies of aripiprazole].
Topics: Aripiprazole; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperazines; Quinolones; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet | 2007 |
Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Acoustic Stimulation; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta-Cyclodextrins; Circadian Rhythm; Excipients; Lighting; Male; Mice; Mice, Inbred DBA; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Species Specificity | 2007 |
Aripiprazole in a patient susceptible to urinary side effects of antipsychotics.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Urinary Retention | 2007 |
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Electron Transport Complex IV; Energy Metabolism; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Succinate Dehydrogenase | 2007 |
Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Aripiprazole; Ferrets; Male; Morphine; Piperazines; Quinolones; Receptors, Dopamine D2; Vomiting | 2007 |
Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Clomipramine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2007 |
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia | 2007 |
Agitation associated with aripiprazole initiation.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Receptors, Dopamine; Schizophrenia, Paranoid; Up-Regulation | 2007 |
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission | 2007 |
Aripiprazole-induced tardive dyskinesia: the role of tamoxifen.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine; Tamoxifen | 2007 |
Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine D2 Receptor Antagonists; Female; Humans; Middle Aged; Parkinsonian Disorders; Piperazines; Quinolones; Receptors, Dopamine D2 | 2007 |
[Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Humans; Motor Activity; Piperazines; Prospective Studies; Quinolones; Tourette Syndrome; Treatment Outcome | 2007 |
Possible psychotropic effects of Aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid | 2007 |
Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Female; Haloperidol; In Situ Hybridization; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; RNA, Messenger; Time | 2008 |
Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Quinolones; Retrospective Studies | 2007 |
Adjunctive aripiprazole in combat-related posttraumatic stress disorder.
Topics: Aripiprazole; Combat Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones; Stress Disorders, Post-Traumatic | 2007 |
Combined use of ECT with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Electroconvulsive Therapy; Hospitalization; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2009 |
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2008 |
Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Blotting, Western; Cerebral Cortex; Gene Expression Profiling; Male; Oligonucleotide Array Sequence Analysis; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transcription, Genetic | 2008 |
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2007 |
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clonazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Piperazines; Prolactin; Quinolones; Valproic Acid | 2007 |
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Remission Induction; Schizophrenia; Substance-Related Disorders | 2007 |
Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline.
Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Severity of Illness Index; Surveys and Questionnaires | 2007 |
Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration.
Topics: Adult; Aripiprazole; Drug Administration Schedule; Humans; Male; Piperazines; Psychoses, Substance-Induced; Quinolones; Schizophrenia, Paranoid; Severity of Illness Index | 2007 |
Reversal of trichotillomania with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Morpholines; Piperazines; Quinolones; Reboxetine; Self Concept; Sertraline; Social Adjustment; Trichotillomania | 2008 |
Practical strategies for assessing and stabilizing bipolar patients in urgent situations.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Emergency Services, Psychiatric; Humans; Impulsive Behavior; Injections, Intramuscular; Olanzapine; Piperazines; Practice Guidelines as Topic; Quinolones; Risperidone; Suicide, Attempted; Thiazoles; Time Factors | 2007 |
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia | 2007 |
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Ephedrine; Feeding and Eating Disorders; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2007 |
Augmentation of aripiprazole with low-dose clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Sleep; Treatment Outcome | 2007 |
A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Time Factors | 2007 |
Psychotic episode associated with Bikram yoga.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome; Yoga | 2007 |
Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Bayes Theorem; Biological Availability; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Humans; Itraconazole; Japan; Male; Metabolic Clearance Rate; Models, Theoretical; Piperazines; Polymorphism, Genetic; Quinolones; Software; Tablets | 2007 |
Successful treatment of catatonia with aripiprazole in an adolescent with psychosis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Child Development Disorders, Pervasive; Child, Preschool; Female; Hospitalization; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones | 2007 |
Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.
Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Comorbidity; Epilepsy; Female; Humans; Kidney Failure, Chronic; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2007 |
Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats.
Topics: Animals; Animals, Newborn; Aripiprazole; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Agonists; Lisuride; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Sprague-Dawley | 2008 |
Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Brain; Cocaine-Related Disorders; Diffusion Magnetic Resonance Imaging; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Piperazines; Quinolones; Substance-Related Disorders | 2007 |
Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Mood Disorders; Piperazines; Quinolones; Risperidone; Withholding Treatment | 2007 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Databases, Factual; Dementia; Dibenzothiazepines; Drug Utilization Review; Health Services for the Aged; Humans; Olanzapine; Pharmaceutical Services; Piperazines; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Stroke; Thiazoles; Treatment Outcome | 2007 |
Repeated creatine kinase elevation under treatment with quetiapine, clozapine, and aripiprazole in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Creatine Kinase; Dibenzothiazepines; Humans; Male; Personality Disorders; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2007 |
Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Central Nervous System Stimulants; Cocaine; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Partial Agonism; Excitatory Amino Acid Antagonists; Glutamine; Haloperidol; Hyperkinesis; Ketamine; Locomotion; Male; Mice; Motor Activity; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Time Factors | 2008 |
[The neuroleptic treatment of delusional parasitosis: first experiences with aripiprazole].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Ectoparasitic Infestations; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2008 |
Effectiveness of aripiprazole in treating obsessive compulsive symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Conditioning, Classical; Dopamine Agents; Drug Interactions; Inhibition, Psychological; Ion Channel Gating; Male; Neural Inhibition; Piperazines; Quinolones; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D2; Reflex, Startle | 2008 |
Aripiprazole and perphenazine: no difference.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Marketing; Perphenazine; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires | 2007 |
A case of aripiprazole-related tardive akathisia and its treatment with ropinirole.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Indoles; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2007 |
Aripiprazole treatment of patients with borderline personality disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Male; Piperazines; Quinolones; Severity of Illness Index | 2007 |
Tardive dystonic symptoms associated with aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dyskinesia, Drug-Induced; Dystonia; Humans; Intellectual Disability; Male; Ocular Motility Disorders; Piperazines; Quinolones; Schizophrenia | 2008 |
Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
Topics: Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Data Interpretation, Statistical; Dopamine Agonists; Hallucinogens; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Motor Activity; N-Methylaspartate; Piperazines; Postural Balance; Psychoses, Substance-Induced; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Serotonin Receptor Agonists | 2008 |
Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome | 2008 |
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Male; Piperazines; Quinolones; Schizophrenia; Sulpiride | 2008 |
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Severity of Illness Index | 2007 |
Aripiprazole treatment for risperidone-associated tic movement: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Risperidone; Schizophrenia; Tic Disorders | 2008 |
Aripiprazole: effectiveness and safety under naturalistic conditions.
Topics: Adult; Antipsychotic Agents; Anxiety; Aripiprazole; Female; Humans; Inpatients; Italy; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Recurrence; Retrospective Studies; Schizoid Personality Disorder; Schizophrenia, Paranoid; Schizotypal Personality Disorder; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome | 2007 |
Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain Injuries; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome; Withholding Treatment | 2008 |
Effectiveness of aripiprazole in treatment of adults with attention deficit disorder and restless legs syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Female; Humans; Piperazines; Quinolones; Restless Legs Syndrome | 2008 |
[Aripiprazole for the treatment of Tourette's syndrome].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome | 2008 |
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Hyperphagia; Motor Activity; Olanzapine; Piperazines; Quinolones; Rats; Thiazoles; Weight Gain | 2008 |
Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Blood Cell Count; Dibenzothiazepines; Female; Humans; Leukopenia; Neutropenia; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride | 2008 |
Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Movement Disorders; Piperazines; Quinolones; Schizophrenia | 2008 |
Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Stereotyped Behavior | 2008 |
Aripiprazole diminishes cannabis use in schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Piperazines; Quinolones; Schizophrenia | 2008 |
Partial agonists and suicide: the role of the mental health nurse.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Nurse's Role; Piperazines; Quinolones; Schizophrenia; Suicide Prevention | 2008 |
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Male; Piperazines; Quinolones; Risk Assessment; Risperidone; Schizophrenia | 2009 |
Change in sexual dysfunction with aripiprazole: a switching or add-on study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Ejaculation; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Libido; Male; Menstruation Disturbances; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Sex Characteristics; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2008 |
Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Delusional disorder, somatic type treated with aripiprazole--mirtazapine combination.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Employment; Female; Humans; Mianserin; Middle Aged; Mirtazapine; Piperazines; Quinolones; Schizophrenia, Paranoid; Social Behavior | 2008 |
Use of Aripiprazole in treatment resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2008 |
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia | 2008 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea | 2008 |
Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Cyanides; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Glutathione; Humans; Microsomes, Liver; Piperazines; Quinolones; Triazoles | 2008 |
Photo-onycholysis caused by olanzapine and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Erythema; Female; Humans; Middle Aged; Olanzapine; Onycholysis; Photosensitivity Disorders; Piperazines; Quinolones | 2008 |
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials.
Topics: Affective Symptoms; Aggression; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Conduct Disorder; Double-Blind Method; Humans; Irritable Mood; Mood Disorders; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dystonia; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2008 |
The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Prescriptions; Drug Therapy, Combination; Female; Hospital Bed Capacity, 300 to 499; Hospitals, Psychiatric; Hospitals, University; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Retrospective Studies; Schizophrenia | 2008 |
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors | 2008 |
Development and validation of a high-performance liquid chromatography method using diode array detection for the simultaneous quantification of aripiprazole and dehydro-aripiprazole in human plasma.
Topics: Adolescent; Adult; Aripiprazole; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2008 |
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Haloperidol; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Histamine H1; RNA, Messenger; Time Factors; Ventromedial Hypothalamic Nucleus; Weight Gain | 2008 |
Analysis of the recent antipsychotic aripiprazole in human plasma by capillary electrophoresis and high-performance liquid chromatography with diode array detection.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Humans; Molecular Structure; Piperazines; Quinolones; Reproducibility of Results | 2008 |
The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine-induced locomotor stimulation in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Ethanol; Male; Mice; Motor Activity; Piperazines; Quinolones; Receptors, Dopamine D2 | 2008 |
Delayed presentation of an aripiprazole overdose.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disorders of Excessive Somnolence; Drug Overdose; Female; Half-Life; Humans; Piperazines; Quinolones; Suicide, Attempted; Time Factors | 2008 |
Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Electrocardiography; Female; Haloperidol; Heart Conduction System; Humans; Long QT Syndrome; Piperazines; Quinolones; Schizophrenia | 2008 |
Antipsychotic-induced oxidative stress in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Haloperidol; Hippocampus; Male; Olanzapine; Oxidative Stress; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Wistar; Superoxides; Thiobarbituric Acid Reactive Substances | 2008 |
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding Sites; Brain; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia | 2008 |
Effect of aripiprazole on 5-HT2 receptor-mediated wet-dog shake responses and disruption of prepulse inhibition in rats.
Topics: Amphetamines; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Behavior, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Models, Animal; Piperazines; Quinolones; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine; Reflex, Startle; Serotonin Receptor Agonists; Stereotyped Behavior; Time Factors | 2008 |
Do dopamine partial agonists have partial efficacy as antipsychotics?
Topics: Antipsychotic Agents; Aripiprazole; Brain; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Treatment Outcome | 2008 |
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding, Competitive; Brain; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Pituitary Gland; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult | 2008 |
Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Brain; Calcium; Cell Survival; Cells, Cultured; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Interferon-gamma; Mice; Microglia; Neurons; Nitric Oxide; Piperazines; Quinolones; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Tumor Necrosis Factor-alpha | 2008 |
Aripiprazole improves neuroleptic-associated tardive dyskinesia, but it does not meliorate psychotic symptoms.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones | 2008 |
Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Chlordiazepoxide; Female; Fluoxetine; GABA Modulators; Phencyclidine; Piperazines; Pyridines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Social Behavior Disorders | 2008 |
Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemic Hyperosmolar Nonketotic Coma; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2009 |
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome | 2008 |
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Parkinsonian Disorders; Piperazines; Polymorphism, Genetic; Psychotic Disorders; Quinolones; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risk Factors | 2008 |
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benztropine; Corpus Striatum; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Prolactin; Quinolones; Receptors, Dopamine D2; Schizophrenia | 2008 |
Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Male; Methylphenidate; Mice; Mice, Inbred Strains; Motivation; Motor Activity; Motor Skills; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Self Administration | 2008 |
Adjunctive aripiprazole for bupropion-resistant major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2008 |
Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Drug Administration Schedule; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Time; Up-Regulation | 2008 |
Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy.
Topics: Antipsychotic Agents; Aripiprazole; Child; Diabetic Ketoacidosis; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2008 |
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Apomorphine; Aripiprazole; Benzoxazoles; Dopamine; Dopamine D2 Receptor Antagonists; Electroshock; Haloperidol; Male; Neurons; Piperazines; Pyridines; Quinolones; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Ultrasonics; Ventral Tegmental Area; Vocalization, Animal | 2009 |
A case of aripiprazole and tardive dyskinesia.
Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult | 2009 |
[Reaction to 'Augmentation with atypical antipsychotics in the treatment of patients with a therapy-resistant depression: a review'].
Topics: Antipsychotic Agents; Aripiprazole; Depression; Evidence-Based Medicine; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia | 2008 |
Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzazepines; Bipolar Disorder; Depressive Disorder; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotherapy; Quinolones; Quinoxalines; Smoking Cessation; Stress, Psychological; Varenicline | 2008 |
Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Panic Disorder; Personality Inventory; Piperazines; Prospective Studies; Quinolones; Treatment Outcome | 2008 |
Case report of aripiprazole usage during pregnancy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Infant, Newborn; Maternal Behavior; Piperazines; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Quinolones; Schizophrenia; Treatment Outcome | 2008 |
Successful treatment of delusional disorder with low-dose aripiprazole.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Parkinsonian Disorders; Piperazines; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2008 |
Significance of findings in aripiprazole for treatment of psychoses in Alzheimer dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Research Design; Treatment Outcome | 2008 |
D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cholesterol; Delayed-Action Preparations; Lactic Acid; Microspheres; Particle Size; Piperazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Quinolones; Schizophrenia; Solubility; Solvents | 2008 |
Leukopenia and thrombocytopenia on adding aripiprazole to phenytoin.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Leukopenia; Phenytoin; Piperazines; Quinolones; Schizophrenia, Paranoid; Thrombocytopenia | 2009 |
Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats.
Topics: Anesthetics, Local; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clinical Trials as Topic; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Partial Agonism; Food, Fortified; Infusions, Intravenous; Male; Piperazines; Proteins; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reinforcement Schedule; Self Administration | 2008 |
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2008 |
Aripiprazole in a case presenting with tourette syndrome and obsessive-compulsive disorder.
Topics: Adult; Aripiprazole; Dopamine Agonists; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Tourette Syndrome | 2008 |
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Humans; Hypertriglyceridemia; Mental Disorders; Piperazines; Quinolones; Substance-Related Disorders; Triglycerides; Weight Gain | 2008 |
Case report of aripiprazole for persistent developmental stuttering.
Topics: Adult; Anti-Anxiety Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Stuttering | 2008 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
Topics: Adolescent; Adult; Aging; Antipsychotic Agents; Aripiprazole; Biotransformation; Body Mass Index; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quinolones; Regression Analysis; Schizophrenia; Sex Characteristics; Young Adult | 2008 |
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Catalepsy; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Indoles; Ketanserin; Male; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Piperidines; Postural Balance; Psychomotor Performance; Pyridines; Quinolones; Quinpirole; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2008 |
Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis.
Topics: Adult; Aripiprazole; Female; Humans; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones | 2008 |
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
Topics: Antipsychotic Agents; Aripiprazole; Corpus Striatum; Humans; Piperazines; Positron-Emission Tomography; Quality of Life; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Time Factors | 2008 |
Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Antagonists; Exploratory Behavior; Haloperidol; Male; Memory Disorders; Mice; Mice, Inbred ICR; Motor Activity; Phencyclidine; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Recognition, Psychology | 2009 |
Aripiprazole joins the family of second-generation mood stabilizers.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
Intrinsic activity of aripiprazole is not 30% of dopamine, but only about 6% under ideal antipsychotic therapy.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Receptors, Dopamine D2 | 2008 |
Remission of chronic severe selective serotonin-reuptake inhibitor/selective norepinephrine-reuptake inhibitor refractory depression following adjunctive aripiprazole.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Depression; Drug Therapy, Combination; Female; Humans; Middle Aged; Norepinephrine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2008 |
Apparent commercial bias in supplement.
Topics: Antipsychotic Agents; Aripiprazole; Bias; Commerce; Health Status; Humans; Patient Satisfaction; Piperazines; Psychopharmacology; Psychotic Disorders; Quinolones | 2008 |
Is aripiprazole an efficacious adjunct for unipolar depression?
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred Strains; Olanzapine; Piperazines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Serotonin Receptor Agonists; Species Specificity | 2008 |
Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Male; Mental Disorders; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Personality Disorders; Piperazines; Psychotropic Drugs; Quinolones; Retrospective Studies; Schizophrenia; Spain | 2008 |
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin-Secreting Cells; Male; Olanzapine; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2008 |
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Netherlands; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia | 2008 |
Practical guidance for prescribing with aripiprazole in bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Male; Piperazines; Quinolones | 2008 |
Amphetamine as a risk factor for aripiprazole-induced acute dystonia.
Topics: Acute Disease; Adult; Amphetamine; Aripiprazole; Dystonia; Humans; Male; Piperazines; Quinolones; Risk Factors | 2008 |
Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia.
Topics: Animals; Aripiprazole; Dose-Response Relationship, Drug; Glutamic Acid; Humans; Male; Neuroprotective Agents; Piperazines; Prefrontal Cortex; Presynaptic Terminals; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia | 2008 |
Diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diabetic Ketoacidosis; Fluid Therapy; Humans; Hypoglycemic Agents; Insulin; Male; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Aripiprazole in the treatment of primary delusional parasitosis.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Ectoparasitic Infestations; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Huntington Disease; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Weight Gain | 2008 |
Catatonia resolution and aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Female; Humans; Piperazines; Quinolones; Severity of Illness Index | 2008 |
Aripiprazole-induced orthostatic hypotension and cardiac arrhythmia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Humans; Hypotension, Orthostatic; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachycardia, Supraventricular | 2008 |
Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Protein Binding; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2008 |
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Libido; Piperazines; Quinolones; Schizophrenia; Sexual Dysfunction, Physiological | 2008 |
Is a high dosage aripiprazole-clozapine combination an effective strategy for treatment-resistant schizophrenic patients? A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia, Paranoid | 2009 |
Bipolar drug development: are we getting closer to the real world?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compounds; Patient Dropouts; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Valproic Acid | 2008 |
Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Mutation; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D3; Tetrahydronaphthalenes; Transfection | 2008 |
Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Receptors, Dopamine D2; Retrospective Studies; Tourette Syndrome | 2009 |
Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Anxiety; Aripiprazole; Borderline Personality Disorder; Diagnostic and Statistical Manual of Mental Disorders; Drug Resistance; Drug Therapy, Combination; Headache; Humans; Middle Aged; Personality Inventory; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2008 |
Aripiprazole treatment for depression in schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Genetic Predisposition to Disease; Hospitalization; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taiwan; Treatment Outcome; Young Adult | 2009 |
Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Severity of Illness Index; Tourette Syndrome; Treatment Outcome | 2008 |
Psychosis or atypical neuroleptic malignant syndrome in an adolescent?
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Short-term physical compatibility of intramuscular aripiprazole with intramuscular lorazepam.
Topics: Aripiprazole; Drug Combinations; Drug Incompatibility; Humans; Injections, Intramuscular; Lorazepam; Piperazines; Quinolones; Time Factors | 2008 |
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Decision Support Techniques; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Olanzapine; Patient Acceptance of Health Care; Piperazines; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; United Kingdom | 2008 |
Unusual weight fluctuation under corticosteroid and psychotropic treatment.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Aripiprazole; Body Weight; Cyclosporine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Eating; Female; Humans; Mianserin; Paroxetine; Piperazines; Prednisolone; Quinolones; Sertraline; Takayasu Arteritis | 2008 |
Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Long-Term Care; Piperazines; Quinolones; Schizophrenia, Paranoid; Sulpiride; Thiazoles; Young Adult | 2008 |
Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Hyperkinesis; Male; Mice; Mice, Inbred ICR; Morphine; Nucleus Accumbens; Piperazines; Prochlorperazine; Quinolones; Reward; Severity of Illness Index | 2008 |
Aripiprazole-induced rabbit syndrome: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quinolones; Syndrome | 2010 |
Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benztropine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Intellectual Disability; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Olanzapine; Piperazines; Quinolones; Risk Factors | 2008 |
Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Blood Glucose; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Hindlimb Suspension; Male; Mice; Mice, Inbred ICR; Models, Animal; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Time Factors | 2008 |
Conformational polymorphism in aripiprazole: Preparation, stability and structure of five modifications.
Topics: Antipsychotic Agents; Aripiprazole; Calorimetry, Differential Scanning; Crystallization; Crystallography, X-Ray; Humans; Kinetics; Molecular Conformation; Piperazines; Quinolones; Solvents; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Thermodynamics | 2009 |
A UK consensus on the administration of aripiprazole for the treatment of mania.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Humans; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinolones; United Kingdom | 2009 |
Antidepressant-induced sweating alleviated by aripiprazole.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Hyperhidrosis; Middle Aged; Piperazines; Quinolones; Sweating; Thiophenes | 2008 |
Predictors of aripiprazole treatment continuation in hospitalized patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Discharge; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome | 2008 |
Market watch : Pharma industry strategic performance: 2007-2012E.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antipsychotic Agents; Aripiprazole; Bevacizumab; Costs and Cost Analysis; Drug and Narcotic Control; Drug Industry; Drug Therapy; Humans; Infliximab; Marketing of Health Services; Piperazines; Quinolones; Reward; United States | 2008 |
An olfactory reference syndrome successfully treated by aripiprazole augmentation of antidepressant therapy.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Delusions; Electroencephalography; Female; Hallucinations; Humans; Magnetic Resonance Imaging; Neuropsychological Tests; Olfactory Bulb; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Smell | 2008 |
Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Creatine Kinase; Documentation; Female; Humans; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Asian People; Chromatography, Liquid; Humans; Piperazines; Quinolones; Reproducibility of Results; Tandem Mass Spectrometry | 2009 |
Treatment of alternating hemiplegia of childhood with aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Behavior Therapy; Child Behavior Disorders; Combined Modality Therapy; Dopamine Agonists; Female; Follow-Up Studies; Hemiplegia; Humans; Neurologic Examination; Piperazines; Quinolones; Recurrence | 2009 |
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Risperidone; Schizophrenia; Valproic Acid | 2009 |
An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Selective Serotonin Reuptake Inhibitors | 2009 |
Aripiprazole in refractory depression?
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2009 |
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2009 |
Successful switch from clozapine to aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Administration Schedule; Drug Resistance; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Enzyme Repression; Humans; Lithium Compounds; Piperazines; Quinolones; Trimeprazine | 2009 |
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult | 2009 |
Aripiprazole-induced sialorrhea.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Male; Piperazines; Quinolones; Sialorrhea; Valproic Acid | 2009 |
Supersensitivity psychosis after tapering aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Fear; Hallucinations; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenic Psychology | 2009 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells.
Topics: Analysis of Variance; Antipsychotic Agents; Aripiprazole; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Humans; Luciferases; Neuroblastoma; Piperazines; Proto-Oncogene Proteins c-bcl-2; Quinolones; Signal Transduction; Transfection | 2009 |
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brain; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation, Enzymologic; Haloperidol; Limbic System; Nucleus Accumbens; Olanzapine; Piperazines; Putamen; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation; Ventral Tegmental Area | 2009 |
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2009 |
Aripiprazole-induced agitation after clozapine discontinuation: a case report.
Topics: Akathisia, Drug-Induced; Alcoholism; Antipsychotic Agents; Aripiprazole; Clozapine; Cocaine-Related Disorders; Comorbidity; Delayed-Action Preparations; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Middle Aged; Molindone; Piperazines; Quinolones; Schizophrenia, Paranoid; Substance Withdrawal Syndrome | 2009 |
Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Infant; Piperazines; Poisoning; Quinolones | 2009 |
A case of late-onset Tourette's disorder successfully treated with aripiprazole: view from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF).
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Brain; Brain-Derived Neurotrophic Factor; Catecholamines; Diagnostic and Statistical Manual of Mental Disorders; Humans; Male; Piperazines; Quinolones; Severity of Illness Index; Tomography, X-Ray Computed; Tourette Syndrome; Young Adult | 2009 |
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Aripiprazole brain concentration is altered in P-glycoprotein deficient mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Chromatography, High Pressure Liquid; Male; Mice; Mice, Knockout; Piperazines; Quinolones; Time Factors; Tissue Distribution | 2009 |
Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
Topics: Amisulpride; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Biperiden; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Schizophrenic Psychology; Sulpiride; Young Adult | 2009 |
Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Medical Records Systems, Computerized; Mental Health Services; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index | 2009 |
Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia | 2009 |
Refractory restless legs syndrome likely caused by olanzapine.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Restless Legs Syndrome; Valproic Acid | 2009 |
Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
Topics: Adult; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Data Interpretation, Statistical; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Socioeconomic Factors; Treatment Failure | 2009 |
[Aripiprazole and priapism].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Priapism; Quinolones; Young Adult | 2009 |
Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells.
Topics: Alternative Splicing; Antipsychotic Agents; Aripiprazole; Astrocytoma; Benzodiazepines; Cell Line, Tumor; Clozapine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; RNA-Binding Proteins; RNA, Messenger; Time Factors | 2009 |
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Courses of aripiprazole-associated tardive dyskinesia: report of two cases.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Piperazines; Quinolones | 2009 |
Supersensitivity psychosis and aripiprazole tapering.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones | 2009 |
Influence of TAAR6 polymorphisms on response to aripiprazole.
Topics: Adult; Aripiprazole; Cell Cycle Proteins; Female; Genetic Linkage; Genetic Markers; Haplotypes; Humans; Male; Middle Aged; Nuclear Proteins; Piperazines; Polymorphism, Single Nucleotide; Prospective Studies; Quinolones; Receptors, G-Protein-Coupled; Schizophrenia | 2009 |
Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats.
Topics: Animals; Aripiprazole; Conditioning, Classical; Male; Morphine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 2009 |
Multiple sclerosis presenting with erotomanic delusions in the context of "Don't ask, don't tell".
Topics: Adjuvants, Immunologic; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Erotica; Female; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Military Personnel; Military Psychiatry; Multiple Sclerosis; Organizational Policy; Piperazines; Quinolones; Recognition, Psychology; Schizophrenia, Paranoid; Sex Offenses; Sexual Harassment; Stress, Psychological; Syndrome | 2009 |
Benign clinical picture after ingestion of 780 milligrams of aripiprazole and 1050 milligrams of amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Drug Overdose; Humans; Male; Piperazines; Quinolones; Suicide, Attempted | 2009 |
Treatment of delusional parasitosis with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; HIV Infections; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Piperazines; Quinolones; Skin Diseases, Parasitic | 2009 |
Transport of aripiprazole across Caco-2 monolayer model.
Topics: Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cyclosporine; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Piperazines; Quinolones; Temperature; Time Factors | 2009 |
Treatment of catatonic schizophrenia with lorazepam and aripiprazole.
Topics: Adult; Aripiprazole; Female; Humans; Hypnotics and Sedatives; Lorazepam; Piperazines; Quinolones; Schizophrenia, Catatonic | 2009 |
Update on neuropsychiatric symptoms of dementia: antipsychotic use.
Topics: Aged; Aggression; Antipsychotic Agents; Aripiprazole; Dementia; Geriatric Psychiatry; Humans; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Severity of Illness Index | 2009 |
Aripiprazole augmentation for a patient with partial remission of panic disorder.
Topics: Adult; Agoraphobia; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Male; Panic Disorder; Paroxetine; Piperazines; Quinolones; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Atypical antipsychotic drugs and the risk of sudden cardiac death.
Topics: Antipsychotic Agents; Aripiprazole; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Humans; Mental Disorders; Piperazines; Quinolones; Risk; Thiazoles | 2009 |
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Topics: Action Potentials; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Indoles; Male; Neurons; Piperazines; Piperidines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulfones; Tetrahydronaphthalenes; Ventral Tegmental Area | 2009 |
Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study.
Topics: Antipsychotic Agents; Aripiprazole; Germany; Health Status Indicators; Humans; Physicians' Offices; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychology; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2009 |
A novel operant conflict procedure using incrementing shock intensities to assess the anxiolytic and anxiogenic effects of drugs.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Benzodiazepines; Chlordiazepoxide; Conditioning, Operant; Conflict, Psychological; Dextroamphetamine; Diazepam; Electroshock; Flumazenil; Male; Piperazines; Punishment; Pyridazines; Quinolones; Rats; Rats, Sprague-Dawley; Triazoles; Yohimbine | 2009 |
Aripiprazole in treatment-refractory schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Consciousness Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Hospitalization; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
Topics: Amygdala; Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Conditioning, Psychological; Dopamine; Dopamine D2 Receptor Antagonists; Electric Stimulation; Fear; Haloperidol; Male; Methamphetamine; Microdialysis; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stress, Psychological | 2009 |
Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Chi-Square Distribution; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Severity of Illness Index | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia | 2009 |
Maintenance treatment received by patients with bipolar I and II disorders--a naturalistic prospective study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium Carbonate; Long-Term Care; Male; Middle Aged; Olanzapine; Oxcarbazepine; Piperazines; Prospective Studies; Quinolones; Risperidone; Triazines; Valproic Acid | 2010 |
Olfactory disturbance in Parkinson disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; Cognition Disorders; Constipation; Diagnosis, Differential; Disease Progression; Electroencephalography; Hallucinations; Humans; Levetiracetam; Lewy Body Disease; Male; Olfactory Pathways; Parkinson Disease; Piperazines; Piracetam; Quinolones; REM Sleep Behavior Disorder; Treatment Failure; Tremor | 2009 |
Tardive dyskinesia due to aripiprazole: report of 2 cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2009 |
Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Synergism; Drug Therapy, Combination; Male; Mice; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Stress, Psychological | 2009 |
Aripiprazole treatment of psychosis in a child with posterior fossa retrocerebellar arachnoid cyst.
Topics: Antipsychotic Agents; Arachnoid Cysts; Aripiprazole; Child; Cranial Fossa, Posterior; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Radiography | 2009 |
Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats.
Topics: Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Aripiprazole; Astrocytes; Body Weight; Dose-Response Relationship, Drug; Gene Expression Regulation; Genetic Markers; In Situ Hybridization; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Time Factors; Transcription, Genetic | 2009 |
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Diabetes Mellitus; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Piperazines; Quinolones; Retrospective Studies; Thiazoles; United States | 2009 |
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Costs and Cost Analysis; Dibenzothiazepines; Drug Therapy, Combination; Female; Health Care Costs; Humans; Male; Middle Aged; Mood Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; Dibenzothiazepines; Humans; Mass Screening; Olanzapine; Piperazines; Predictive Value of Tests; Prospective Studies; Quetiapine Fumarate; Quinolones; Severity of Illness Index | 2009 |
Aripiprazole for the treatment of agitation in persons with dementia?
Topics: Antipsychotic Agents; Aripiprazole; Dementia; Drug Labeling; Humans; Piperazines; Psychomotor Agitation; Quinolones; United States; United States Food and Drug Administration | 2009 |
Improvement of risperidone-related tardive parkinsonism with a switch to aripiprazole.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Quinolones; Risperidone | 2009 |
Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
Aripiprazole for the management of olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2009 |
Risk assessment of isolated aripiprazole exposures and toxicities: a retrospective study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Dystonia; Female; Humans; Infant; Male; Middle Aged; Nausea; Piperazines; Poison Control Centers; Poisoning; Quinolones; Retrospective Studies; Risk Assessment; Tachycardia, Sinus; Vomiting; Young Adult | 2009 |
Chronic motor tic disorder and aripiprazole.
Topics: Adult; Aripiprazole; Humans; Male; Piperazines; Quinolones; Tic Disorders | 2009 |
Reversible Pisa syndrome associated with switching from haloperidol to aripiprazole during lithium treatment.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chloroquinolinols; Dystonia; Female; Humans; Lithium Compounds; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Spasm | 2009 |
Aripiprazole: new indication. Treatment and prevention of manic episodes: just another neuroleptic.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Drug Approval; Europe; Humans; Piperazines; Quinolones | 2009 |
Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder.
Topics: Action Potentials; Analysis of Variance; Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Brain; Citalopram; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Lysergic Acid Diethylamide; Male; Neurons; Norepinephrine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Time Factors | 2009 |
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia | 2009 |
Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Treatment Outcome | 2009 |
Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
A liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitation of aripiprazole in human plasma.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Haloperidol; Humans; Middle Aged; Piperazines; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Young Adult | 2009 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride; Thiazoles | 2009 |
An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Child; Conduct Disorder; Female; Follow-Up Studies; Humans; Male; Piperazines; Prospective Studies; Quinolones; Tremor; Vomiting | 2009 |
Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Chronic Disease; Dizziness; Dopamine Agents; Drug Resistance; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Quinolones; Tic Disorders; Treatment Outcome | 2009 |
Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole.
Topics: Aripiprazole; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone | 2009 |
Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder.
Topics: Adult; Aripiprazole; Autistic Disorder; Bipolar Disorder; Catatonia; Humans; Male; Piperazines; Quinolones | 2009 |
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole.
Topics: Adult; Aripiprazole; Female; Humans; Hyperamylasemia; Lipase; Pancreatitis; Piperazines; Quinolones | 2009 |
A case of aripiprazole-associated paroxysmal supraventricular tachycardia.
Topics: Aripiprazole; Electrocardiography; Humans; Male; Piperazines; Quinolones; Tachycardia, Supraventricular; Young Adult | 2009 |
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Dopamine Plasma Membrane Transport Proteins; Glycine Plasma Membrane Transport Proteins; Hyperkinesis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Piperazines; Quinolones; Receptors, N-Methyl-D-Aspartate | 2010 |
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Young Adult | 2009 |
Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Syndrome; Treatment Outcome | 2009 |
Serious generalized tonic-clonic seizures induced by aripiprazole.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Humans; Male; Phenytoin; Piperazines; Psychotic Disorders; Quinolones; Seizures | 2010 |
The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Female; Haloperidol; Limbic System; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT1; RNA, Messenger | 2009 |
Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Secondary Prevention; Self Administration | 2009 |
Therapy and quality of life of patients with psychosis.
Topics: Adult; Animal Assisted Therapy; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Family Therapy; Humans; Male; Object Attachment; Piperazines; Psychotherapy; Psychotherapy, Group; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Environment | 2009 |
[Aripiprazole and acute dystonia].
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Depressive Disorder; Dystonia; Female; Humans; Piperazines; Product Surveillance, Postmarketing; Quinolones; Young Adult | 2009 |
Treatment of tardive dyskinesia with aripiprazole.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Male; Mood Disorders; Piperazines; Quinolones | 2010 |
Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens.
Topics: Analysis of Variance; Animals; Aripiprazole; Attention; Choice Behavior; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Routes; Impulsive Behavior; Male; Naphthalenes; Neuropsychological Tests; Nucleus Accumbens; Piperazines; Pyrrolidines; Quinolones; Rats; Reaction Time; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2010 |
[Aripiprazole induced Parkinsonism: A case report].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Parkinsonian Disorders; Piperazines; Quinolones; Schizophrenia, Paranoid | 2009 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Preschool; Cohort Studies; Dibenzothiazepines; Female; Humans; Lipid Metabolism; Lipids; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Weight Gain | 2009 |
Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: clinical efficacy and successful management of neutropenia with lithium.
Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Female; Humans; Lithium Carbonate; Neutropenia; Piperazines; Quinolones; Schizophrenia | 2009 |
Aripiprazole and hypertension in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Calcium Channel Blockers; Female; Humans; Hypertension; Nifedipine; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index | 2009 |
No influence of FAT polymorphisms in response to aripiprazole.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cadherins; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2010 |
Life events, medical comorbidity, and somatic symptoms in pediatric mood disorders.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Comorbidity; Female; Humans; Hungary; Life Change Events; Male; Mood Disorders; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Somatoform Disorders; United States | 2009 |
Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder.
Topics: Aripiprazole; Child; Drug Resistance; Drug Synergism; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychotropic Drugs; Quinolones | 2009 |
Movement disorders associated with aripiprazole use: a case series.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Quinolones; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2010 |
Effectiveness of intramuscular aripiprazole injection in patients with catatonia: report on three cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Myxedema coma associated with combination aripiprazole and sertraline therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Coma; Drug Interactions; Humans; Male; Myxedema; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sertraline | 2009 |
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Carbamazepine; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Male; Medical Audit; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk Factors; Risperidone | 2009 |
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heart; Hormones; Humans; Japan; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Schizophrenia; Triglycerides | 2010 |
Pediatric bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Child Psychiatry; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Humans; Lithium Carbonate; Nursing Assessment; Parents; Patient Education as Topic; Piperazines; Psychiatric Nursing; Psychotherapy; Quinolones; Risperidone; Social Support | 2009 |
Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Approval; Europe; Humans; Piperazines; Quinolones; Schizophrenia | 2009 |
Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Central Nervous System Stimulants; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Locomotion; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Self Stimulation | 2010 |
Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Drug Administration Schedule; Dystonia; Humans; Male; Methylphenidate; Piperazines; Quinolones; Substance Withdrawal Syndrome | 2010 |
Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Pituitary Neoplasms; Quinolones | 2010 |
Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2010 |
Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dizocilpine Maleate; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Quinolones; Reflex, Startle; Signal Transduction | 2010 |
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Aripiprazole; Brain; Cell Line; Cricetinae; Cricetulus; Cyclic AMP; Dopamine; Dopamine D2 Receptor Antagonists; Drug Partial Agonism; Guinea Pigs; Humans; In Vitro Techniques; Inositol Phosphates; Male; Mice; Piperazines; Quinolones; Radioligand Assay; Rats; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Serotonin; Recombinant Proteins; Reserpine; Serotonin | 2010 |
The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Corticosterone; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Hindlimb Suspension; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Phenols; Piperazines; Quinolones; Receptors, Serotonin; Serotonin Antagonists; Sulfonamides; Swimming | 2010 |
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Central Nervous System Stimulants; Cluster Analysis; Drug Evaluation, Preclinical; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Humans; Hydrolysis; Inactivation, Metabolic; Male; Methylphenidate; Mice; Models, Molecular; Piperazines; Quinolones | 2010 |
Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Resistance; HEK293 Cells; Humans; Mutagenesis, Site-Directed; Neuroleptic Malignant Syndrome; Nursing Research; Olanzapine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Quinolones; Receptor, Serotonin, 5-HT2A; Risperidone; Thiazoles | 2011 |
[Aripiprazole-induced stuttering treated with risperidone].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia; Stuttering | 2009 |
Use of aripiprazole in clozapine induced enuresis: report of two cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Enuresis; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia, Paranoid | 2010 |
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Drug Utilization; Evidence-Based Medicine; Female; Humans; Infant; Insurance Claim Review; Male; Medicaid; Mental Disorders; Off-Label Use; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2010 |
The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword.
Topics: Antipsychotic Agents; Aripiprazole; Canada; Clinical Trials as Topic; Comorbidity; Drug Utilization; Drug Utilization Review; Humans; Metabolic Diseases; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Risk Factors | 2010 |
Aripiprazole, hypertension, and confusion.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Confusion; Depressive Disorder, Major; Female; Humans; Hypertension; Piperazines; Quinolones | 2010 |
Improvement of restless legs syndrome and trichotillomania with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Restless Legs Syndrome; Trichotillomania | 2009 |
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
Topics: Acoustic Stimulation; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Blinking; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Secondary Prevention | 2010 |
Pathological gambling and compulsive eating associated with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Dose-Response Relationship, Drug; Eating; Female; Gambling; Humans; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D3; Schizophrenia; Weight Gain | 2010 |
[Disappearance of paroxysmal perceptual alteration by switching to aripiprazole in a schizophrenic patient].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Perceptual Distortion; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports.
Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Bulimia Nervosa; Female; Humans; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2011 |
Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Brain Mapping; Chlorpromazine; Female; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxygen; Photic Stimulation; Piperazines; Quinolones; Reaction Time; Schizophrenia; Schizophrenic Psychology; Time Factors; Visual Cortex; Young Adult | 2010 |
Drug-induced Pisa syndrome associated with aripiprazole during clozapine treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2010 |
Symptomatic bradycardia with oral aripiprazole and oral ziprasidone.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bradycardia; Delusions; Electrocardiography; Female; Humans; Lithium Carbonate; Piperazines; Psychotic Disorders; Quinolones; Thiazoles | 2010 |
Second-generation antipsychotics cause weight gain in youths.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Dibenzothiazepines; Humans; Olanzapine; Overweight; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Weight Gain | 2010 |
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Female; Homovanillic Acid; Humans; Longitudinal Studies; Male; Methoxyhydroxyphenylglycol; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Young Adult | 2010 |
Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Treatment Failure; Young Adult | 2010 |
Aripiprazole augmentation for the treatment of an adolescent with posttraumatic stress disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Stress Disorders, Post-Traumatic; Treatment Outcome | 2010 |
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses | 2010 |
Aripiprazole-induced gray matter growth in a patient with major depressive disorder with panic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Comorbidity; Depressive Disorder, Major; Female; Humans; Magnetic Resonance Imaging; Organ Size; Panic Disorder; Piperazines; Quinolones; Receptors, Serotonin | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Autoreceptors; Brain Chemistry; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Drug Interactions; Female; Haloperidol; Male; Piperazines; Quinolones; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2010 |
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia | 2010 |
Aripiprazole monotherapy in a patient with major depressive disorder.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Piperazines; Quinolones; Treatment Outcome | 2010 |
Warning on treating depression.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Depression; Dopamine Antagonists; Gastrointestinal Diseases; Humans; Metoclopramide; Piperazines; Quinolones | 2010 |
Trial of aripiprazole in the treatment of first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2010 |
Hyperprolactinaemia during treatment with paliperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult | 2010 |
Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and rat mesencephalic cultures: Implication of inhibition of vesicular transport.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Aripiprazole; Ascorbic Acid; Biological Transport; Dopamine; Extracellular Space; Gene Expression Regulation, Enzymologic; Haloperidol; Homovanillic Acid; Mesencephalon; Neurons; Pargyline; PC12 Cells; Pimozide; Piperazines; Quinolones; Rats; Spiperone; Transport Vesicles; Tyrosine 3-Monooxygenase | 2010 |
Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Carrier Proteins; Female; Humans; Intracellular Signaling Peptides and Proteins; Korea; Male; Neuropsychological Tests; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2010 |
Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient.
Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Middle Aged; Piperazines; Quinolones | 2010 |
Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; DiGeorge Syndrome; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Memory Disorders; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Antipsychotic dosing: still a work in progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Severity of Illness Index | 2010 |
Aripiprazole in pregnancy and lactation: a case report.
Topics: Adult; Aripiprazole; Breast Feeding; Female; Humans; Infant, Newborn; Lactation; Male; Milk, Human; Piperazines; Pregnancy; Quinolones; Schizophrenia | 2010 |
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia | 2010 |
The use of aripiprazole in early onset schizophrenia: safety and efficacy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2009 |
Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2010 |
Aripiprazole attenuates established behavioral sensitization induced by methamphetamine.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Stimulants; Dopamine Antagonists; Male; Methamphetamine; Mice; Motor Activity; Piperazines; Quinolones; Random Allocation; Sulpiride | 2010 |
Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Croatia; Dose-Response Relationship, Drug; Feeding Behavior; Humans; Life Style; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia; Triglycerides; Weight Loss | 2010 |
Delusional parasitosis in a patient with brain atrophy and renal failure treated with aripiprazole: case report.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Humans; Kidney Failure, Chronic; Male; Piperazines; Quinolones; Renal Dialysis; Treatment Outcome | 2010 |
Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Crime; Forensic Psychiatry; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Violence | 2010 |
Catatonia and CPK elevation in neurosyphilis: role of plural pharmacodynamic mechanisms.
Topics: Adult; Aripiprazole; Catatonia; Creatine Kinase; Dose-Response Relationship, Drug; Doxycycline; Humans; Lorazepam; Male; Neurosyphilis; Piperazines; Quinolones; Temazepam; Valproic Acid | 2009 |
Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia | 2010 |
Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Blotting, Western; Brain; Chromatography, High Pressure Liquid; Mass Spectrometry; Mice; Mice, Knockout; Piperazines; Quinolones | 2010 |
A case of Cotard's Syndrome successfully treated with aripiprazole monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder; Female; Humans; Piperazines; Quinolones; Young Adult | 2010 |
Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures.
Topics: Animals; Aripiprazole; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Embryo, Mammalian; Glutamic Acid; Mesencephalon; Neurons; Neuroprotective Agents; Piperazines; Quinolones; Rats; Time Factors | 2010 |
Case of tardive dystonia improved by aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dystonia; Female; Humans; Piperazines; Quinolones | 2010 |
[Long-term (prophylactic) therapy of bipolar patients with aripiprazole].
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2010 |
[Use of aripiprazole in the treatment of catatonia].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Depressive Disorder, Major; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Performance; Quinolones; Schizoid Personality Disorder; Schizophrenia, Catatonic | 2010 |
[Aripiprazole - a medical treatment alternative for Tourette Syndrome in childhood and adolescence].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Behavior Therapy; Child; Combined Modality Therapy; Comorbidity; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome | 2010 |
Aripiprazole for the tic symptoms in a child receiving atomoxetine treatment for ADHD.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Piperazines; Propylamines; Quinolones; Tic Disorders | 2010 |
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Topics: Absenteeism; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzothiazepines; Drug Therapy, Combination; Fees, Pharmaceutical; Health Care Costs; Hospital Charges; Humans; Lamotrigine; Lithium Compounds; Markov Chains; Models, Economic; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quetiapine Fumarate; Quinolones; Risk; Tablets; Triazines; United States; Valproic Acid | 2010 |
Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Depressive Disorder, Major; Humans; Male; Panic Disorder; Piperazines; Quinolones; Treatment Outcome | 2010 |
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2010 |
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2010 |
Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia.
Topics: Adult; Amlodipine; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Electrophoresis, Capillary; Female; Humans; Hydrogen-Ion Concentration; Male; Piperazines; Quinolones; Reference Values; Schizophrenia; Solvents | 2010 |
Neuroleptic malignant syndrome with aripiprazole in Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Huntington Disease; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2010 |
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Huntington Disease; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Effects of atypical antipsychotics and haloperidol on PC12 cells: only aripiprazole phosphorylates AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Antipsychotic Agents; Appetite Regulation; Aripiprazole; Fatty Acids; Haloperidol; Oxidative Phosphorylation; PC12 Cells; Piperazines; Potassium Channels; Quinolones; Rats; RNA, Messenger | 2010 |
Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Substance-Related Disorders | 2010 |
Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Male; Maze Learning; Motor Activity; Piperazines; Quinolones; Rats; Rats, Wistar | 2011 |
Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Dysmorphic Disorders; Drug Partial Agonism; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzamides; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Quinolones; Risperidone; Young Adult | 2010 |
Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; China; Electrocardiography; Female; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Tics; Tourette Syndrome; Treatment Outcome | 2010 |
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
Tardive dyskinesia and other movement disorders secondary to aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Female; Humans; Male; Middle Aged; Movement Disorders; Piperazines; Quinolones | 2011 |
No influence of DTNBP1 polymorphisms on the response to aripiprazole.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Carrier Proteins; Dysbindin; Dystrophin-Associated Proteins; Female; Haplotypes; Humans; Linkage Disequilibrium; Male; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia | 2010 |
Repetitive administration of aripiprazole enhances locomotor response to methamphetamine in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Stimulants; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Male; Methamphetamine; Mice; Mice, Inbred ICR; Motor Activity; Piperazines; Quinolones | 2011 |
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Behavioral Symptoms; Disease Models, Animal; Dizocilpine Maleate; Haloperidol; In Situ Nick-End Labeling; Inhibition, Psychological; Male; Methamphetamine; Microdialysis; Motor Activity; Neuroprotective Agents; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia | 2011 |
Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010).
Topics: Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Metabolic Syndrome; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2010 |
A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Meige Syndrome; Piperazines; Quinolones; Schizophrenia; Thiazoles; Young Adult | 2011 |
Aripiprazole can treat psychotic features but not motor symptoms of Parkinson's disease: evidence from a SPECT study.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Protein Binding; Psychotic Disorders; Quinolones; Tomography, Emission-Computed, Single-Photon | 2011 |
Differential pharmacological responses of catatonia-like signs in frontotemporal dementia.
Topics: Aged; Amantadine; Antipsychotic Agents; Aripiprazole; Benzothiazoles; Catatonia; Citalopram; Clinical Trials as Topic; Dibenzothiazepines; Donepezil; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Frontotemporal Dementia; Humans; Hypnotics and Sedatives; Indans; Lorazepam; Memantine; Middle Aged; Nootropic Agents; Piperazines; Piperidines; Pramipexole; Quetiapine Fumarate; Quinolones; Selective Serotonin Reuptake Inhibitors | 2010 |
Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Japan; Male; Piperazines; Quinolones; Schizophrenia; Stupor; Treatment Outcome | 2010 |
Epidemiologic study of aripiprazole use and the incidence of suicide events.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Risk; Schizophrenia; Suicide; Suicide, Attempted; Young Adult | 2010 |
Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Behavior; Blood Pressure; Cardiovascular System; Central Nervous System Stimulants; Cocaine; Dextroamphetamine; Discrimination Learning; Female; Heart Rate; Humans; Male; Middle Aged; Piperazines; Quinolones; Substance-Related Disorders; Surveys and Questionnaires | 2011 |
Worsening psychosis after adding aripiprazole to clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2011 |
Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Depression; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; HIV Infections; HIV Protease Inhibitors; Humans; Male; Piperazines; Quinolones; Ritonavir; Sulfonamides; Thiophenes | 2010 |
Aripiprazole treatment for coprophagia in autistic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Human Coprophagia; Humans; Male; Piperazines; Quinolones | 2010 |
Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Humans; Male; Piperazines; Quinolones; Risperidone | 2011 |
A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Humans; Male; Molecular Structure; Piperazines; Quinolones; Reproducibility of Results; Sensitivity and Specificity; Young Adult | 2010 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3 | 2011 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Middle Aged; Neutropenia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia | 2011 |
Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Topics: Animals; Apomorphine; Aripiprazole; Buffers; Catalepsy; Cell Membrane; Cerebral Cortex; Corpus Striatum; Domperidone; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Antagonism; Drug Partial Agonism; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Hippocampus; Male; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Stereotyped Behavior; Up-Regulation | 2011 |
The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2010 |
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Immunohistochemistry; Locomotion; Male; Nerve Tissue Proteins; Neurons; Nucleus Accumbens; Piperazines; Proto-Oncogene Proteins c-fos; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2011 |
Aripiprazole protects cortical neurons from glutamate toxicity.
Topics: Animals; Aripiprazole; Benzodiazepines; Cell Nucleus; Cerebral Cortex; Cytoprotection; Dopamine D2 Receptor Antagonists; Glutamic Acid; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Molecular Imaging; Neurons; Neuroprotective Agents; Olanzapine; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Risperidone; Serotonin 5-HT1 Receptor Antagonists; Signal Transduction; Tetrazolium Salts; Thiazoles | 2011 |
Restless legs syndrome due to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Piperazines; Quinolones; Restless Legs Syndrome | 2011 |
Use of aripiprazole in a patient with multiple sclerosis presenting with paranoid psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Multiple Sclerosis; Paranoid Disorders; Piperazines; Quinolones; Treatment Outcome | 2010 |
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Synergism; Duloxetine Hydrochloride; Female; Humans; Hypertension; Middle Aged; Piperazines; Quinolones; Thiophenes | 2011 |
Aripiprazole as a viable alternative for treating delusions of parasitosis.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Mental Disorders; Movement Disorders; Parasitic Diseases; Pimozide; Piperazines; Quinolones; Risperidone | 2010 |
New-onset psychosis and emergence of suicidal ideation with aripiprazole.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Suicidal Ideation | 2010 |
Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Humans; Male; Methylphenidate; Piperazines; Psychoses, Substance-Induced; Quinolones; Risperidone | 2011 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2011 |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Alleles; Antipsychotic Agents; Aripiprazole; Asian People; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Genotype; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
Three cases of hypomania and one case of mania during aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Young Adult | 2011 |
Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationship, Drug; Male; Motivation; Motor Activity; Piperazines; Psychomotor Performance; Quinolones; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reinforcement, Psychology; Self Administration; Sucrose | 2011 |
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine | 2010 |
Temporomandibular dislocation due to aripiprazole induced dystonia.
Topics: Antipsychotic Agents; Aripiprazole; Dystonia; Female; Humans; Joint Dislocations; Piperazines; Quinolones; Temporomandibular Joint; Young Adult | 2010 |
Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders.
Topics: Adolescent; Aripiprazole; Child; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Severity of Illness Index; Tic Disorders; Treatment Outcome | 2011 |
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2011 |
Micturition difficulty associated with aripiprazole: report of 2 cases.
Topics: Adult; Aripiprazole; Humans; Male; Piperazines; Quinolones; Urinary Retention; Urination; Young Adult | 2011 |
Aripiprazole-associated bruxism, akathisia, and parkinsonism in a bipolar patient.
Topics: Akathisia, Drug-Induced; Aripiprazole; Bipolar Disorder; Bruxism; Female; Humans; Parkinson Disease, Secondary; Piperazines; Quinolones; Young Adult | 2011 |
Aripiprazole: striving towards euthymia with a novel mechanism of action.
Topics: Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Humans; Mood Disorders; Piperazines; Quinolones | 2011 |
Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Aripiprazole; bcl-2-Associated X Protein; Benzodiazepines; Blotting, Western; Cell Survival; Haloperidol; Herbicides; Olanzapine; Oxidative Stress; PC12 Cells; Piperazines; Quinolones; Rats; Reactive Oxygen Species; Superoxide Dismutase; Thiazoles | 2011 |
Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Labeling; Drug Resistance; Female; Humans; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Aripiprazole-induced pathological gambling: a report of 3 cases.
Topics: Adolescent; Aripiprazole; Gambling; Humans; Male; Piperazines; Quinolones; Schizophrenia; Young Adult | 2011 |
Aripiprazole adjunctive to antidepressant therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones | 2011 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Topics: Animals; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Butyrophenones; Cell Line, Tumor; Cell Membrane Permeability; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Mice; Models, Molecular; Molecular Structure; Piperazines; Piperidines; Protein Binding; Quantitative Structure-Activity Relationship; Quinolones | 2011 |
Aripiprazole-related acute transient myopia and diplopia: a case report.
Topics: Acute Disease; Aripiprazole; Diplopia; Female; Humans; Myopia; Piperazines; Quinolones; Young Adult | 2011 |
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Clozapine; Constipation; Enema; Fecal Impaction; Female; Gastrointestinal Agents; Humans; Lactulose; Male; Middle Aged; Piperazines; Polyethylene Glycols; Prevalence; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2011 |
Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Long-Term Care; Male; Methamphetamine; Motor Activity; Piperazines; Psychoses, Substance-Induced; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2012 |
Placental transfer of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Maternal-Fetal Exchange; Piperazines; Pregnancy; Quinolones; Schizophrenia | 2011 |
Efficacy of aripiprazole in sulpiride-induced tardive oromandibular dystonia.
Topics: Aged, 80 and over; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Jaw; Movement Disorders; Piperazines; Quinolones; Sulpiride | 2011 |
Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Linear Models; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Behavior; Treatment Outcome; Young Adult | 2011 |
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Germany; Humans; Male; Matched-Pair Analysis; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia; Serotonin Antagonists; Severity of Illness Index; Sulpiride | 2011 |
Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Autoradiography; Binding Sites; Brain; Dopamine; Dose-Response Relationship, Drug; Gene Expression; In Situ Hybridization; Male; Piperazines; Protein Binding; Protein Subunits; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serotonin; Synaptic Transmission | 2011 |
Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Brain; Calcium; Cells, Cultured; Drug Interactions; Electron Spin Resonance Spectroscopy; Microglia; NADPH Oxidases; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Superoxides; Tetradecanoylphorbol Acetate | 2011 |
Effectiveness of aripiprazole for medication overuse headache: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Drug Resistance; Female; Headache Disorders, Secondary; Humans; Middle Aged; Piperazines; Quinolones | 2011 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2011 |
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia | 2011 |
Calculating occupancy when one does not have baseline: a comparison of different options.
Topics: Adult; Alkaloids; Antipsychotic Agents; Aripiprazole; Humans; Male; Methods; Piperazines; Positron-Emission Tomography; Protein Binding; Quinolones; Receptors, Dopamine D2; Reproducibility of Results; Schizophrenia; Young Adult | 2011 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones | 2011 |
Aripiprazole-associated leukopenia with coadministration of fluoxetine: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Fluoxetine; Humans; Leukopenia; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2011 |
Perinatal use of aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Fetal Blood; Humans; Maternal-Fetal Exchange; Milk, Human; Piperazines; Postnatal Care; Pregnancy; Prenatal Care; Quinolones; Schizophrenia | 2011 |
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Risperidone; Schizophrenia | 2011 |
Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
Topics: Animals; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Hyperprolactinemia; Lactotrophs; Male; Methyltyrosines; Piperazines; Piperidines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine | 2011 |
Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
Topics: Aripiprazole; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Ligands; Piperazines; Protein Binding; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, sigma | 2011 |
[Aripiprazole-induced parkinsonism in a 64-year-old female patient diagnosed with bipolar disorder].
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Quinolones | 2011 |
Aripiprazole associated hyponatraemia.
Topics: Aripiprazole; Female; Humans; Hyponatremia; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2011 |
High dosage of aripiprazole-induced dysphagia.
Topics: Antipsychotic Agents; Aripiprazole; Deglutition Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2012 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Treatment Outcome | 2011 |
Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinolones; Retrospective Studies; Stress Disorders, Post-Traumatic; Veterans | 2011 |
Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
Topics: Adolescent; Adrenal Cortex Hormones; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Remission Induction; Treatment Outcome; Weight Gain | 2011 |
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden | 2011 |
The quantitative detection of aripiprazole and its main metabolite by using capillary-electrophoresis.
Topics: Antipsychotic Agents; Aripiprazole; Calibration; Electrophoresis, Capillary; Gas Chromatography-Mass Spectrometry; Humans; Piperazines; Quinolones | 2011 |
Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors.
Topics: Animals; Aripiprazole; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2011 |
Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Clomipramine; Compulsive Behavior; Conditioning, Operant; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drinking Behavior; Haloperidol; Male; Piperazines; Quinolones; Quinpirole; Rats; Rats, Sprague-Dawley | 2011 |
Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Hallucinations; Humans; Loxapine; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2011 |
Aripiprazole-related body-weight gain and nutritional counseling.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2011 |
Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole.
Topics: Aripiprazole; Blood Pressure; Discrimination Learning; Female; Heart Rate; Humans; Male; Methamphetamine; Piperazines; Psychomotor Performance; Quinolones; Surveys and Questionnaires; Young Adult | 2011 |
Low-dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome).
Topics: Aged; Antipsychotic Agents; Aripiprazole; Cerebral Infarction; Dominance, Cerebral; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hallucinations; Hemianopsia; Humans; Occipital Lobe; Piperazines; Quinolones; Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Visual Fields | 2011 |
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.
Topics: Adolescent; Adult; Aripiprazole; Asian People; Benzodiazepines; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Young Adult | 2011 |
A retrospective study exploring the effects of intramuscular aripiprazole on QTc change in agitated medically ill patients.
Topics: Aged; Aripiprazole; Cohort Studies; Female; Heart Rate; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies | 2011 |
Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Male; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2012 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden | 2011 |
Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2011 |
Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Male; Piperazines; Quinolones; Recurrence; Schizophrenia | 2011 |
Optimality, sample size, and power calculations for the sequential parallel comparison design.
Topics: Antipsychotic Agents; Aripiprazole; Computer Simulation; Data Interpretation, Statistical; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Piperazines; Placebo Effect; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size | 2011 |
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
Topics: Animals; Aripiprazole; CHO Cells; Clozapine; Cricetinae; Cricetulus; Cyclic AMP; Dopamine; Drug Partial Agonism; Humans; Organic Chemicals; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Substrate Specificity | 2011 |
Tolerability profile of aripiprazole in patients with Tourette syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Retrospective Studies; Tourette Syndrome; Young Adult | 2012 |
Aripiprazole induced transient myopia: a case report and review of literature.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Myopia; Piperazines; Quinolones; Schizophrenia | 2012 |
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia; Skin Diseases; Treatment Outcome | 2012 |
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Databases, Factual; Depressive Disorder, Major; Dibenzothiazepines; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Young Adult | 2011 |
Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Behavior, Animal; Brain; Comet Assay; Humans; Lipid Peroxidation; Male; Mice; Micronucleus Tests; Mutagens; Piperazines; Quinolones; Schizophrenia | 2011 |
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Female; Gene Expression Regulation; Hyperphagia; Lipid Metabolism; Lipogenesis; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Triglycerides; Weight Gain | 2012 |
Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report.
Topics: Adolescent; Aripiprazole; Autistic Disorder; Child; Double-Blind Method; Humans; Irritable Mood; Piperazines; Quinolones; Randomized Controlled Trials as Topic | 2011 |
Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole.
Topics: Animals; Aripiprazole; Drug Partial Agonism; HeLa Cells; Humans; Ligands; Mice; Piperazines; Protein Binding; Quinolones; Receptors, Dopamine D2; Signal Transduction | 2012 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2011 |
Safety of antipsychotics in the setting of QTc prolongation: the utility of the JT index.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bundle-Branch Block; Combined Modality Therapy; Cooperative Behavior; Electrocardiography; Electroconvulsive Therapy; Female; Haloperidol; Humans; Interdisciplinary Communication; Long QT Syndrome; Piperazines; Quinolones; Risk Factors; Torsades de Pointes | 2011 |
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hippocampus; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Restraint, Physical; Schizophrenia; Stress, Psychological | 2011 |
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depression; Dystonia; Female; Fluoxetine; Humans; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones | 2012 |
Adjunctive antipsychotics for major depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; United States; United States Food and Drug Administration | 2011 |
Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Male; Microdialysis; Nucleus Accumbens; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Sulpiride; Synaptic Transmission; Ventral Tegmental Area | 2012 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2011 |
Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Rhabdomyolysis; Schizophrenia; Taiwan | 2011 |
Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Conditioning, Operant; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Kinetics; Models, Biological; Motor Activity; Motor Skills; Piperazines; Quinolones; Rats; Rats, Wistar; Reaction Time; Reinforcement Schedule; Serotonin Antagonists; Sulpiride | 2012 |
Manic induction with interferon alpha therapy.
Topics: Adult; Antipsychotic Agents; Antiviral Agents; Aripiprazole; Bipolar Disorder; Hepatitis C; Humans; Interferon-alpha; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats.
Topics: Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Cognition; Depression; Disease Models, Animal; Male; Maze Learning; Memory; Piperazines; Quinolones; Rats; Rats, Wistar; Toxicity Tests | 2011 |
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Female; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2011 |
Aripiprazole monotherapy in the treatment of vascular parkinsonism.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Parkinson Disease, Secondary; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2011 |
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Autopsy; Benzodiazepines; Death, Sudden, Cardiac; Drug Therapy, Combination; Eosinophilia; Forensic Pathology; Forensic Toxicology; Humans; Male; Mianserin; Mirtazapine; Myocarditis; Myocardium; Olanzapine; Piperazines; Quinolones; Risk Factors | 2011 |
Effect of vehicle systems, pH and enhancers on the permeation of highly lipophilic aripiprazole from Carbopol 971P gel systems across human cadaver skin.
Topics: Acrylates; Administration, Cutaneous; Antipsychotic Agents; Aripiprazole; Drug Delivery Systems; Fatty Acids; Gels; Humans; Hydrogen-Ion Concentration; Permeability; Pharmaceutical Vehicles; Piperazines; Quinolones; Skin; Skin Absorption | 2012 |
Pituitary microadenoma treated with antipsychotic drug aripiprazole.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Drug Partial Agonism; Humans; Male; Mental Disorders; Piperazines; Pituitary Neoplasms; Quinolones; Receptors, Dopamine D2 | 2011 |
Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
Topics: Animals; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Brain; Citalopram; Cyclohexanols; Gene Knockout Techniques; Genotype; Mice; Piperazines; Quinolones; Rats; Risperidone; Species Specificity; Venlafaxine Hydrochloride | 2012 |
A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2011 |
Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2011 |
Reinforcement learning and Gilles de la Tourette syndrome: dissociation of clinical phenotypes and pharmacological treatments.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Case-Control Studies; Computer Simulation; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive-Compulsive Disorder; Phenotype; Piperazines; Quinolones; Reinforcement, Psychology; Tourette Syndrome | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Depression; Europe; Fluoxetine; Fluvoxamine; Health Care Surveys; Humans; Methylphenidate; Obsessive-Compulsive Disorder; Physicians; Piperazines; Propylamines; Psychiatry; Quinolones; Risperidone; Sertraline; Sulpiride; Tourette Syndrome | 2012 |
Neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Severity of Illness Index; Taiwan; Young Adult | 2012 |
Comparison of academic and nonacademic sites in multi-center clinical trials.
Topics: Academic Medical Centers; Academies and Institutes; Adult; Antipsychotic Agents; Aripiprazole; Boston; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hospitals, General; Humans; Interview, Psychological; Male; Middle Aged; Multicenter Studies as Topic; Patient Dropouts; Patient Selection; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Young Adult | 2012 |
The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cross-Cultural Comparison; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Thailand; Young Adult | 2012 |
Intermittent aripiprazole for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia | 2012 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol; Humans; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Recurrence; Risperidone | 2012 |
Adjunctive aripiprazole for depression: predictive value of early assessment.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Health Status Indicators; Humans; Logistic Models; Models, Psychological; Multivariate Analysis; Piperazines; Predictive Value of Tests; Prospective Studies; Psychometrics; Quinolones; Time Factors | 2011 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
An efficient synthesis of aripiprazole, buspirone and NAN-190 by the reductive alkylation of amines procedure.
Topics: Alkylation; Amines; Aripiprazole; Buspirone; Chemistry Techniques, Synthetic; Chromatography, High Pressure Liquid; Hydrolysis; Molecular Structure; Oxidation-Reduction; Piperazines; Quinolones; Spectrometry, Mass, Electrospray Ionization | 2012 |
Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.
Topics: Adolescent; Aripiprazole; Child; Child Development Disorders, Pervasive; Drug Substitution; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Risperidone; Treatment Outcome; Young Adult | 2012 |
Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2012 |
Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Animals; Aripiprazole; Brain Chemistry; Chromatography, High Pressure Liquid; Drug Stability; Linear Models; Male; Piperazines; Quinolones; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2012 |
Nowhere patients.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2012 |
[Misuse of alcohol and new drug treatments].
Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Baclofen; GABA-B Receptor Agonists; Humans; Ondansetron; Piperazines; Quinolones; Serotonin Antagonists | 2011 |
Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference.
Topics: Alcoholism; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Dopamine; Ethanol; Male; Mice; Piperazines; Pyridines; Quinolones; Substance Withdrawal Syndrome; Time Factors | 2012 |
Aripiprazole may be free from tachyphylaxis: preliminary findings.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachyphylaxis; Treatment Outcome | 2012 |
An improved simple LC-MS/MS method for the measurement of serum aripiprazole and its major metabolite.
Topics: Antipsychotic Agents; Aripiprazole; Calibration; Chromatography, Liquid; Humans; Limit of Detection; Piperazines; Quinolones; Reference Standards; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2012 |
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.
Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoxetine; Immune System; Male; Motor Activity; Piperazines; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2012 |
Emergence of psychotic symptoms during Internet withdrawal.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Humans; Internet; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2012 |
Tardive laryngeal dystonia associated with aripiprazole monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Laryngeal Diseases; Movement Disorders; Piperazines; Quinolones; Schizophrenia; Young Adult | 2012 |
Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Carbon; Cell Survival; Clozapine; Dihydrolipoamide Dehydrogenase; Dose-Response Relationship, Drug; Electron Transport Complex IV; Extracellular Fluid; Gene Expression Regulation, Enzymologic; Glucose; Glycolysis; Hypoxanthine Phosphoribosyltransferase; Isocitrate Dehydrogenase; Ketone Oxidoreductases; Lactic Acid; Membrane Potential, Mitochondrial; NAD; Oxidoreductases; PC12 Cells; Piperazines; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Pyruvic Acid; Quinolones; Rats; RNA, Messenger; Time Factors | 2012 |
Factors influencing the adherence of antipsychotic medication (Aripiprazole) in first-episode psychosis: findings from a grounded theory study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Data Collection; Disability Evaluation; England; Female; Health Status; Humans; Interview, Psychological; Male; Medication Adherence; Nursing Theory; Patient Participation; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Young Adult | 2012 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Prolactin; Prospective Studies; Quinolones; Retreatment; Risperidone; Schizophrenia; Sex Hormone-Binding Globulin; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Sulpiride; Testosterone | 2012 |
Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Diabetes Complications; Dibenzothiepins; Dopamine; Drug Interactions; Female; Haloperidol; Humans; Hyperhidrosis; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2012 |
Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Dose-Response Relationship, Drug; Humans; Irritable Mood; Piperazines; Quality of Life; Quinolones; Randomized Controlled Trials as Topic | 2012 |
[Potentiation of Aripiprazole extrapiramidal adverse effects with the concomitant use of serotonin selective reuptake inhibitors].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2011 |
Does aripiprazole protect from serotonin syndrome?
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Tremor; Venlafaxine Hydrochloride; Young Adult | 2012 |
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Publication Bias; Pyrimidines; Quetiapine Fumarate; Quinolones; Risperidone; United States; United States Food and Drug Administration | 2012 |
Serotonin toxicity in aripiprazole augmentation.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Cyproheptadine; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 2012 |
The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Statistics as Topic; Treatment Outcome; Young Adult | 2012 |
Aripiprazole: polymorphs and solvatomorphs.
Topics: Aripiprazole; Crystallization; Molecular Weight; Piperazines; Quinolones; Terminology as Topic; X-Ray Diffraction | 2012 |
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Dibenzothiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quetiapine Fumarate; Quinolones; Review Literature as Topic; Risperidone; Schizophrenia; Sulpiride | 2012 |
Efficacy of aripiprazole in comorbid addiction in bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Male; Piperazines; Quinolones; Substance-Related Disorders; Treatment Outcome | 2012 |
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substitution; Female; Humans; Hyperprolactinemia; Medication Therapy Management; Pharmacovigilance; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2012 |
Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Behavior; Child; Child Development Disorders, Pervasive; Female; Humans; Male; Piperazines; Quinolones; Treatment Outcome; Young Adult | 2012 |
Improvement of aripiprazole solubility by complexation with (2-hydroxy)propyl-β-cyclodextrin using spray drying technique.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Computer Simulation; Drug Carriers; Drug Stability; Hydrogen-Ion Concentration; Kinetics; Models, Chemical; Molecular Structure; Piperazines; Povidone; Powders; Quinolones; Solubility; Solvents; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Thermogravimetry; Water | 2012 |
A retrospective review of the effectiveness of aripiprazole in the treatment of sensory abnormalities in autism.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Registries; Retrospective Studies; Sensation Disorders; Surveys and Questionnaires; Time Factors | 2012 |
Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Mice; Mice, Inbred C57BL; Piperazines; Quinolones | 2012 |
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Costs; Drug Resistance; Fluoxetine; Health Care Costs; Humans; Piperazines; Quetiapine Fumarate; Quinolones | 2012 |
A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro.
Topics: Animals; Aripiprazole; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Partial Agonism; In Vitro Techniques; Male; Piperazines; Piperidines; Quinolones; Quinpirole; Rats; Rats, Wistar | 2012 |
Aripiprazole use in early pregnancy: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Quinolones; Schizophrenia, Paranoid | 2012 |
Chemical structure does not define obviousness.
Topics: Antipsychotic Agents; Aripiprazole; Drug Industry; Drugs, Generic; Legislation, Drug; Patents as Topic; Pharmaceutical Preparations; Piperazines; Quinolones | 2012 |
Aripiprazole salts. II. Aripiprazole perchlorate.
Topics: Aripiprazole; Crystallography, X-Ray; Molecular Structure; Perchlorates; Piperazines; Quinolones; Salts | 2012 |
Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain Injuries; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones | 2011 |
Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; Combined Modality Therapy; Dopamine Agents; Female; Fluvoxamine; GABA Modulators; Humans; Lorazepam; Memantine; Neurosurgical Procedures; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2011 |
Oculogyric crisis: a rare extrapyramidal side effect in the treatment of Tourette syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Eye Movements; Female; Humans; Piperazines; Quinolones; Tourette Syndrome; Young Adult | 2012 |
Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 months.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Severity of Illness Index; Time Factors; Tourette Syndrome; Treatment Outcome; Young Adult | 2012 |
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Auditory Cortex; Benzodiazepines; Dibenzothiazepines; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Reaction Time; Receptor, Adenosine A2A; Risperidone; Schizophrenia; Sensory Gating; Up-Regulation | 2012 |
Is there a role for loading dose regimes in aripiprazole therapy?
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quinolones | 2012 |
Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Quinolones; Retrospective Studies; Tics; Tourette Syndrome | 2012 |
Improvement in intractable tardive dystonia in bipolar disorder after aripiprazole treatment: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Resistance; Humans; Male; Movement Disorders; Piperazines; Quinolones | 2012 |
Use of aripiprazole in treatment of cannabis dependence in a patient presenting with Borderline Personality Disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Diagnosis, Dual (Psychiatry); Female; Humans; Marijuana Abuse; Piperazines; Quinolones | 2012 |
Efficacy of aripiprazole in a child with involuntary emotional expression disorder.
Topics: Affective Symptoms; Antipsychotic Agents; Aripiprazole; Child; Compulsive Behavior; Humans; Male; Piperazines; Quinolones | 2012 |
A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania.
Topics: Acute Disease; Anhedonia; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; Humans; Long-Term Care; Metabolic Diseases; Patient Participation; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Sexual Dysfunction, Physiological; Treatment Outcome | 2012 |
Low-dose aripiprazole in the treatment of selective serotonin reuptake inhibitors-induced orofacial and buccal dystonia.
Topics: Adult; Agoraphobia; Antipsychotic Agents; Aripiprazole; Dystonia; Face; Female; Humans; Panic Disorder; Paroxetine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2012 |
Complex visual hallucinations and delusional infestation comorbidity.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Ectoparasitic Infestations; Female; Hallucinations; Humans; Piperazines; Quinolones | 2012 |
Graves' hyperthyroidism-induced psychosis treated with aripiprazole--a case report.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Graves Disease; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Arrestins; beta-Arrestins; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Female; HEK293 Cells; Humans; Hyperkinesis; Ligands; Male; Mice; Mice, Knockout; Phencyclidine; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Structure-Activity Relationship | 2012 |
Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Topics: Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biotransformation; Blood-Brain Barrier; Digoxin; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Humans; Intestinal Mucosa; Intestines; Madin Darby Canine Kidney Cells; Models, Biological; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Permeability; Piperazines; Quinolones; Transfection | 2012 |
INN common stem: -piprazole.
Topics: Antipsychotic Agents; Aripiprazole; Piperazines; Quinolones | 2012 |
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Humans; Male; Medication Adherence; Patient Discharge; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2012 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss | 2012 |
Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole.
Topics: Adult; Area Under Curve; Aripiprazole; Drug Interactions; Female; Humans; Lithium Compounds; Male; Piperazines; Quinolones; Valproic Acid | 2012 |
Aripiprazole differentially regulates the expression of Gad67 and γ-aminobutyric acid transporters in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain Chemistry; Cationic Amino Acid Transporter 1; Dose-Response Relationship, Drug; GABA Plasma Membrane Transport Proteins; Gene Expression; Glutamate Decarboxylase; In Situ Hybridization; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Vesicular Inhibitory Amino Acid Transport Proteins | 2013 |
[Dysphagia or dysphagias during neuroleptic medication?].
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Clonazepam; Deglutition Disorders; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Homicide; Humans; Ill-Housed Persons; Loxapine; Male; Mental Disorders; Piperazines; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology | 2012 |
Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Biological Availability; Calorimetry, Differential Scanning; Chemical Precipitation; Dogs; Drug Stability; Hydrogen-Ion Concentration; Male; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Piperazines; Powder Diffraction; Quinolones; Solubility; X-Ray Diffraction | 2012 |
Aripiprazole induced tardive dyskinesia--accruing evidence.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Movement Disorders; Piperazines; Quinolones | 2013 |
Autism spectrum disorders.
Topics: Adolescent; Aripiprazole; Child Development Disorders, Pervasive; Child, Preschool; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Risperidone | 2012 |
[Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders].
Topics: Administration, Inhalation; Antipsychotic Agents; Arachidonic Acid; Aripiprazole; Child Development Disorders, Pervasive; Child, Preschool; Humans; Interpersonal Relations; Oxytocin; Piperazines; Quinolones; Risperidone | 2012 |
Treatment of cerebellar cognitive affective syndrome with aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cerebellar Diseases; Cognition Disorders; Female; Humans; Infratentorial Neoplasms; Mood Disorders; Neurosurgical Procedures; Papilloma, Choroid Plexus; Piperazines; Postoperative Complications; Quinolones; Syndrome | 2012 |
Heterogeneity in aripiprazole diffusion for bipolar disorder treatment in the Veterans Health Administration.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cross-Sectional Studies; Diffusion of Innovation; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Registries; United States; United States Department of Veterans Affairs; United States Food and Drug Administration | 2012 |
Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Carbon Radioisotopes; Caudate Nucleus; Dopamine; Dopamine D2 Receptor Antagonists; Humans; Levodopa; Male; Neuroimaging; Piperazines; Positron-Emission Tomography; Putamen; Quinolones; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Tissue Distribution; Young Adult | 2012 |
Combination therapy of zonisamide with aripiprazole on ECT- and benzodiazepine-resistant periodic catatonia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Isoxazoles; Male; Piperazines; Quinolones; Schizophrenia, Catatonic; Zonisamide | 2012 |
Low-dose aripiprazole in the treatment of SSRI-induced bruxism.
Topics: Antipsychotic Agents; Aripiprazole; Bruxism; Citalopram; Female; Humans; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2012 |
Probable aripiprazole-induced tardive writer's cramp.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dystonic Disorders; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Young Adult | 2012 |
Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naïve non-psychotic major depressive disorder.
Topics: Aripiprazole; Brain; Depressive Disorder, Major; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Piperazines; Quinolones | 2012 |
Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Heat-Shock Proteins; Immunohistochemistry; Inositol 1,4,5-Trisphosphate Receptors; Nerve Growth Factor; Neurites; PC12 Cells; Piperazines; Proteomics; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; RNA Interference; Signal Transduction | 2012 |
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Diagnostic and Statistical Manual of Mental Disorders; DNA; Drug Interactions; Female; Genotype; Humans; Japan; Luminescence; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Postmenopause; Prolactin; Quinolones; Receptors, Dopamine D2; Regression Analysis; Schizophrenia; Sex Characteristics | 2012 |
Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
Topics: Adrenergic alpha-Agonists; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Asthma; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Chest Pain; Child; Dyskinesia, Drug-Induced; Family; Female; Guanfacine; Humans; Lithium Chloride; Male; Mood Disorders; Neuropsychological Tests; Obesity; Paroxetine; Piperazines; Polypharmacy; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Agitation; Quinolones; Selective Serotonin Reuptake Inhibitors; Smoking; Social Environment | 2012 |
Synthetic cannabinoid-induced psychosis: two adolescent cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cannabinoids; Delusions; Designer Drugs; Humans; Male; Marijuana Abuse; Olanzapine; Piperazines; Psychoses, Substance-Induced; Quinolones | 2012 |
A case of antipsychotic-induced hyperglycemia in a child with insulin dependent diabetes mellitus.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Blood Glucose; Diabetes Mellitus, Type 1; Hospitalization; Humans; Hyperglycemia; Language Disorders; Learning Disabilities; Male; Piperazines; Quinolones; Risperidone | 2012 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
[Efficacy of aripiprazole on cognitive and behavioral changes in a young woman with systemic lupus erythematosus].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Lupus Erythematosus, Systemic; Mental Disorders; Piperazines; Quinolones | 2012 |
The effect of ethyl alcohol on the function of spatial memory in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Depressants; Drug Interactions; Ethanol; Female; Maze Learning; Memory; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenic Psychology; Stress, Psychological | 2012 |
Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study).
Topics: Adult; Amisulpride; Antioxidants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Catalase; Clozapine; Dibenzothiazepines; Enzyme Activation; Erythrocytes; Glutathione Peroxidase; Glutathione Reductase; Humans; Imidazoles; Indoles; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Sulpiride; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Child; Cholesterol; Female; Humans; Longitudinal Studies; Male; Pimozide; Piperazines; Quinolones; Tourette Syndrome; Treatment Outcome; Triglycerides | 2012 |
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Piperazines; Quinolones; Recurrence | 2012 |
Acute laryngeal dystonia associated with aripiprazole.
Topics: Acute Disease; Adolescent; Aripiprazole; Dystonia; Female; Humans; Laryngeal Muscles; Piperazines; Quinolones | 2012 |
Daily dose of 105 mg aripiprazole because of delusional origin: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Drug Overdose; Female; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Self Medication | 2012 |
Treatments: In the waiting room.
Topics: Adolescent; Adult; Animals; Aripiprazole; Autistic Disorder; Brain; Child; Clinical Trials as Topic; Drug Approval; Drug Repositioning; Humans; Oxytocin; Piperazines; Quinolones; Risperidone; Selective Serotonin Reuptake Inhibitors; Trichuris; United States; United States Food and Drug Administration | 2012 |
Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Piperazines; Quinolones; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Secondary Prevention; Substance-Related Disorders | 2013 |
Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Depressants; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Exploratory Behavior; Male; Mice; Motor Activity; Motor Neurons; Piperazines; Postural Balance; Quinolones; Rotarod Performance Test | 2013 |
Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Arrestins; Behavior, Animal; beta Catenin; beta-Arrestins; Dopaminergic Neurons; Gene Knockout Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Lithium; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Piperazines; Quinolones; Receptors, Dopamine D2; Signal Transduction | 2012 |
Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys.
Topics: Animals; Aripiprazole; Choice Behavior; Cocaine; Cocaine-Related Disorders; Dominance-Subordination; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Partial Agonism; Feeding Behavior; Ligands; Macaca fascicularis; Male; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Reinforcement, Psychology; Self Administration | 2013 |
Rhabdomyolysis in a patient on aripiprazole with traumatic hip prosthesis luxation.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Arthroplasty, Replacement, Hip; Bipolar Disorder; Female; Hip Prosthesis; Humans; Piperazines; Prosthesis Failure; Quinolones; Rhabdomyolysis | 2012 |
Aripiprazole augmentation for clozapine-associated tardive torticollis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia; Torticollis; Treatment Outcome | 2012 |
Aripiprazole for the treatment of involuntary movement symptoms in patients with major depressive disorder.
Topics: Aripiprazole; Depressive Disorder, Major; Dyskinesias; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2012 |
Drug-nutrient interactions: a case and clinical guide.
Topics: Alcohol Drinking; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder; Dietary Supplements; Food; Food-Drug Interactions; Humans; Male; Malnutrition; Middle Aged; Piperazines; Prescription Drugs; Quinolones | 2011 |
Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cohort Studies; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Prescriptions; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Retrospective Studies; Spatio-Temporal Analysis; United States; United States Food and Drug Administration; Young Adult | 2013 |
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Case-Control Studies; Cerebral Cortex; Drug Partial Agonism; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Positron-Emission Tomography; Pyridines; Quinolones; Radiopharmaceuticals; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2013 |
Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Isoquinolines; Mice; Molecular Structure; Motor Activity; Piperazines; Quinolines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Serotonin; Structure-Activity Relationship; Sulfonamides | 2013 |
Aripiprazole-related severe neuroleptic malignant syndrome with deep coma and organic brain changes in an antipsychotic-naive adolescent boy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Brain; Coma; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Predictive Value of Tests; Psychotic Disorders; Quinolones; Treatment Outcome | 2013 |
Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia.
Topics: Antipsychotic Agents; Aripiprazole; Frontotemporal Dementia; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Sexual Behavior; Treatment Outcome; Verbal Behavior | 2013 |
Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brain; Cognition; Electroencephalography; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2013 |
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Tranquilizing Agents | 2013 |
Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Astemizole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Energy Metabolism; Epoxy Compounds; Fatty Acids; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Olanzapine; Oxygen Consumption; Piperazines; Quinolones; Receptors, Histamine H1; Respiration; Risperidone; Terfenadine; Time Factors | 2014 |
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult | 2013 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult | 2013 |
Neural correlates of treatment response in depressed bipolar adolescents during emotion processing.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Citalopram; Depressive Disorder; Dibenzothiazepines; Drug Therapy, Combination; Emotions; Facial Expression; Female; Humans; Lamotrigine; Magnetic Resonance Imaging; Male; Piperazines; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Sertraline; Triazines; Valproic Acid | 2013 |
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Depressive Disorder, Major; Humans; Linear Models; Piperazines; Placebo Effect; Quinolones; Randomized Controlled Trials as Topic; Research Design | 2013 |
Torsades de pointes after administration of low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Complications; Drug Monitoring; Heart Arrest; Humans; Hypertension; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Stroke; Torsades de Pointes; Treatment Outcome | 2013 |
Aripiprazole salts. III. Bis(aripiprazolium) oxalate-oxalic acid (1/1).
Topics: Aripiprazole; Crystallography, X-Ray; Hydrogen Bonding; Ions; Molecular Conformation; Molecular Structure; Oxalates; Piperazines; Quinolones | 2013 |
[Application of HPLC-UV method for aripiprazole determination in serum].
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Piperazines; Quinolones; Reference Standards; Serum; Spectrophotometry, Ultraviolet | 2012 |
Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Aripiprazole; Biological Availability; Brain; Corpus Striatum; Dose-Response Relationship, Drug; Male; Models, Animal; Piperazines; Quinolones; Rats; Receptors, Dopamine D2; Self Administration | 2013 |
Aripiprazole-associated acute dystonia, akathisia, and parkinsonism in a patient with bipolar I disorder.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dystonia; Female; Humans; Parkinsonian Disorders; Piperazines; Quinolones | 2013 |
Aripiprazole in the treatment of delusional parasitosis with ocular and dermatologic presentations.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Delusions; Ectoparasitic Infestations; Eye Infections, Parasitic; Humans; Male; Piperazines; Quinolones | 2013 |
Aripiprazole-montmorillonite: a new organic-inorganic nanohybrid material for biomedical applications.
Topics: Animals; Aripiprazole; Bentonite; Biological Availability; Humans; Hydrogen-Ion Concentration; Male; Nanostructures; Piperazines; Polymers; Quinolones; Rats; Rats, Sprague-Dawley; Solubility; Taste | 2013 |
Treatment of youth with bipolar disorder: long-term versus maintenance.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Male; Piperazines; Quinolones | 2013 |
Safety first.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Male; Piperazines; Quinolones | 2013 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult | 2013 |
Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study.
Topics: Acetates; Aripiprazole; Chromatography, Liquid; Drug Stability; Humans; Least-Squares Analysis; Liquid-Liquid Extraction; Male; Piperazines; Quinolones; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome | 2013 |
[Is there a place for the physician's hopelesness in the treatment of depression?].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Physician's Role; Piperazines; Quinolones; Remission Induction; Risk Factors; Thiophenes; Treatment Outcome | 2013 |
LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Dose-related reversible hypotension during aripiprazole treatment.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Hypotension; Male; Piperazines; Quinolones; Schizophrenia; Young Adult | 2013 |
Effectiveness of a clozapine-aripiprazole combination in Tourette syndrome and bipolar spectrum disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Tourette Syndrome | 2013 |
Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia.
Topics: Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Asian People; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; DNA; Estrogen Receptor alpha; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Male; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2013 |
SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study.
Topics: Aripiprazole; Chromatography, High Pressure Liquid; Humans; Linear Models; Piperazines; Quinolones; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors | 2013 |
Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cattle; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Drug Stability; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
[Possible malignant neuroleptic syndrome associated with aripiprazole and imipramine and treated with bromocriptine].
Topics: Antipsychotic Agents; Aripiprazole; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combination; Emergencies; Frontotemporal Dementia; Humans; Imipramine; Lorazepam; Male; Mental Disorders; Middle Aged; Neuroleptic Malignant Syndrome; Oxygen Inhalation Therapy; Piperazines; Quinolones; Respiration, Artificial; Respiratory Insufficiency | 2013 |
[Clinical observation of aripiprazole in the treatment of autism].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child, Preschool; Female; Humans; Male; Piperazines; Quinolones | 2013 |
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Biomarkers; Disease Progression; Histone Deacetylase Inhibitors; Humans; Piperazines; Quinolones; Schizophrenia | 2013 |
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Huntington Disease; Male; Morpholines; Piperazines; Psychotic Disorders; Quinolones; Reboxetine; Treatment Outcome | 2013 |
Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Chi-Square Distribution; Child; Drug Synergism; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Risperidone; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tics | 2013 |
Cavum septum pellucidum and cavum vergae with late-onset catatonia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Brain; Catatonia; Cysteine; Electroconvulsive Therapy; Female; Humans; Hypnotics and Sedatives; Lorazepam; Magnetic Resonance Imaging; Organotechnetium Compounds; Piperazines; Quinolones; Radiopharmaceuticals; Septum Pellucidum; Somatoform Disorders; Tomography, Emission-Computed, Single-Photon | 2013 |
Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Republic of Korea; Schizophrenia | 2014 |
Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans; Piperazines; Pregabalin; Quinolones | 2013 |
Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Athetosis; Chorea; Humans; Huntington Disease; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Clozapine-induced restless legs syndrome treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Restless Legs Syndrome; Schizophrenia, Paranoid | 2013 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
Comparison of nanomilling and coprecipitation on the enhancement of in vitro dissolution rate of poorly water-soluble model drug aripiprazole.
Topics: Aripiprazole; Cellulose; Chemical Precipitation; Nanoparticles; Particle Size; Piperazines; Poloxamer; Povidone; Powders; Quinolones; Solubility; Tablets; Water | 2014 |
Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Topics: Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buspirone; Haloperidol; Ketanserin; Male; Mice; Mice, Knockout; Motor Activity; Piperazines; Quinolones; Rotarod Performance Test; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 2013 |
Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Agents; Humans; Methylphenidate; Models, Theoretical; Piperazines; Quinolones | 2013 |
A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Defecation; Drug Substitution; Drug Therapy, Combination; Humans; Intestinal Obstruction; Lamotrigine; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Treatment Outcome; Triazines | 2013 |
Dermoscopy in delusions of parasitosis.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clothing; Delusional Parasitosis; Dermoscopy; Humans; Insecta; Male; Middle Aged; Piperazines; Quinolones; Skin Diseases | 2013 |
Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Cognition; Female; Humans; Male; Neuropsychological Tests; Piperazines; Prospective Studies; Psychotic Disorders; Quality of Life; Quinolones; Schizophrenia; Taiwan; Treatment Outcome; Young Adult | 2014 |
Biological perspectives: akathisia: ants in your pants.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Treatment Outcome | 2013 |
Aripiprazole, an atypical antipsychotic drug, improves maturation and complexity of neuroblast dendrites in the mouse dentate gyrus via increasing superoxide dismutases.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Differentiation; Cell Proliferation; Dentate Gyrus; Doublecortin Protein; Male; Mice; Mice, Inbred ICR; Neurons; Piperazines; Quinolones; Superoxide Dismutase | 2013 |
An evaluation of inpatient treatment continuation and hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine.
Topics: Adolescent; Adult; Age Factors; Aged; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Cohort Studies; Dibenzothiazepines; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Hospitals, Psychiatric; Humans; Inpatients; Male; Middle Aged; Odds Ratio; Patient Readmission; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Valproic Acid; Young Adult | 2013 |
Loss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental area.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Carrier Proteins; Cocaine; Dopamine Uptake Inhibitors; Down-Regulation; Excitatory Postsynaptic Potentials; Female; Glutamic Acid; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuronal Plasticity; Organ Culture Techniques; Piperazines; Quinolones; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials; Ventral Tegmental Area | 2013 |
Development of a novel RP-HPLC method for the efficient separation of aripiprazole and its nine impurities.
Topics: Aripiprazole; Chromatography, High Pressure Liquid; Drug Contamination; Least-Squares Analysis; Piperazines; Quantitative Structure-Activity Relationship; Quinolones; Time Factors | 2013 |
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quinolones; Schizophrenia | 2014 |
Clinical effectiveness of aripiprazole in short-term treatment of tic disorder in children and adolescents: a naturalistic study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Tic Disorders | 2014 |
Aripiprazole increases NADPH level in PC12 cells: the role of NADPH oxidase.
Topics: Animals; Antipsychotic Agents; Aripiprazole; NADP; NADPH Oxidases; Neurons; PC12 Cells; Piperazines; Quinolones; Rats; Reactive Oxygen Species | 2014 |
Influence of aripiprazole pretreatment on the reinforcing effects of methamphetamine in humans.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Methamphetamine; Piperazines; Quinolones; Reinforcement, Psychology; Self Administration; Substance-Related Disorders; Surveys and Questionnaires; Young Adult | 2013 |
Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Aripiprazole; Binding Sites; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Female; Haloperidol; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Time Factors; Up-Regulation | 2014 |
Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Brain; Cell Survival; Cells, Cultured; Coculture Techniques; Drug Interactions; Haloperidol; Interferon-gamma; Microglia; Minocycline; Myelin Proteolipid Protein; Nitrites; Oligodendroglia; Piperazines; Quinolinium Compounds; Quinolones; Rats; STAT1 Transcription Factor | 2013 |
Case series: extrapyramidal symptoms associated with use of aripiprazole in older adults.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Male; Piperazines; Quinolones; Risk Factors | 2013 |
Aspirin as an adjunctive treatment for childhood onset schizophrenia.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aripiprazole; Aspirin; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2013 |
Prenatal exposure of a novel antipsychotic aripiprazole: impact on maternal, fetal and postnatal body weight modulation in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Birth Weight; Body Weight; Eating; Female; Fetal Weight; Male; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar | 2014 |
Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Blotting, Western; Cocaine; Disease Models, Animal; Dopamine Uptake Inhibitors; Excitatory Amino Acid Antagonists; Fragile X Mental Retardation Protein; Fragile X Syndrome; Immunoenzyme Techniques; Male; Mice; Mice, Knockout; Motor Activity; Muscarinic Antagonists; Piperazines; Pyridines; Quinolones; Receptor, Metabotropic Glutamate 5; Reward; Trihexyphenidyl; Tyrosine 3-Monooxygenase | 2013 |
ECG parameters in children and adolescents treated with aripiprazole and risperidone.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Electrocardiography; Female; Heart Rate; Humans; Male; Mental Disorders; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Risperidone | 2014 |
Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
Topics: Adenosine A2 Receptor Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Cebus; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Motor Activity; Phosphodiesterase Inhibitors; Piperazines; Pyrazoles; Pyrimidines; Quinolines; Quinolones; Triazoles | 2014 |
Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats.
Topics: Alcoholism; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Drug Therapy, Combination; Ethanol; Fluoxetine; Male; Maze Learning; Piperazines; Quinolones; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Spatial Memory; Swimming | 2014 |
Lyme neuroborreliosis presenting with alexithymia and suicide attempts.
Topics: Adult; Affective Symptoms; Anti-Bacterial Agents; Antibodies, Bacterial; Antipsychotic Agents; Aripiprazole; Borrelia; Ceftriaxone; Citalopram; Hospitalization; Humans; Injections, Intravenous; Intelligence Tests; Interview, Psychological; Lyme Neuroborreliosis; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Treatment Outcome | 2013 |
Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: applying guidelines in the real world.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Humans; Piperazines; Practice Guidelines as Topic; Psychiatric Status Rating Scales; Quinolones; Risk Assessment; Risperidone | 2013 |
Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Aripiprazole; Child; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Piperazines; Quinolones; Retrospective Studies; Risperidone; Young Adult | 2014 |
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss | 2014 |
Syndrome of inappropriate antidiuretic hormone associated with aripiprazole.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Hospitalization; Humans; Inappropriate ADH Syndrome; Male; Piperazines; Quinolones; Severity of Illness Index | 2013 |
Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Basic Helix-Loop-Helix Transcription Factors; Brain-Derived Neurotrophic Factor; Cytoskeletal Proteins; Drug Administration Schedule; Gene Expression Regulation; Male; Nerve Tissue Proteins; Piperazines; Prefrontal Cortex; Quinolones; Rats; Stress, Physiological | 2014 |
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
Topics: Academic Medical Centers; Adult; Ambulatory Care Facilities; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; California; Dibenzothiazepines; Drug Therapy; Female; Humans; Lamotrigine; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Referral and Consultation; Risperidone; Triazines | 2014 |
Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Young Adult | 2014 |
Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Sensitization; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Male; Mice; Motor Activity; Piperazines; Quinolones; Thiazoles | 2014 |
Ceftriaxone and infection in first episode adolescent psychosis.
Topics: Adolescent; Anti-Bacterial Agents; Aripiprazole; Bacterial Infections; Ceftriaxone; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Beneficial in vivo effect of aripiprazole on neuronal regeneration following neuronal loss in the dentate gyrus: evaluation using a mouse model of trimethyltin-induced neuronal loss/self-repair in the dentate gyrus.
Topics: Animals; Aripiprazole; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Cell Survival; Dentate Gyrus; Disease Models, Animal; Male; Mice; Mice, Inbred Strains; Nerve Regeneration; Nestin; Neural Stem Cells; Piperazines; Quinolones; Trimethyltin Compounds | 2014 |
Micturition difficulty and urinary retention associated with aripiprazole and citalopram treatment in a male adolescent with Asperger syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Citalopram; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Urinary Retention; Urination Disorders | 2014 |
Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia.
Topics: Aripiprazole; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2014 |
Transfer of aripiprazole to breast milk: a case report.
Topics: Adult; Aripiprazole; Female; Humans; Milk, Human; Piperazines; Quinolones | 2014 |
Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome | 2014 |
Reversible dopamine transporter reduction in drug-induced Parkinsonism.
Topics: Aged; Aripiprazole; Bipolar Disorder; Brain; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Lithium Carbonate; Parkinson Disease, Secondary; Piperazines; Quinolones; Radionuclide Imaging | 2014 |
Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Dibenzothiazepines; ErbB Receptors; Frontal Lobe; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Piperazines; Proto-Oncogene Proteins c-fos; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Ribosomal Protein S6 Kinases, 90-kDa; Tissue Distribution | 2014 |
Long-acting atypical antipsychotics: characterization of the local tissue response.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Inflammation Mediators; Injections, Subcutaneous; Macaca fascicularis; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2014 |
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Risperidone; Weight Gain; Young Adult | 2014 |
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Humans; Intellectual Disability; Male; Middle Aged; Pilot Projects; Piperazines; Quinolones; Retrospective Studies; Risk Factors; Risperidone; Self-Injurious Behavior; Treatment Failure; Young Adult | 2015 |
Prolonged penile erections associated with the use of atomoxetine and aripiprazole in an 11-year-old boy.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Child; Humans; Male; Penile Erection; Piperazines; Propylamines; Quinolones | 2014 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
Two cases of olfactory reference syndrome responding to an atypical antipsychotic and SSRI.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Male; Piperazines; Quinolones; Risperidone; Selective Serotonin Reuptake Inhibitors; Young Adult | 2014 |
Self-mutilation of the tongue in a patient with schizophrenia.
Topics: Adolescent; Adult; Amputation, Traumatic; Aripiprazole; Humans; Male; Medication Adherence; Piperazines; Quinolones; Replantation; Schizophrenia, Paranoid; Self Mutilation; Tongue; Young Adult | 2014 |
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Time Factors | 2014 |
Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department.
Topics: Administration, Oral; Adult; Alcoholic Intoxication; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Hospitals, University; Humans; Male; Middle Aged; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2014 |
Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biotransformation; Brain Chemistry; Injections, Intravenous; Mice; Piperazines; Quinolones | 2014 |
Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine D2 Receptor Antagonists; Female; Histamine H1 Antagonists; Hospitals, Psychiatric; Humans; Israel; Male; Mianserin; Middle Aged; Mirtazapine; Off-Label Use; Piperazines; Quinolones; Retrospective Studies; Severity of Illness Index; Young Adult | 2014 |
Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Schizophrenia; Young Adult | 2014 |
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Treatment; Female; Haloperidol; Humans; Hungary; Male; Middle Aged; Olanzapine; Piperazines; Practice Patterns, Physicians'; Promethazine; Psychiatry; Psychomotor Agitation; Psychotic Disorders; Quinolones; Surveys and Questionnaires | 2014 |
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Clozapine; Dibenzothiazepines; Estrogens; Female; Humans; Male; Middle Aged; Osteoporosis; Perphenazine; Piperazines; Prolactin; Prospective Studies; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sulpiride | 2014 |
Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2014 |
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Piperazines; Quinolones; Schizophrenia; United States | 2014 |
Worsening of psychosis with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2014 |
Rapid responses of high-dose combined therapy of escitalopram and aripiprazole in a case of severe obsessive compulsive disorder with delusion.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Delusions; Drug Therapy, Combination; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Young Adult | 2014 |
Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion.
Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Retrospective Studies | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
Aripiprazole in difficult-to-treat delusional disorder with co-morbid epilepsy.
Topics: Antipsychotic Agents; Aripiprazole; Drug Resistance; Epilepsy; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Young Adult | 2014 |
Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.
Topics: Acoustic Stimulation; Amisulpride; Antipsychotic Agents; Aripiprazole; Auditory Perception; Benzhydryl Compounds; Brain; Double-Blind Method; Electroencephalography; Electromyography; Humans; Lorazepam; Male; Modafinil; Piperazines; Prepulse Inhibition; Psychometrics; Psychotropic Drugs; Quinolones; Risperidone; Sensory Gating; Sulpiride; Valproic Acid; Young Adult | 2014 |
Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats.
Topics: Alcoholism; Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Fluoxetine; Male; Piperazines; Quinolones; Rats; Rats, Wistar; Spatial Memory | 2014 |
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats.
Topics: Animals; Antidepressive Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Depression; Environment; Female; Hippocampus; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Quinolones; Rats; Rats, Wistar; Spatial Memory | 2014 |
Prolactin deficiency by aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Piperazines; Prolactin; Quinolones | 2014 |
Active-state model of a dopamine D2 receptor-Gαi complex stabilized by aripiprazole-type partial agonists.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Ligands; Molecular Dynamics Simulation; Piperazines; Protein Binding; Protein Conformation; Quinolones; Receptors, Dopamine D2 | 2014 |
Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Drinking Behavior; Feeding Behavior; Haloperidol; Male; Motor Activity; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Weight Gain | 2014 |
An aripiprazole discontinuation syndrome.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2013 |
[Psychosis due to vitamin B12 deficiency in an elderly patient].
Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Gastritis, Atrophic; Humans; Paranoid Disorders; Piperazines; Psychological Tests; Quinolones; Remission Induction; Risperidone; Vitamin B 12; Vitamin B 12 Deficiency | 2014 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Agents; Humans; Obsessive-Compulsive Disorder; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Stress, Psychological; Thinking | 2014 |
Preparation and characterization of high-content aripiprazole-loaded core-shell structure microsphere for long-release injectable formulation.
Topics: Animals; Aripiprazole; Chemistry, Pharmaceutical; Crystallization; Delayed-Action Preparations; Isomerism; Lactic Acid; Microspheres; Molecular Weight; Piperazines; Polyesters; Polymers; Porosity; Quinolones; Rabbits; Temperature; Viscosity | 2014 |
Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Valproic Acid; Young Adult | 2014 |
Reflex sympathetic dystrophy-like syndrome, possibly caused by aripiprazole, in an adolescent patient.
Topics: Adolescent; Aripiprazole; Female; Humans; Piperazines; Quinolones; Reflex Sympathetic Dystrophy | 2014 |
Combination of omega-3 Fatty acids, lithium, and aripiprazole reduces oxidative stress in brain of mice with mania.
Topics: Animals; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Brain Chemistry; Disease Models, Animal; Fatty Acids, Omega-3; Glutathione; Lithium Compounds; Male; Mice; Oxidative Stress; Oxidoreductases; Piperazines; Quinolones | 2014 |
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hypertriglyceridemia; Liver; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Transaminases; Treatment Outcome | 2014 |
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Dietary Sucrose; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Imipramine; Male; Piperazines; Quinolones; Rats, Wistar; Stress, Psychological | 2014 |
Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population.
Topics: Adult; Age of Onset; Aripiprazole; China; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; MicroRNAs; Phenotype; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2014 |
"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Aripiprazole; Bias; Case-Control Studies; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Databases, Pharmaceutical; Humans; Isoxazoles; Ketolides; Marketing; Medicaid; Pharmacoepidemiology; Piperazines; Product Surveillance, Postmarketing; Quinolones; Sulfonamides; United States | 2014 |
Aripiprazole for the treatment of a manic patient with clozapine-related colonic obstruction receiving total colectomy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Colectomy; Humans; Intestinal Obstruction; Male; Piperazines; Quinolones | 2014 |
Aripiprazole as monotherapy at bedtime was effective for treatment of two cases of obsessive-compulsive disorder and insomnia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Sleep Initiation and Maintenance Disorders | 2014 |
Aripiprazole-associated hiccups: a case and closer look at the association between hiccups and antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Hiccup; Humans; Male; Piperazines; Quinolones; Young Adult | 2014 |
Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Quinolones; Treatment Outcome | 2014 |
Aripiprazole-associated QTc prolongation in a geriatric patient.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Long QT Syndrome; Piperazines; Quinolones | 2014 |
High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2015 |
The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Conditioning, Psychological; Disease Models, Animal; Male; Mice; Morphine; Motor Activity; Nociception; Opioid-Related Disorders; Piperazines; Quinolones; Reward | 2014 |
Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depression, Postpartum; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2015 |
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive Behavior; Olanzapine; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Schizophrenia; Sulpiride | 2015 |
How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
Topics: Adult; Antidepressive Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Precision Medicine; Prognosis; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Self Report; Treatment Outcome | 2014 |
Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dibenzothiazepines; Drug Synergism; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Taiwan; Treatment Outcome | 2014 |
[Aripiprazol potentiates NGF-induced neurite outgrowth].
Topics: Animals; Aripiprazole; HSP90 Heat-Shock Proteins; Nerve Growth Factor; Neurites; PC12 Cells; Piperazines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Signal Transduction | 2013 |
Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
Topics: Adult; Aged; Aripiprazole; Benzothiazoles; Compulsive Behavior; Consumer Behavior; Dopamine Agonists; Drug Labeling; Female; Gambling; Humans; Hyperprolactinemia; Impulsive Behavior; Indoles; Male; Middle Aged; Parkinson Disease; Piperazines; Pramipexole; Quinolones; Receptors, Dopamine D3; Restless Legs Syndrome; Retrospective Studies; Sexual Behavior; United States; United States Food and Drug Administration | 2014 |
Quantitative levels of aripiprazole parent drug and metabolites in urine.
Topics: Adult; Aripiprazole; Humans; Middle Aged; Piperazines; Prospective Studies; Quinolones; Substance Abuse Detection | 2014 |
Atypical antipsychotics are not all alike: side effects and risk assessment.
Topics: Antipsychotic Agents; Aripiprazole; Decision Making; Humans; Mental Disorders; Off-Label Use; Patient Education as Topic; Piperazines; Quinolones; Risk Assessment; Risperidone | 2014 |
Aripiprazole may be effective as an add-on treatment in bulimic symptoms of eating disorders.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bulimia Nervosa; Drug Therapy, Combination; Feeding and Eating Disorders; Female; Humans; Piperazines; Quinolones; Treatment Outcome; Young Adult | 2015 |
New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling.
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; GTP-Binding Protein beta Subunits; GTP-Binding Protein gamma Subunits; Haloperidol; HEK293 Cells; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Signal Transduction | 2015 |
What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2014 |
Long-acting injectable antipsychotics: an underutilized treatment option.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2014 |
Aripiprazole induced non-cardiogenic pulmonary edema: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6 Inhibitors; Diagnosis, Differential; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Pulmonary Edema; Quinolones; Tomography, X-Ray Computed | 2014 |
Light and electron microscopic study on the effect of antischizophrenic drugs on the structure of seminiferous tubules of adult male albino rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Male; Piperazines; Quinolones; Rats; Rats, Wistar; Seminiferous Tubules; Testis | 2014 |
Aripiprazole adjunct treatment in bipolar I or II disorder, depressed state: a 2-year clinical study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Synergism; Drug Therapy, Combination; Female; Humans; Lithium; Male; Middle Aged; Piperazines; Quinolones; Time Factors; Treatment Outcome; Young Adult | 2015 |
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; Hippocampus; Neuregulin-1; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Schizophrenia; Signal Transduction; Time Factors; Up-Regulation | 2015 |
Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzophenanthridines; Bipolar Disorder; Cell Proliferation; Disease Models, Animal; Fluoxetine; Hippocampus; Lithium Chloride; Male; Piperazines; Prefrontal Cortex; Protein Kinase C; Protein Kinase Inhibitors; Quinolones; Rats, Sprague-Dawley; Sleep Deprivation; Tamoxifen | 2014 |
Approximating the detection limit of an infrared spectroscopic imaging microscope operating in an attenuated total reflection (ATR) modality: theoretical and empirical results for an instrument using a linear array detector and a 1.5 millimeter germanium
Topics: Acetaminophen; Aripiprazole; Equipment Design; Germanium; Image Processing, Computer-Assisted; Lactose; Limit of Detection; Microscopy; Models, Theoretical; Oxycodone; Particle Size; Piperazines; Quinolones; Reproducibility of Results; Signal-To-Noise Ratio; Spectrophotometry, Infrared; Spectroscopy, Fourier Transform Infrared; Tablets | 2015 |
Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Mining; Databases, Factual; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2015 |
Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Substitution; Humans; Italy; Piperazines; Quinolones; Schizophrenia | 2015 |
Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Topics: Animals; Aripiprazole; Boron Compounds; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; HSP90 Heat-Shock Proteins; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Nerve Growth Factor; Neurites; Oxazoles; PC12 Cells; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Agents; Thiophenes | 2015 |
Aripiprazole-induced acute hiccups: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Depression; Hiccup; Humans; Male; Middle Aged; Piperazines; Quinolones | 2015 |
[Case of graves' disease with remarkable psychiatric symptoms].
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Antithyroid Agents; Aripiprazole; Bipolar Disorder; Delusions; Female; Graves Disease; Hallucinations; Humans; Lithium Compounds; Methimazole; Piperazines; Propranolol; Quinolones; Treatment Outcome | 2015 |
Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features.
Topics: Antipsychotic Agents; Aripiprazole; Coloring Agents; Dark Adaptation; Electrooculography; Electroretinography; Female; Fluorescein Angiography; Humans; Indocyanine Green; Middle Aged; Multimodal Imaging; Piperazines; Quinolones; Retina; Retinal Diseases; Retinal Pigment Epithelium; Schizophrenia; Tomography, Optical Coherence; Visual Acuity | 2015 |
Efficacy of aripiprazole in antidepressants-induced tardive dystonia and tardive dyskinesia: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2015 |
Hiccups Associated with Aripiprazole in an Adolescent with Bipolar Disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Hiccup; Humans; Quinolones; Treatment Outcome | 2016 |
The Use of Aripiprazole in Young Children with Autism Spectrum Disorders: The Treatment and 16 Week Follow-Up of a 23-Month-old Male Patient.
Topics: Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child, Preschool; Follow-Up Studies; Humans; Infant; Male; Quinolones; Treatment Outcome | 2016 |
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes | 2015 |
Mechanism of action of brexpiprazole: comparison with aripiprazole.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes | 2016 |
Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyperprolactinemia; Male; Prolactin; Quinolones; Schizophrenia | 2016 |
The use of aripiprazole for tic disorders in children and adolescents and implications for resource limited settings in the developing world.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Quinolones; Tic Disorders | 2018 |
Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies.
Topics: Aripiprazole; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Phospholipids; Piperazines; Quinolones; Solid Phase Extraction; Tandem Mass Spectrometry | 2018 |
The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; New York; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Thiophenes; Treatment Outcome; Young Adult | 2018 |
SIMULTANEOUS ASSAY OF ARIPIPRAZOLE AND ITS ACTIVE METABOLITE IN SERUM BY HPLC.
Topics: Acetonitriles; Activation, Metabolic; Antipsychotic Agents; Aripiprazole; Buffers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Compounding; Drug Monitoring; Humans; Hydrogen-Ion Concentration; Phosphoric Acids; Piperazines; Quinolones; Schizophrenia; Solvents; Water | 2017 |
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Topics: Adult; Age Factors; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Expenditures; Health Resources; Health Services; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Middle Aged; Models, Econometric; Quetiapine Fumarate; Quinolones; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors; Thiophenes; Time-to-Treatment | 2018 |
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2018 |
Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin Antagonists; Thiophenes | 2019 |
Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Arousal; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Drug Approval; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Practice Patterns, Physicians'; Quality of Life; Quetiapine Fumarate; Quinolones; Sleep Initiation and Maintenance Disorders; Thiophenes | 2019 |
Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
Topics: Adolescent; Adult; Age Factors; Aged; Aripiprazole; Child; Cytochrome P-450 CYP2D6; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Retrospective Studies; Sex Factors | 2020 |
A Dilute and Shoot LC-MS/MS Method for Antipsychotics in Urine.
Topics: Antipsychotic Agents; Aripiprazole; Chromatography, Liquid; Drug Monitoring; Humans; Limit of Detection; Quinolones; Tandem Mass Spectrometry; Thiophenes | 2020 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States | 2020 |
Aripiprazole in youth with intellectual disabilities: A retrospective chart study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Intellectual Disability; Piperazines; Quinolones; Retrospective Studies | 2021 |
Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes | 2020 |
Concentrations of aripiprazole and dehydroaripiprazole in hair segments from deceased individuals with mental disorders.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Forensic Toxicology; Hair; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Polypharmacy; Postmortem Changes; Quinolones; Tandem Mass Spectrometry; Young Adult | 2020 |
Interest-Activity Dimension and Response to Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Humans; Quinolones | 2020 |
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.
Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; Drug Substitution; GABA Modulators; Humans; Male; Parkinsonian Disorders; Pelvis; Propranolol; Quinolones; Serotonin Agents; Tardive Dyskinesia; Tetrabenazine; Thiophenes; Treatment Failure; Valine | 2020 |
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Japan; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2021 |
Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study.
Topics: Antipsychotic Agents; Aripiprazole; Piperazines; Quinolones; Thiophenes | 2021 |
Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Genotype; Humans; Phenotype; Piperazines; Quinolones | 2021 |
Gamma oscillations predict treatment response to aripiprazole in bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Retrospective Studies; Treatment Outcome | 2021 |
Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D
Topics: Animals; Aripiprazole; Binding Sites; Blood-Brain Barrier; Cell Death; Central Nervous System; CHO Cells; Cricetulus; Drug Design; Ligands; Models, Molecular; Quinolones; Receptors, Dopamine D2 | 2021 |
Comparing the efficacy of aripiprazole as an add-on to valproate with other second-generation antipsychotics in acute mania symptoms in manic patients in Iran.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Iran; Mania; Piperazines; Quinolones; Treatment Outcome; Valproic Acid | 2022 |
[Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult | 2022 |
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior | 2022 |
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Quinolones; Schizophrenia; Schizophrenia, Treatment-Resistant; Thiophenes; Young Adult | 2022 |
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Humans; Hyperphagia; Lurasidone Hydrochloride; Olanzapine; Pharmacovigilance; Quinolones; Receptors, Serotonin; Thiophenes; United States; United States Food and Drug Administration | 2022 |
Do Not Panic About Prenatal Exposure to Antipsychotics Except for Aripiprazole?
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Prenatal Exposure Delayed Effects; Quinolones | 2022 |
Do Not Panic About Prenatal Exposure to Antipsychotics Except for Aripiprazole?-Reply.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Prenatal Exposure Delayed Effects; Quinolones | 2022 |
Significant Extrapyramidal Side Effects on Low-Dose Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Quinolones | 2022 |
Persistent hiccups related to long-acting aripiprazole injection: A case report.
Topics: Antipsychotic Agents; Aripiprazole; Hiccup; Humans; Quinolones | 2022 |
[Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Recurrence; Schizophrenia | 2022 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia | 2023 |
Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Duloxetine Hydrochloride; Humans; Piperazines; Quinolones | 2023 |
Gestational exposure to haloperidol changes Cdkn1a and Apaf1 mRNA expressions in mouse hippocampus.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Haloperidol; Hippocampus; Mice; Piperazines; Quinolones; RNA, Messenger | 2023 |
Dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating D
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Psychotic Disorders; Quinolones; Rats; Receptors, Serotonin | 2023 |
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hospitals; Humans; Olanzapine; Patient Discharge; Piperazines; Quinolones; Retrospective Studies; Schizophrenia | 2023 |